FEMSTATE™ FORMULATION

FEMSTATE™ FORMULATION

Core Vitamins

• Vitamin C
• Vitamin D3
• Vitamin K2
• Vitamin E
• Vitamin A
• B6
• B12
• Folate
• Pantothenic Acid
• Thiamin
• Riboflavin
• Niacin

Minerals

• Magnesium Glycinate
• Magnesium Bisglycinate
• Iron (Ferrochel®)
• Zinc
• Selenium
• Chromium
• Potassium
• Sodium

Amino Acids & Neuroactives

• L-Theanine
• L-Tryptophan
• GABA
• Myo-Inositol

Botanicals

• Ginger
• Tart Cherry
• Broccoli Sprout Extract (Sulforaphane source)
• Chamomile
• Saffron
• Resveratrol
• Quercetin

Structural & Metabolic Ingredients

• CoQ10
• Hyaluronic Acid
• Astaxanthin
• Ceramides
• Inulin
• Probiotic Blend

Ingredient Scientific Monograph

Vitamin C (Ascorbic Acid)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Vitamin C

Chemical Name: L-Ascorbic Acid

Ingredient Form: Ascorbic Acid

FEMSTATE™ Daily Dose

Vitamin C is incorporated into RESET™ and SHINE™ because both physiological phases involve active connective tissue remodeling, extracellular matrix turnover, angiogenesis, antioxidant regulation, and increased cellular metabolism. Rather than serving as a general immune-support ingredient, vitamin C was selected because of its established physiological roles in collagen biosynthesis, iron metabolism, tissue repair, and maintenance of endogenous antioxidant systems.

2. Physiological Role

Vitamin C is a water-soluble vitamin that functions as an essential enzymatic cofactor, antioxidant, and regulator of connective tissue biology. Humans cannot synthesize vitamin C because of the absence of L-gulonolactone oxidase; therefore, adequate intake depends entirely upon dietary or supplemental sources.(1-3)

Vitamin C participates in numerous physiological processes including:

• Collagen synthesis
• Extracellular matrix remodeling
• Angiogenesis
• Wound healing
• Iron absorption
• Antioxidant defense
• Immune regulation
• Catecholamine synthesis
• Mitochondrial redox homeostasis

These biological functions become particularly relevant during menstrual tissue repair (RESET™) and ovulatory tissue remodeling (SHINE™).

3. Mechanism of Action

Vitamin C exerts multiple complementary biological actions.

Collagen Synthesis

Vitamin C serves as an obligate cofactor for:

• Prolyl hydroxylase
• Lysyl hydroxylase

These enzymes stabilize collagen molecules through hydroxylation of proline and lysine residues.

Adequate vitamin C is therefore essential for:

• connective tissue integrity
• extracellular matrix formation
• angiogenesis
• wound repair

Iron Absorption

Vitamin C enhances intestinal absorption of non-heme iron by reducing ferric iron (Fe³⁺) to the more absorbable ferrous form (Fe²⁺).

This mechanism is particularly relevant during the menstrual phase when physiological iron loss occurs.

Antioxidant Physiology

Vitamin C functions as a potent water-soluble antioxidant.

It contributes to:

• scavenging reactive oxygen species
• regeneration of oxidized vitamin E
• maintenance of endogenous antioxidant systems
• preservation of physiological redox balance

Importantly, vitamin C supports normal oxidative balance without suppressing physiological oxidative signaling required for tissue remodeling.

Immune Physiology

Vitamin C contributes to normal immune function by supporting:

• neutrophil migration
• macrophage function
• lymphocyte physiology
• cytokine regulation

Its role is best described as maintenance of normal immune physiology, not immune stimulation.

4. Why Included in FEMSTATE™

RESET™

The menstrual phase emphasizes:

• tissue regeneration
• connective tissue remodeling
• angiogenesis
• restoration of iron homeostasis
• controlled inflammatory repair

Vitamin C supports these physiological processes through collagen synthesis, antioxidant regulation, and enhancement of dietary iron absorption.

SHINE™

Ovulation represents one of the most metabolically active transitions of the menstrual cycle.

Physiological priorities include:

• extracellular matrix remodeling
• angiogenesis
• ovarian tissue repair
• endogenous antioxidant regulation
• mitochondrial metabolism

The higher vitamin C dose in SHINE™ supports these coordinated biological processes during physiological ovulatory remodeling.

5. Dose Justification

RESET™

Selected Dose: 250 mg

Scientific Rationale

The selected dose was chosen because it:

• supports collagen synthesis
• enhances non-heme iron absorption
• contributes to endogenous antioxidant physiology
• supports connective tissue remodeling
• remains well within established safety limits

Randomized controlled trials have consistently demonstrated physiological activity within the 200-500 mg/day range for collagen synthesis and antioxidant support.

SHINE™

Selected Dose: 500 mg

Scientific Rationale

The ovulatory phase is associated with increased physiological oxidative metabolism and extracellular matrix remodeling.

The higher dose was selected to:

• support endogenous antioxidant defenses
• participate in collagen remodeling
• support vascular physiology
• maintain physiological redox balance during ovulation

The selected dose remains substantially below the established Tolerable Upper Intake Level while providing robust physiological exposure.

6. Human Clinical Evidence

Vitamin C is among the best-studied micronutrients in nutritional science.

Human evidence supports its physiological roles in:

• collagen synthesis
• connective tissue repair
• iron absorption
• antioxidant physiology
• immune cell function

Evidence Summary

7. Safety Considerations

Vitamin C possesses one of the strongest safety profiles among nutritional ingredients.

Recommended Dietary Allowance (Women): 75 mg/day

FEMSTATE Dose

RESET™: 250 mg

SHINE™: 500 mg

Tolerable Upper Intake Level

2,000 mg/day

The FEMSTATE doses remain substantially below the adult UL.

Potential adverse effects associated with excessive intake include:

• gastrointestinal discomfort
• osmotic diarrhea
• increased urinary oxalate in susceptible individuals

Neither FEMSTATE dose approaches levels commonly associated with toxicity.

8. HR+ Safety Review

Vitamin C was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for evidence of:

• estrogen receptor agonism
• progesterone receptor activity
• aromatase stimulation
• phytoestrogen content
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable oncology safety profile

Vitamin C is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Iron (Ferrochel®)

Vitamin C significantly improves absorption of non-heme iron -> Strong positive synergy

Vitamin E

Vitamin C regenerates oxidized vitamin E -> Positive antioxidant synergy

Collagen-dependent physiology

Vitamin C is essential for collagen maturation -> Strong connective tissue synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Magnesium
• Zinc
• Selenium
• Chromium
• Potassium

at the doses used in FEMSTATE™.

Known Considerations

Individuals with hereditary hemochromatosis or other iron overload disorders should consult a healthcare professional before using high-dose vitamin C because of its ability to enhance iron absorption.

10. Regulatory Status

Vitamin C is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized as an essential nutrient by the National Institutes of Health Office of Dietary Supplements.
• Widely accepted for use in dietary supplements.
• Included in international nutritional recommendations and clinical guidelines.

11. Evidence Gaps & Future Research

Current evidence strongly supports vitamin C for:

• collagen synthesis
• iron absorption
• antioxidant physiology
• connective tissue biology

Areas requiring further investigation include:

• Phase-specific vitamin C metabolism across the menstrual cycle.
• Whether vitamin C requirements differ according to endocrine phase.
• Clinical evaluation of vitamin C within a complete phase-aligned nutritional system such as FEMSTATE™.

No randomized controlled trials have specifically evaluated vitamin C as part of a phase-aligned formulation.

12. Conclusion

Vitamin C is a foundational ingredient within the FEMSTATE™ platform because of its established roles in connective tissue biology, collagen synthesis, antioxidant homeostasis, immune physiology, and iron metabolism. Its inclusion in RESET™ (250 mg) and SHINE™ (500 mg) reflects the changing physiological priorities of these two endocrine environments. The selected doses were derived through a structured framework integrating physiological relevance, human clinical evidence, safety, formulation compatibility, and HR+ considerations. Rather than targeting endocrine regulation directly, vitamin C supports the normal biological processes of tissue regeneration during menstruation and connective tissue remodeling during ovulation, making it a key component of the phase-aligned formulation strategy.

References

• National Institutes of Health Office of Dietary Supplements. Vitamin C Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on vitamin C physiology and human requirements.
• Nutrients. Systematic reviews on vitamin C, collagen synthesis, and antioxidant physiology.
• Free Radical Biology and Medicine. Reviews on vitamin C and redox biology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on connective tissue remodeling and reproductive physiology.

Ingredient Scientific Monograph

Vitamin D3 (Cholecalciferol)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Vitamin D3

Chemical Name: Cholecalciferol

Ingredient Form: Vitamin D3 (Cholecalciferol)

FEMSTATE™ Daily Dose

Vitamin D3 is included in all four formulations because its physiological functions support multiple biological systems throughout the menstrual cycle rather than one specific endocrine phase.

2. Physiological Role

Vitamin D is a fat-soluble secosteroid hormone precursor that regulates calcium and phosphate homeostasis while also influencing immune physiology, skeletal remodeling, muscle function, cellular differentiation, mitochondrial function, and gene transcription. After cutaneous synthesis or dietary intake, vitamin D3 is converted in the liver to 25-hydroxyvitamin D [25(OH)D], then in the kidney and selected peripheral tissues to its biologically active form, 1,25-dihydroxyvitamin D (calcitriol).(1-4)

Vitamin D receptors (VDRs) are expressed in:

• Bone
• Skeletal muscle
• Immune cells
• Brain
• Cardiovascular tissue
• Skin
• Gastrointestinal tract
• Ovaries
• Endometrium

This widespread receptor distribution explains why vitamin D contributes to systemic physiology throughout the menstrual cycle rather than exhibiting phase-specific actions.

3. Mechanism of Action

Vitamin D acts primarily through the vitamin D receptor (VDR), a nuclear transcription factor regulating the expression of hundreds of genes involved in cellular function.

Its principal mechanisms include:

Bone and Calcium Homeostasis

Vitamin D promotes:

• intestinal calcium absorption
• phosphate absorption
• bone mineralization
• normal skeletal remodeling

Immune Regulation

Vitamin D contributes to:

• regulation of innate immunity
• adaptive immune function
• cytokine balance
• maintenance of immune homeostasis

Importantly, vitamin D supports immune regulation, not generalized immune stimulation.

Muscle Function

Vitamin D supports:

• skeletal muscle physiology
• neuromuscular function
• muscle protein metabolism

Cellular Physiology

Vitamin D influences:

• cell differentiation
• gene regulation
• mitochondrial function
• oxidative balance
• cellular homeostasis

4. Why Included in FEMSTATE™

Unlike many ingredients that are phase-specific, vitamin D supports physiological processes active throughout the menstrual cycle.

RESET™

Supports:

• immune homeostasis
• tissue repair
• maintenance of calcium physiology

LIFT™

Supports:

• skeletal physiology
• connective tissue biology
• mitochondrial function
• cellular proliferation

SHINE™

Supports:

• immune regulation
• cellular homeostasis
• maintenance of musculoskeletal physiology

SOOTHE™

Supports:

• bone remodeling
• neuromuscular physiology
• immune balance
• metabolic stability

For this reason, vitamin D is maintained at the same dose across all four formulations, providing a stable nutritional foundation while phase-specific ingredients address changing physiological priorities.

5. Dose Justification

Selected Dose: 25 mcg (1,000 IU)

The selected dose was based on five scientific criteria:

Physiological Relevance

A daily dose of 25 mcg (1,000 IU) supports maintenance of vitamin D status in many healthy adults and provides physiological support for skeletal, muscular, immune, and metabolic functions.

6. Human Clinical Evidence

Clinical trials evaluating vitamin D have commonly used doses between 10 and 50 mcg/day (400–2,000 IU/day), with approximately 20–25 mcg/day (800-1,000 IU) representing one of the most frequently studied maintenance ranges.

Vitamin D is among the most extensively studied nutrients in medicine.

Human evidence supports physiological roles in:

• bone health
• calcium homeostasis
• skeletal muscle function
• immune regulation
• maintenance of normal vitamin D status

The strongest evidence exists for skeletal physiology and correction of vitamin D deficiency. Evidence supporting broader systemic outcomes is more variable and depends on baseline vitamin D status, dose, and population studied. Recent clinical guidelines emphasize meeting recommended intakes rather than routine high-dose supplementation for healthy adults.

7. Safety Considerations

The selected dose is well below the adult Tolerable Upper Intake Level (UL) of 100 mcg/day (4,000 IU) established by the National Institutes of Health Office of Dietary Supplements.

Vitamin D has an excellent safety profile at the dose used in FEMSTATE™.

Recommended Dietary Allowance (Adults): 15 mcg (600 IU)

FEMSTATE Dose: 25 mcg (1,000 IU)

The FEMSTATE dose is 25% of the adult UL.

Potential adverse effects of excessive long-term intake include:

• hypercalcemia
• nephrolithiasis in susceptible individuals
• soft tissue calcification
• vitamin D toxicity (rare and typically associated with intakes far exceeding FEMSTATE levels)

Formulation Compatibility

Using the same dose across RESET™, LIFT™, SHINE™, and SOOTHE™:

• simplifies daily intake
• maintains nutritional consistency
• supports long-term compliance
• complements phase-specific ingredients without unnecessarily increasing total capsule burden

8. HR+ Safety Review

Vitamin D was selected because of its favorable endocrine safety profile and its physiological importance across multiple organ systems without direct estrogenic or progesterone receptor activity.

Vitamin D3 was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor agonism
• progesterone receptor agonism
• aromatase stimulation
• phytoestrogen activity
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor agonist activity

✔ No phytoestrogen properties

✔ No aromatase stimulation

✔ Favorable safety profile within nutritional dosing ranges

Vitamin D is considered compatible with the HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin K2

Supports coordinated calcium utilization and skeletal physiology -> Strong positive synergy

Magnesium

Required for activation and metabolism of vitamin D -> Strong physiological synergy

Calcium (dietary)

Vitamin D enhances intestinal calcium absorption -> Strong physiological synergy

Neutral Interactions

• Vitamin C
• Zinc
• Selenium
• Chromium
• CoQ10

No clinically meaningful antagonistic interactions at FEMSTATE doses.

Known Considerations

Individuals using medications affecting vitamin D metabolism or those with disorders causing hypercalcemia should consult their healthcare provider before supplementation.

10. Regulatory Status

Vitamin D3 is:

• Widely recognized for use in dietary supplements.
• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an essential nutrient.
• Addressed in recent Endocrine Society Clinical Practice Guidelines on vitamin D supplementation.

11. Evidence Gaps & Future Research

Current evidence strongly supports vitamin D for maintenance of skeletal health and correction of deficiency.

Areas requiring additional investigation include:

• Phase-specific vitamin D physiology across the menstrual cycle.
• Whether maintaining vitamin D sufficiency differentially influences distinct endocrine environments.
• The role of vitamin D within a comprehensive phase-aligned nutritional system such as FEMSTATE™.

No randomized controlled trials have specifically evaluated vitamin D as part of a phase-aligned formulation.

12. Conclusion

Vitamin D3 is a foundational nutrient within the FEMSTATE™ platform rather than a phase-specific ingredient. Its inclusion at 25 mcg (1,000 IU) across RESET™, LIFT™, SHINE™, and SOOTHE™ reflects its established roles in bone remodeling, calcium homeostasis, immune regulation, muscle physiology, and cellular health. The selected dose was chosen using a structured framework integrating physiological relevance, human clinical evidence, safety, formulation compatibility, and HR+ considerations. Maintaining a consistent vitamin D intake across all four formulations provides a stable nutritional foundation while allowing the phase-specific ingredients to address the changing biological priorities generated by the menstrual cycle.

References

• Williams Textbook of Endocrinology.
• National Institutes of Health Office of Dietary Supplements. Vitamin D Fact Sheet for Health Professionals.
• Endocrine Society. Clinical Practice Guideline: Vitamin D for the Prevention of Disease.
• Guyton and Hall Textbook of Medical Physiology.
• Yen and Jaffe's Reproductive Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on vitamin D physiology and women's health.

Ingredient Scientific Monograph

Vitamin K2 (Menaquinone-7, MK-7)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Vitamin K2

Chemical Name: Menaquinone-7 (MK-7)

Ingredient Form: Vitamin K2 (Menaquinone-7)

FEMSTATE™ Daily Dose

Vitamin K2 is included in all four FEMSTATE™ formulations because of its fundamental role in calcium homeostasis, skeletal physiology, connective tissue biology, and vascular health. Unlike phase-specific ingredients, vitamin K2 provides a stable physiological foundation that supports long-term tissue maintenance throughout the menstrual cycle.

2. Physiological Role

Vitamin K2 is a fat-soluble vitamin that functions as an essential cofactor for the enzyme γ-glutamyl carboxylase, which activates vitamin K-dependent proteins involved in calcium regulation, bone remodeling, vascular physiology, and connective tissue biology. Unlike vitamin K1, which is primarily involved in hepatic blood coagulation, vitamin K2 (MK-7) has a longer half-life and preferentially supports extrahepatic tissues such as bone, blood vessels, and connective tissue.(1-4)

Vitamin K-dependent proteins include:

• Osteocalcin
• Matrix Gla Protein (MGP)
• Growth Arrest-Specific Protein 6 (Gas6)

Through activation of these proteins, vitamin K2 contributes to:

• Bone mineralization
• Calcium homeostasis
• Vascular integrity
• Connective tissue maintenance
• Normal cellular physiology

These biological functions remain important throughout every phase of the menstrual cycle.

3. Mechanism of Action

Vitamin K2 exerts its physiological effects by activating vitamin K-dependent proteins through y-carboxylation.

Bone Remodeling

Vitamin K2 activates osteocalcin, enabling:

• calcium incorporation into bone matrix
• bone mineralization
• maintenance of skeletal integrity

Vascular Physiology

Vitamin K2 activates Matrix Gla Protein (MGP), which contributes to:

• regulation of vascular calcium deposition
• maintenance of vascular tissue integrity
• physiological cardiovascular function

Calcium Homeostasis

Vitamin K2 helps regulate the physiological distribution of calcium by supporting its incorporation into mineralized tissues rather than soft tissues.

Connective Tissue

Emerging evidence suggests vitamin K-dependent proteins also participate in:

• extracellular matrix biology
• cartilage physiology
• connective tissue maintenance

Although these mechanisms continue to be investigated, they support the inclusion of vitamin K2 within a systems physiology framework.

4. Why Included in FEMSTATE™

Vitamin K2 is maintained at a constant dose across all four formulations because its physiological functions support long-term tissue maintenance rather than phase-specific endocrine transitions.

RESET™

Supports:

• connective tissue regeneration
• bone remodeling
• maintenance of calcium physiology during tissue repair

LIFT™

Supports:

• connective tissue synthesis
• extracellular matrix maintenance
• skeletal physiology during anabolic growth

SHINE™

Supports:

• connective tissue integrity
• vascular physiology
• extracellular matrix maintenance during ovulatory remodeling

SOOTHE™

Supports:

• bone remodeling
• connective tissue maintenance
• long-term calcium homeostasis during physiological stabilization

5. Dose Justification

Selected Dose: 90 mcg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A daily intake of 90 mcg MK-7 has been shown to effectively support activation of vitamin K-dependent proteins involved in bone and vascular physiology.

6. Human Clinical Evidence

Human intervention studies consistently demonstrate improved activation of vitamin K-dependent proteins with MK-7 supplementation. Multiple human studies evaluating MK-7 have used doses ranging from 45–180 mcg/day, with 90 mcg/day representing one of the most frequently studied maintenance doses for extrahepatic vitamin K function.(2-5)

Vitamin K2 has been investigated extensively in relation to:

• bone health
• calcium metabolism
• vascular physiology
• activation of osteocalcin and Matrix Gla Protein

Safety

Vitamin K2 demonstrates an excellent safety profile with no established tolerable upper intake level in healthy adults.

Formulation Compatibility

Using the same dose throughout all four formulations:

• simplifies daily use
• maintains consistent nutritional support
• complements vitamin D3 and magnesium
• supports long-term skeletal physiology

7. Safety Considerations

Vitamin K2 possesses an excellent safety profile.

Adequate Intake (Women): 90 mcg/day

FEMSTATE Dose: 90 mcg/day

Tolerable Upper Intake Level. No UL has been established for vitamin K because adverse effects have not been identified in healthy individuals at nutritional doses.²

Potential consideration:

Vitamin K may interact with vitamin K antagonist anticoagulants (e.g., Warfarin), and individuals taking these medications should consult their healthcare provider before supplementation.

8. HR+ Safety Review

Vitamin K2 demonstrates no known estrogenic or progesterone receptor activity and aligns well with the HR+-conscious formulation philosophy. Vitamin K2 was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• phytoestrogen properties
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonism

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Vitamin K2 is considered fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin D3

Vitamin D promotes synthesis of osteocalcin.

Vitamin K2 activates osteocalcin -> Strong physiological synergy

Magnesium

Magnesium supports vitamin D metabolism, indirectly complementing vitamin K2-dependent calcium regulation -> Positive synergy

Calcium (dietary)

Vitamin K2 supports physiological utilization of absorbed calcium -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Zinc
• Selenium
• Chromium
• CoQ10

at FEMSTATE doses.

Known Considerations

Individuals taking vitamin K antagonist anticoagulants require medical supervision before initiating vitamin K supplementation.

10. Regulatory Status

Vitamin K2 (MK-7) is:

• Widely used in dietary supplements.
• Recognized as a dietary ingredient in multiple international markets.
• Included in dietary reference recommendations for vitamin K.
• Supported by numerous clinical investigations evaluating bone and vascular physiology.

11. Evidence Gaps & Future Research

Current evidence strongly supports vitamin K2 for:

• activation of osteocalcin
• calcium homeostasis
• bone physiology
• vascular biology

Areas requiring further investigation include:

• Phase-specific vitamin K physiology across the menstrual cycle.
• Connective tissue remodeling during reproductive physiology.
• Evaluation of vitamin K2 within a comprehensive phase-aligned nutritional system.

No randomized controlled trials have specifically evaluated vitamin K2 within a phase-aligned formulation such as FEMSTATE™.

12. Conclusion

Vitamin K2 (MK-7) is a foundational nutrient within the FEMSTATE™ platform because of its established roles in calcium homeostasis, skeletal remodeling, connective tissue biology, and vascular physiology. The selected dose of 90 mcg/day is supported by human clinical evidence, aligns with established nutritional recommendations, and complements vitamin D3 and magnesium within the formulation architecture. Its inclusion across all four FEMSTATE™ formulations reflects its continuous physiological importance rather than phase-specific endocrine changes. The dose was selected using a structured framework integrating biological plausibility, human clinical evidence, safety, formulation compatibility, and HR+ considerations, providing a stable nutritional foundation that supports long-term tissue integrity throughout the menstrual cycle.

References

• Williams Textbook of Endocrinology.
• National Institutes of Health Office of Dietary Supplements. Vitamin K Fact Sheet for Health Professionals.
• Osteoporosis International. Reviews on vitamin K2 and bone health.
• Nutrients. Systematic reviews on menaquinone-7, osteocalcin activation, and calcium physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on vitamin K-dependent proteins and skeletal physiology.
• Endocrine Reviews. Reviews on calcium homeostasis and endocrine regulation.

Ingredient Scientific Monograph

Vitamin E (D-Alpha Tocopheryl Succinate)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Vitamin E

Chemical Name: D-Alpha Tocopheryl Succinate

Ingredient Form: Natural Vitamin E (D-Alpha Tocopheryl Succinate)

FEMSTATE™ Daily Dose

Vitamin E is incorporated into all four formulations because of its role as a lipid-soluble antioxidant that protects cellular membranes from oxidative damage. The higher dose in SHINE™ reflects the increased physiological oxidative metabolism and membrane remodeling associated with ovulation.

2. Physiological Role

Vitamin E is the principal fat-soluble antioxidant in human physiology. It protects polyunsaturated fatty acids within cell membranes from lipid peroxidation and contributes to maintenance of membrane integrity throughout the body. Vitamin E also participates in immune regulation, vascular biology, mitochondrial function, skeletal muscle physiology, and cellular signaling.(1-4)

Vitamin E is distributed throughout numerous tissues including:

• Brain
• Skeletal muscle
• Liver
• Skin
• Cardiovascular system
• Immune cells
• Reproductive tissues

Its primary physiological role is preservation of cell membrane integrity under conditions of normal oxidative metabolism.

3. Mechanism of Action

Vitamin E exerts its physiological actions primarily through antioxidant protection of lipid membranes.

Membrane Protection

Vitamin E resides within phospholipid membranes where it:

• scavenges lipid peroxyl radicals
• interrupts lipid peroxidation chain reactions
• preserves membrane fluidity
• maintains cellular integrity

Antioxidant Network

Vitamin E functions together with:

• Vitamin C
• Glutathione
• Superoxide dismutase
• Catalase

Vitamin C regenerates oxidized vitamin E, allowing continued antioxidant activity.

Immune Physiology

Vitamin E contributes to:

• maintenance of immune cell membrane integrity
• normal lymphocyte physiology
• regulation of oxidative signaling

Vascular Physiology

Vitamin E supports:

• endothelial membrane stability
• protection of lipoproteins from oxidation
• maintenance of normal vascular physiology

4. Why Included in FEMSTATE™

Vitamin E supports cellular physiology throughout the menstrual cycle, with greatest physiological relevance during periods of increased oxidative metabolism.

RESET™

Supports:

• antioxidant homeostasis
• tissue regeneration
• membrane protection during endometrial repair

LIFT™

Supports:

• mitochondrial physiology
• connective tissue growth
• protection of proliferating cells

SHINE™

Supports:

• physiological oxidative balance during ovulation
• membrane integrity
• extracellular matrix remodeling
• vascular physiology

For this reason, SHINE™ contains a higher dose.

SOOTHE™

Supports:

• maintenance of cellular membranes
• neurophysiology
• immune homeostasis
• long-term tissue stability

5. Dose Justification

Selected Dose: 15 mg RESET™, LIFT™ & SOOTHE™

Scientific Rationale

The selected dose:

• corresponds to the adult Recommended Dietary Allowance
• supports normal antioxidant physiology
• maintains membrane integrity
• complements vitamin C and selenium
• provides foundational antioxidant support

Selected Dose: 35 mg SHINE™

Scientific Rationale

Ovulation is associated with:

• localized oxidative metabolism
• extracellular matrix remodeling
• angiogenesis
• increased mitochondrial respiration

The increased dose was selected to:

• support endogenous antioxidant systems
• protect membrane lipids
• maintain physiological redox balance
• complement vitamin C, astaxanthin, CoQ10, quercetin, and resveratrol

The dose remains substantially below the established Tolerable Upper Intake Level while providing enhanced physiological support during this metabolically active phase.

6. Human Clinical Evidence

Vitamin E has been extensively investigated in human nutrition.

The strongest evidence supports its physiological roles in:

• membrane protection
• antioxidant physiology
• immune function
• maintenance of vitamin E status

Evidence for broader clinical outcomes varies depending on study population and baseline nutritional status.

7. Safety Considerations

Vitamin E has an excellent safety profile at FEMSTATE™ doses.

Recommended Dietary Allowance (Women): 15 mg/day

FEMSTATE Doses = RESET™: 15 mg / LIFT™”:15 mg / SHINE™: 35 mg / SOOTHE™: 15 mg

Tolerable Upper Intake Level: 1,000 mg/day (1,500 IU natural vitamin E).(2)

All FEMSTATE doses remain far below the UL.

Potential considerations at excessive doses include:

• increased bleeding risk
• interaction with anticoagulants
• gastrointestinal discomfort (rare)

These concerns are associated with doses substantially higher than those used in FEMSTATE™.

8. HR+ Safety Review

Vitamin E was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• phytoestrogen properties
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable oncology safety profile at nutritional doses

Vitamin E is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin C

Vitamin C regenerates oxidized vitamin E -> Strong antioxidant synergy

Selenium

Supports glutathione peroxidase activity, complementing vitamin E within endogenous antioxidant systems. -> Positive synergy

Astaxanthin

Works together to support lipid membrane protection during SHINE™ -> Positive synergy

CoQ10

Supports mitochondrial antioxidant physiology -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Magnesium
• Zinc
• Vitamin D
• Vitamin K2

at FEMSTATE doses.

Known Considerations

Individuals using anticoagulant therapy or with bleeding disorders should consult their healthcare provider before taking high-dose vitamin E supplements. The doses included in FEMSTATE™ remain within nutritional ranges.

10. Regulatory Status

Vitamin E is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an essential nutrient.
• Widely accepted for use in dietary supplements.
• Included in international nutritional recommendations.

11. Evidence Gaps & Future Research

Current evidence strongly supports vitamin E for:

• antioxidant physiology
• membrane protection
• maintenance of vitamin E status

Areas requiring further investigation include:

• Phase-specific vitamin E requirements across the menstrual cycle.
• Lipid antioxidant physiology during ovulation.
• Evaluation of vitamin E within comprehensive phase-aligned nutritional systems.

No randomized controlled trials have specifically evaluated vitamin E within a phase-aligned formulation such as FEMSTATE™.

12. Conclusion

Vitamin E is a foundational antioxidant within the FEMSTATE™ platform because of its established roles in membrane protection, antioxidant physiology, immune regulation, and cellular homeostasis. The inclusion of 15 mg in RESET™, LIFT™, and SOOTHE™ provides consistent physiological support throughout the menstrual cycle, while the increased dose of 35 mg in SHINE™ reflects the greater oxidative metabolism and membrane remodeling associated with ovulation. The selected doses were determined through a structured framework integrating biological plausibility, human clinical evidence, safety, formulation compatibility, and HR+ considerations. Rather than functioning as a general antioxidant supplement, vitamin E was incorporated to support the changing physiological environments generated by the HPO axis, particularly the increased lipid membrane protection required during the ovulatory transition.

References

• National Institutes of Health Office of Dietary Supplements. Vitamin E Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on vitamin E physiology and antioxidant biology.
• Free Radical Biology and Medicine. Reviews on lipid peroxidation, membrane biology, and vitamin E.
• Nutrients. Systematic reviews on vitamin E supplementation and human physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on oxidative physiology and women's health.

Ingredient Scientific Monograph

Vitamin A (as Beta-Carotene)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Vitamin A

Chemical Name: Provitamin A (Beta-Carotene)

Ingredient Form: Natural Beta-Carotene

FEMSTATE™ Daily Dose

Vitamin A is included in all four FEMSTATE™ formulations as beta-carotene, the principal provitamin A carotenoid. Beta-carotene was intentionally selected instead of preformed retinol because it provides physiological vitamin A activity while maintaining a wider margin of safety for long-term daily supplementation. Vitamin A supports epithelial integrity, immune physiology, vision, cellular differentiation, and reproductive tissue maintenance throughout the menstrual cycle.

2. Physiological Role

Vitamin A is an essential fat-soluble nutrient involved in the regulation of cellular growth, differentiation, epithelial maintenance, immune homeostasis, vision, and reproductive physiology. Following intestinal absorption, beta-carotene is converted enzymatically into retinal and retinoic acid according to physiological need, allowing endogenous regulation of vitamin A production.(1-4)

Vitamin A receptors (retinoic acid receptors [RAR] and retinoid X receptors [RXR]) regulate the expression of hundreds of genes involved in:

• epithelial regeneration
• immune regulation
• cellular differentiation
• embryonic development
• skin physiology
• reproductive tissue maintenance
• vision
• mucosal integrity

These biological functions remain important throughout all phases of the menstrual cycle.

3. Mechanism of Action

Vitamin A functions primarily through regulation of gene transcription.

Cellular Differentiation

Retinoic acid binds to nuclear receptors (RAR/RXR), regulating genes responsible for:

• epithelial maturation
• tissue differentiation
• cellular development
• extracellular matrix organization

Epithelial Integrity

Vitamin A supports maintenance of:

• skin
• gastrointestinal epithelium
• reproductive tract epithelium
• respiratory mucosa

Healthy epithelial barriers are essential for normal tissue homeostasis.

Immune Physiology

Vitamin A contributes to:

• innate immune regulation
• adaptive immune function
• maintenance of mucosal immunity
• lymphocyte differentiation

Importantly, vitamin A regulates normal immune physiology rather than stimulating immune activity indiscriminately.

Antioxidant Activity

Beta-carotene also functions as a carotenoid antioxidant, helping protect cellular membranes against oxidative damage under normal physiological conditions.

4. Why Included in FEMSTATE™

Vitamin A supports fundamental biological processes active throughout the menstrual cycle.

RESET™

Supports:

• epithelial regeneration
• endometrial repair
• immune homeostasis
• tissue restoration

LIFT™

Supports:

• cellular differentiation
• connective tissue growth
• epithelial maintenance
• anabolic physiology

SHINE™

Supports:

• epithelial integrity
• antioxidant physiology
• reproductive tissue maintenance

SOOTHE™

Supports:

• tissue maintenance
• immune regulation
• skin physiology
• mucosal integrity

Because these physiological functions remain active throughout the menstrual cycle, vitamin A is maintained at a consistent dose across all four formulations.

5. Dose Justification

Selected Dose: 900 mcg RAE

The selected dose was based on five scientific criteria.

Physiological Relevance

The dose provides the Recommended Dietary Allowance for adult women while supporting normal epithelial physiology, immune regulation, and cellular differentiation.

Human Clinical Evidence

Vitamin A has been extensively studied in relation to:

• epithelial biology
• immune physiology
• reproductive health
• vision
• skin

The selected dose aligns with established nutritional recommendations and supports long-term maintenance of vitamin A status.

Safety

Beta-carotene provides a favorable safety profile because conversion to active vitamin A is physiologically regulated according to need.

Unlike preformed retinol, beta-carotene does not readily accumulate to toxic levels under normal conditions.

Formulation Compatibility

The selected dose:

• complements vitamin D3 and vitamin K2
• supports immune physiology
• supports skin and epithelial biology
• fits within long-term daily supplementation

HR+ Philosophy

The provitamin A form (beta-carotene) was selected because of its favorable physiological regulation and safety profile.

6. Human Clinical Evidence

Vitamin A is one of the most extensively studied micronutrients in human physiology.

Human evidence strongly supports its role in:

• epithelial maintenance
• immune regulation
• vision
• cellular differentiation

Evidence specifically evaluating menstrual cycle physiology is more limited.

7. Safety Considerations

Beta-carotene possesses an excellent safety profile when used at nutritional doses.

Recommended Dietary Allowance: 900 mcg RAE/day

FEMSTATE Dose: 900 mcg RAE/day

Tolerable Upper Intake Level

No UL has been established for beta-carotene itself because conversion to vitamin A is physiologically regulated.

The UL of 3,000 mcg RAE/day applies to preformed vitamin A (retinol) rather than beta-carotene.²

Potential considerations:

• High supplemental beta-carotene has been associated with increased lung cancer risk in smokers when administered at pharmacological doses substantially exceeding nutritional intake.

The FEMSTATE dose remains within recommended nutritional ranges.

8. HR+ Safety Review

Beta-carotene was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Beta-carotene is considered fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin E

Both nutrients contribute to maintenance of membrane integrity and antioxidant physiology -> Positive antioxidant synergy

Vitamin C

Vitamin C helps maintain antioxidant network function alongside carotenoids -> Positive synergy

Dietary Fat

Absorption of beta-carotene is enhanced in the presence of dietary fat -> Positive physiological interaction

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Vitamin K2
• Magnesium
• Zinc
• Selenium

at FEMSTATE doses.

Known Considerations

Individuals who smoke or have significant occupational asbestos exposure should avoid high-dose beta-carotene supplementation beyond nutritional recommendations because of evidence from pharmacological-dose intervention studies.

The dose used in FEMSTATE remains within normal dietary ranges.

10. Regulatory Status

Vitamin A (beta-carotene) is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an essential nutrient.
• Widely accepted for use in dietary supplements.
• Recommended in international nutritional guidelines.

11. Evidence Gaps & Future Research

Current evidence strongly supports vitamin A for:

• epithelial integrity
• immune physiology
• cellular differentiation
• vision

Areas requiring additional investigation include:

• Phase-specific vitamin A metabolism across the menstrual cycle.
• Reproductive tissue remodeling during different endocrine environments.
• Evaluation of beta-carotene within comprehensive phase-aligned nutritional systems.

No randomized controlled trials have specifically evaluated vitamin A within a phase-aligned formulation such as FEMSTATE™.

12. Conclusion

Vitamin A, provided as beta-carotene, serves as a foundational nutrient within the FEMSTATE™ platform because of its established roles in epithelial integrity, immune regulation, cellular differentiation, connective tissue biology, and reproductive tissue maintenance. The selected dose of 900 mcg RAE provides the Recommended Dietary Allowance for adult women while maintaining an excellent safety profile through physiologically regulated conversion to active vitamin A. Beta-carotene was intentionally selected over preformed retinol to maximize long-term safety and compatibility with the HR+-conscious formulation philosophy. Its inclusion across all four FEMSTATE™ formulations reflects its continuous importance in maintaining normal cellular function throughout the menstrual cycle rather than supporting a single endocrine phase.

References

• National Institutes of Health Office of Dietary Supplements. Vitamin A and Carotenoids Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on vitamin A physiology and carotenoid metabolism.
• Nutrients. Systematic reviews on vitamin A, epithelial biology, and immune function.
• Endocrine Reviews. Reviews on retinoid signaling and gene regulation.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on vitamin A and reproductive physiology.

Ingredient Scientific Monograph

Vitamin B6 (Pyridoxal-5'-Phosphate, P5P)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Vitamin B6

Chemical Name: Pyridoxal-5'-Phosphate (P5P)

Ingredient Form: Pyridoxal-5'-Phosphate (Active Vitamin B6)

FEMSTATE™ Daily Dose

Vitamin B6 is incorporated into RESET™ and SOOTHE™ because these phases emphasize neuroendocrine regulation, cellular energy metabolism, amino acid metabolism, neurotransmitter synthesis, and hemoglobin production. The active form, Pyridoxal-5'-Phosphate (P5P), was intentionally selected because it is the biologically active coenzyme form and does not require hepatic activation.

2. Physiological Role

Vitamin B6 functions as a coenzyme in more than 140 enzymatic reactions, primarily involving amino acid metabolism, neurotransmitter synthesis, hemoglobin production, glycogen metabolism, immune physiology, and one-carbon metabolism.(1-4)

P5P participates in the synthesis of:

• Serotonin
• Dopamine
• Gamma-aminobutyric acid (GABA)
• Norepinephrine
• Histamine

It also contributes to:

• Hemoglobin synthesis
• Energy metabolism
• Homocysteine metabolism
• Immune regulation
• Protein metabolism

Because these biological processes remain particularly relevant during the menstrual and luteal phases, P5P serves as an important neuro-metabolic support nutrient within FEMSTATE™.

3. Mechanism of Action

P5P functions as the active coenzyme form of vitamin B6.

Neurotransmitter Synthesis

P5P is required for enzymes involved in synthesis of:

• Serotonin from tryptophan
• Dopamine from L-DOPA
• GABA from glutamate
• Norepinephrine from dopamine

This makes vitamin B6 one of the most important nutritional cofactors for normal neurotransmitter physiology.

Amino Acid Metabolism

Vitamin B6 regulates:

• transamination
• decarboxylation
• amino acid utilization
• nitrogen metabolism

These pathways support tissue repair and protein synthesis.

Hemoglobin Synthesis

P5P participates in:

• heme synthesis
• red blood cell production
• oxygen transport

This physiological role is particularly relevant during the menstrual phase.

Energy Metabolism

Vitamin B6 contributes to:

• glycogen metabolism
• mitochondrial ATP production
• glucose utilization

4. Why Included in FEMSTATE™

RESET™

During the menstrual phase, physiological priorities include:

• restoration of iron homeostasis
• hemoglobin synthesis
• tissue repair
• mitochondrial recovery

P5P supports these processes through its role in amino acid metabolism, heme synthesis, and cellular energy production.

SOOTHE™

The luteal phase emphasizes:

• neuroendocrine regulation
• GABA physiology
• serotonin synthesis
• metabolic stability
• cellular maintenance

P5P supports these biological processes by serving as an essential cofactor for neurotransmitter synthesis and normal nervous system physiology.

5. Dose Justification

Selected Dose: 25 mg

The selected dose was based on five scientific criteria.

Physiological Relevance

The dose supports neurotransmitter synthesis, amino acid metabolism, hemoglobin production, and energy metabolism during phases where these biological processes are particularly active.

Human Clinical Evidence

Randomized controlled trials evaluating P5P and vitamin B6 have commonly investigated doses between 10-100 mg/day, depending on the physiological outcome studied. A dose of 25 mg/day falls within clinically studied ranges while remaining substantially below doses associated with chronic toxicity.

Safety

The selected dose remains well below the current adult Tolerable Upper Intake Level (UL) established by the U.S. National Academies (12 mg/day under the 2023 update) but above the RDA. Notably, other authorities, including the European Food Safety Authority and older U.S. guidance, have used different ULs. Peripheral neuropathy has primarily been associated with chronic high-dose supplementation, generally well above typical nutritional intakes. The FEMSTATE dose was selected to balance physiological activity with long-term safety and should be evaluated in the context of total vitamin B6 intake from all supplements.²

Formulation Compatibility

Using the same dose in RESET™ and SOOTHE™:

• supports neurophysiology
• supports hemoglobin synthesis
• complements magnesium and tryptophan
• maintains consistent physiological exposure

HR+ Philosophy

P5P demonstrates no direct estrogenic activity and aligns well with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Vitamin B6 has been extensively studied in human physiology.

Strong evidence supports its roles in:

• neurotransmitter synthesis
• amino acid metabolism
• hemoglobin production
• immune physiology
• homocysteine metabolism

Evidence supporting reproductive physiology is primarily mechanistic, with some clinical studies evaluating luteal-phase symptom outcomes. Those studies are heterogeneous, and they should not be interpreted as establishing efficacy for phase-aligned supplementation.

7. Safety Considerations

Vitamin B6 is generally safe at nutritional doses.

Recommended Dietary Allowance (Women): 1.3-1.5 mg/day (depending on age)

FEMSTATE Dose: 25 mg/day

Tolerable Upper Intake Level

Current U.S. National Academies UL (2023): 12 mg/day for adults, based on peripheral neuropathy risk with chronic supplemental intake. Other authorities have established different limits, reflecting differences in interpretation of the available evidence.(2)

Potential adverse effects associated with prolonged excessive intake include:

• sensory neuropathy
• paresthesia
• gait disturbance (primarily reported with substantially higher chronic doses)

The FEMSTATE dose should be considered in the context of total daily B6 intake from all supplements.

8. HR+ Safety Review

Vitamin B6 was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor agonist activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Vitamin B6 is considered compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Magnesium

Supports multiple shared enzymatic pathways involved in energy metabolism and nervous system physiology -> Strong physiological synergy

L-Tryptophan

P5P is required for conversion of tryptophan into serotonin -> Strong neurophysiological synergy

GABA

Supports endogenous neurotransmitter physiology through complementary pathways -> Positive synergy

Iron

Supports normal hemoglobin synthesis through complementary biochemical pathways -> Positive physiological interaction

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Vitamin K2
• Vitamin C
• Zinc

at FEMSTATE doses.

Known Considerations

Individuals taking levodopa without a peripheral decarboxylase inhibitor or certain anticonvulsants should consult a healthcare professional regarding vitamin B6 supplementation because of potential medication interactions.

10. Regulatory Status

Vitamin B6 (P5P) is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized as an essential nutrient by the National Institutes of Health Office of Dietary Supplements.
• Widely accepted for use in dietary supplements.
• Supported by international nutrition guidelines.

11. Evidence Gaps & Future Research

Current evidence strongly supports vitamin B6 for:

• neurotransmitter synthesis
• amino acid metabolism
• hemoglobin production
• energy metabolism

Areas requiring further investigation include:

• Phase-specific vitamin B6 utilization across the menstrual cycle.
• Long-term outcomes of active P5P supplementation within phase-aligned nutritional systems.
• Clinical evaluation of P5P as part of the complete FEMSTATE™ formulation.

No randomized controlled trials have specifically evaluated P5P within a phase-aligned nutritional system.

12. Conclusion

Vitamin B6, provided as Pyridoxal-5'-Phosphate (P5P), was selected for RESET™ and SOOTHE™ because of its established roles in neurotransmitter synthesis, amino acid metabolism, hemoglobin production, and cellular energy metabolism. The active coenzyme form was intentionally chosen to maximize bioavailability and avoid reliance on metabolic activation. The 25 mg dose was selected based on physiological relevance, clinical evidence, formulation compatibility, and HR+ considerations. Given evolving guidance on upper intake limits, this dose reflects a balance between biological rationale and the need for careful long-term safety consideration within total supplemental intake. Within the FEMSTATE™ platform, P5P supports the neuroendocrine and metabolic priorities of the menstrual and luteal phases without directly modifying reproductive hormone physiology.

References

• National Institutes of Health Office of Dietary Supplements. Vitamin B6 Fact Sheet for Health Professionals.
• Dietary Reference Intakes for Energy.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on vitamin B6 physiology and metabolism.
• Nutrients. Systematic reviews on vitamin B6, neurotransmitter synthesis, and human health.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on reproductive physiology and micronutrient metabolism.

Ingredient Scientific Monograph

Vitamin B12 (Methylcobalamin)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Vitamin B12

Chemical Name: Cobalamin

Ingredient Form: Methylcobalamin

FEMSTATE™ Daily Dose

Vitamin B12 is included in RESET™ and LIFT™ because these phases emphasize cellular regeneration, DNA synthesis, red blood cell production, mitochondrial energy metabolism, and anabolic physiology. The methylcobalamin form was selected because it is one of the biologically active coenzyme forms of vitamin B12 and participates directly in methylation reactions without requiring conversion from cyanocobalamin.

2. Physiological Role

Vitamin B12 is an essential water-soluble vitamin involved in DNA synthesis, methylation, neurological function, erythropoiesis, mitochondrial metabolism, and one-carbon metabolism. Humans cannot synthesize vitamin B12, making dietary intake essential.(1-4)

Vitamin B12 functions primarily as a cofactor for two critical enzymes:

• Methionine synthase
• Methylmalonyl-CoA mutase

Through these enzymes, vitamin B12 contributes to:

• DNA synthesis
• Red blood cell production
• Myelin maintenance
• Homocysteine metabolism
• Cellular energy production
• Methylation reactions

These physiological functions are particularly relevant during the regenerative (RESET™) and anabolic (LIFT™) phases of the menstrual cycle.

3. Mechanism of Action

Vitamin B12 exerts its physiological effects through two major biochemical pathways.

DNA Synthesis

Vitamin B12 functions together with folate in one-carbon metabolism.

It is essential for:

• DNA replication
• cell division
• tissue regeneration
• rapidly proliferating cells

This mechanism supports endometrial regeneration during RESET™ and cellular proliferation during LIFT™.

Methylation

Vitamin B12 converts homocysteine to methionine.

This reaction supports:

• methylation reactions
• neurotransmitter synthesis
• phospholipid synthesis
• gene regulation

Energy Metabolism

Vitamin B12 functions as a cofactor for methylmalonyl-CoA mutase, contributing to:

• mitochondrial metabolism
• fatty acid oxidation
• ATP production

Neurological Function

Vitamin B12 supports:

• myelin synthesis
• neuronal integrity
• nervous system maintenance

These mechanisms make vitamin B12 important for normal neurophysiology throughout the menstrual cycle.

4. Why Included in FEMSTATE™

RESET™

The menstrual phase emphasizes:

• tissue regeneration
• DNA synthesis
• red blood cell production
• restoration of cellular homeostasis

Vitamin B12 supports these physiological processes through its roles in erythropoiesis, DNA synthesis, and methylation.

LIFT™

The follicular phase emphasizes:

• cellular proliferation
• anabolic metabolism
• mitochondrial activation
• protein synthesis

Vitamin B12 supports these biological priorities through methylation, DNA synthesis, and cellular energy metabolism.

5. Dose Justification

Selected Dose: 150 mcg

The selected dose was based upon five scientific criteria.

Physiological Relevance

Vitamin B12 absorption through intrinsic factor becomes saturated at relatively low doses. Larger oral doses rely partly on passive diffusion, allowing meaningful absorption even when intrinsic factor-mediated uptake is limited.

The selected dose ensures consistent physiological exposure while supporting long-term maintenance of vitamin B12 status.

Human Clinical Evidence

Human supplementation studies have evaluated doses ranging from 25 mcg to 1,000 mcg/day, depending on baseline status and clinical objectives.

A dose of 150 mcg/day provides substantially greater exposure than the Recommended Dietary Allowance while remaining well within established safety parameters.

Safety

Vitamin B12 demonstrates one of the strongest safety profiles among vitamins.

No Tolerable Upper Intake Level has been established because toxicity has not been demonstrated at nutritional or supplemental doses.

Formulation Compatibility

The selected dose:

• complements folate
• supports methylation
• supports mitochondrial metabolism
• maintains formulation consistency across RESET™ and LIFT™

HR+ Philosophy

Vitamin B12 demonstrates no known endocrine activity and aligns fully with the HR+-conscious formulation philosophy

6.Human Clinical Evidence

Vitamin B12 has been extensively studied in relation to:

• vitamin B12 deficiency
• red blood cell production
• neurological physiology
• homocysteine metabolism
• DNA synthesis

The strongest human evidence supports correction and prevention of vitamin B12 deficiency and maintenance of normal neurological and hematological function.

7. Safety Considerations

Vitamin B12 has an excellent safety profile.

Recommended Dietary Allowance (Women): 2.4 mcg/day

FEMSTATE Dose: 150 mcg/day

Tolerable Upper Intake Level

No UL has been established because no adverse effects have been consistently associated with high oral vitamin B12 intake.(2)

Occasional reports include:

• mild acneiform eruptions (rare)
• hypersensitivity reactions (extremely rare)

8. HR+ Safety Review

Vitamin B12 was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable oncology safety profile

Vitamin B12 is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Folate (L-5-MTHF)

Vitamin B12 and folate function together in one-carbon metabolism and DNA synthesis -> Strong physiological synergy

Vitamin B6

Supports complementary methylation and amino acid metabolism pathways -> Positive synergy

Iron

Vitamin B12 contributes to normal erythropoiesis alongside iron -> Positive physiological interaction

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Vitamin C
• Magnesium
• Zinc

at FEMSTATE doses.

Known Considerations

Long-term use of metformin, proton pump inhibitors, or certain gastrointestinal disorders may reduce vitamin B12 absorption and increase the likelihood of deficiency, making adequate intake particularly important in these populations.

10. Regulatory Status

Vitamin B12 is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an essential nutrient.
• Widely accepted for use in dietary supplements.
• Included in international nutritional recommendations.

11. Evidence Gaps & Future Research

Current evidence strongly supports vitamin B12 for:

• erythropoiesis
• neurological physiology
• methylation
• DNA synthesis

Areas requiring further investigation include:

• Phase-specific vitamin B12 metabolism throughout the menstrual cycle.
• Vitamin B12 requirements during regenerative versus anabolic physiology.
• Clinical evaluation of methylcobalamin within comprehensive phase-aligned nutritional systems.

No randomized controlled trials have specifically evaluated methylcobalamin within a phase-aligned formulation such as FEMSTATE™.

12. Conclusion

Vitamin B12, provided as methylcobalamin, is a foundational nutrient within the FEMSTATE™ platform because of its established roles in DNA synthesis, methylation, erythropoiesis, mitochondrial metabolism, and neurological physiology. The selected dose of 150 mcg/day provides robust physiological exposure while maintaining an excellent safety profile. Its inclusion in RESET™ and LIFT™ reflects the biological priorities of tissue regeneration, cellular proliferation, and anabolic metabolism that characterize these phases. The dose was selected using a structured framework integrating physiological relevance, human clinical evidence, safety, formulation compatibility, and HR+ considerations, making vitamin B12 a key contributor to the regenerative and growth-oriented physiology of the FEMSTATE™ platform.

References

• National Institutes of Health Office of Dietary Supplements. Vitamin B12 Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on vitamin B12 physiology and human metabolism.
• Nutrients. Systematic reviews on vitamin B12, methylation, and neurological function.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on micronutrients, endocrine physiology, and women's health.
• Endocrine Society. Clinical guidance on vitamin B12 deficiency and endocrine health.

Ingredient Scientific Monograph

Folate (L-5-Methyltetrahydrofolate Calcium)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Folate

Chemical Name: L-5-Methyltetrahydrofolate Calcium (L-5-MTHF)

Ingredient Form: L-5-Methyltetrahydrofolate Calcium (Active Folate)

FEMSTATE™ Daily Dose

Folate is included in RESET™ and LIFT™ because these phases are characterized by cellular regeneration, DNA synthesis, tissue growth, endometrial repair, and cellular proliferation. The active form, L-5-MTHF, was intentionally selected instead of folic acid because it is the biologically active circulating form of folate and bypasses the methylenetetrahydrofolate reductase (MTHFR) enzymatic conversion step.

2. Physiological Role

Folate is an essential water-soluble B vitamin that participates in one-carbon metabolism, a network of biochemical reactions responsible for DNA synthesis, RNA synthesis, methylation, amino acid metabolism, and cellular replication. Folate is particularly important in rapidly dividing tissues, including the endometrium, bone marrow, gastrointestinal epithelium, and developing ovarian follicles.(1-4)

The active form, L-5-MTHF, contributes to:

• DNA synthesis
• Cell division
• Methylation reactions
• Red blood cell production
• Homocysteine metabolism
• Neural tissue physiology
• Endometrial regeneration

These physiological functions are especially relevant during the regenerative (RESET™) and anabolic (LIFT™) phases of the menstrual cycle.

3. Mechanism of Action

L-5-MTHF functions as the biologically active methyl donor within one-carbon metabolism.

DNA Synthesis

Folate provides one-carbon units required for:

• purine synthesis
• thymidine synthesis
• DNA replication
• cellular proliferation

These mechanisms support:

• endometrial regeneration
• tissue repair
• follicular development

Methylation

L-5-MTHF donates methyl groups for conversion of homocysteine to methionine.

This pathway supports:

• gene regulation
• neurotransmitter synthesis
• phospholipid production
• epigenetic regulation

This reaction requires adequate vitamin B12, making these nutrients physiologically interdependent.

Erythropoiesis

Folate supports:

• red blood cell production
• bone marrow function
• normal cell maturation

This function is particularly relevant following menstrual blood loss.

4. Why Included in FEMSTATE™

RESET™

During menstruation, the body emphasizes:

• tissue regeneration
• endometrial repair
• cellular replacement
• restoration of homeostasis

Folate supports these processes through DNA synthesis, cell division, and red blood cell production.

LIFT™

The follicular phase emphasizes:

• follicular growth
• cellular proliferation
• anabolic physiology
• endometrial regeneration

L-5-MTHF supports these physiological priorities through its central role in one-carbon metabolism and DNA synthesis.

5. Dose Justification

Selected Dose: 340 mcg Dietary Folate Equivalents (DFE)

The selected dose was based on five scientific criteria.

Physiological Relevance

A dose of 340 mcg DFE provides approximately 85% of the Daily Value, supplying meaningful physiological support while complementing dietary folate intake.

This dose supports:

• DNA synthesis
• cellular regeneration
• methylation
• erythropoiesis

without approaching excessive intake.

Human Clinical Evidence

Human intervention studies consistently demonstrate that folate supports normal:

• methylation
• homocysteine metabolism
• red blood cell production
• cellular replication

The selected dose aligns with nutritional recommendations while contributing to long-term maintenance of folate status.

Safety

The active L-5-MTHF form has an excellent safety profile at nutritional doses.

Unlike folic acid, L-5-MTHF does not produce unmetabolized folic acid in circulation and may offer theoretical metabolic advantages in individuals with reduced MTHFR activity, although clinical superiority has not been definitively established for all outcomes.

Formulation Compatibility

The selected dose:

• complements methylcobalamin
• supports one-carbon metabolism
• supports tissue regeneration
• supports cellular proliferation

HR+ Philosophy

L-5-MTHF demonstrates no known estrogenic activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Folate has been extensively studied in human nutrition.

Strong evidence supports its role in:

• DNA synthesis
• prevention of folate deficiency
• homocysteine metabolism
• erythropoiesis
• fetal neural tube development (outside the scope of FEMSTATE)

The evidence supporting folate's biochemical functions is among the strongest in nutritional science.

7. Safety Considerations

Folate demonstrates an excellent safety profile at nutritional doses.

Recommended Dietary Allowance (Women): 400 mcg DFE/day

FEMSTATE Dose: 340 mcg DFE/day

Tolerable Upper Intake Level

The adult UL of 1,000 mcg/day applies to synthetic folic acid, not naturally occurring food folate or active L-5-MTHF. Current evidence suggests L-5-MTHF has a favorable safety profile, but total folate intake should still be considered.(2)

Potential consideration:

High folic acid intake may mask vitamin B12 deficiency.

This concern is minimized through concurrent inclusion of methylcobalamin within FEMSTATE.

8. HR+ Safety Review

L-5-MTHF was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

L-5-MTHF is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin B12 (Methylcobalamin)

Essential partner in one-carbon metabolism -> Strong physiological synergy

Vitamin B6

Supports complementary methylation pathways -> Positive synergy

Iron

Supports coordinated erythropoiesis -> Positive physiological interaction

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Vitamin C
• Magnesium
• Zinc

at FEMSTATE doses.

Known Considerations

Adequate vitamin B12 status should accompany folate supplementation to prevent masking of vitamin B12 deficiency, a consideration addressed by the inclusion of methylcobalamin in FEMSTATE™.

10. Regulatory Status

L-5-MTHF is:

• Recognized for use in dietary supplements.
• Considered a bioactive form of folate.
• Included in dietary reference recommendations through Dietary Folate Equivalents (DFE).
• Supported by international nutrition guidelines.

11. Evidence Gaps & Future Research

Current evidence strongly supports folate for:

• DNA synthesis
• methylation
• erythropoiesis
• one-carbon metabolism

Areas requiring further investigation include:

• Phase-specific folate metabolism throughout the menstrual cycle.
• Comparative evaluation of L-5-MTHF versus folic acid within phase-aligned nutritional systems.
• Clinical evaluation of L-5-MTHF within the complete FEMSTATE™ formulation.

No randomized controlled trials have specifically evaluated active folate within a phase-aligned nutritional platform.

13. Conclusion

Folate, provided as L-5-Methyltetrahydrofolate (L-5-MTHF), is a core regenerative nutrient within the FEMSTATE™ platform because of its established roles in DNA synthesis, cellular proliferation, methylation, erythropoiesis, and tissue regeneration. The selected dose of 340 mcg DFE provides meaningful physiological support while complementing dietary intake and remaining within established nutritional recommendations. The active L-5-MTHF form was intentionally selected to provide the biologically active form of folate and avoid reliance on metabolic activation. Within FEMSTATE™, folate supports the regenerative priorities of RESET™ and the anabolic physiology of LIFT™, contributing to normal cellular renewal without directly modifying reproductive hormone physiology.

References

• National Institutes of Health Office of Dietary Supplements. Folate Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on folate physiology and one-carbon metabolism.
• Nutrients. Systematic reviews on folate, methylation, and human health.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on micronutrients, reproductive physiology, and cellular metabolism.

Ingredient Scientific Monograph

Pantothenic Acid (Vitamin B5)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Pantothenic Acid

Chemical Name: Pantothenic Acid

Ingredient Form: Calcium D-Pantothenate

FEMSTATE™ Daily Dose

Pantothenic acid is included in RESET™ and LIFT™ because of its central role in cellular energy production, coenzyme A (CoA) synthesis, fatty acid metabolism, steroid hormone synthesis, and tissue regeneration. As a precursor to coenzyme A, vitamin B5 is essential for virtually every cell in the body and supports the regenerative and anabolic physiology characteristic of the menstrual and follicular phases.

2. Physiological Role

Pantothenic acid is an essential water-soluble B vitamin required for the synthesis of coenzyme A (CoA) and acyl carrier protein (ACP), two molecules fundamental to cellular metabolism. Coenzyme A participates in hundreds of biochemical reactions involving carbohydrate metabolism, lipid metabolism, amino acid metabolism, mitochondrial ATP production, and steroidogenesis.(1-4)

Pantothenic acid contributes to:

• Coenzyme A synthesis
• Cellular energy production
• Fatty acid metabolism
• Cholesterol metabolism
• Steroid hormone synthesis
• Acetylcholine synthesis
• Cellular repair
• Mitochondrial metabolism

Because these metabolic pathways are continuously active but particularly important during tissue regeneration and anabolic growth, pantothenic acid provides foundational metabolic support within FEMSTATE™.

3. Mechanism of Action

Pantothenic acid functions primarily through formation of coenzyme A.

Coenzyme A Synthesis

Pantothenic acid is an obligatory precursor of CoA.

CoA is required for:

• Acetyl-CoA formation
• Citric acid (Krebs) cycle
• Fatty acid oxidation
• Fatty acid synthesis
• ATP production

Without adequate pantothenic acid, efficient cellular energy metabolism cannot occur.

Steroid Hormone Synthesis

Coenzyme A participates in:

Cholesterol -> Pregnenolone -> Steroid hormone synthesis

Although pantothenic acid supports the biochemical pathways involved in steroidogenesis, it does not increase reproductive hormone production under normal physiological conditions.

Cellular Energy Metabolism

Pantothenic acid contributes to:

• glucose metabolism
• lipid metabolism
• mitochondrial ATP production
• cellular repair

These pathways become particularly relevant during regenerative and anabolic physiology.

Acetylcholine Synthesis

Acetyl-CoA generated through pantothenic acid metabolism also contributes to:

• acetylcholine production
• neuronal physiology
• neuromuscular signaling

4. Why Included in FEMSTATE™

RESET™

The menstrual phase emphasizes:

• tissue repair
• cellular regeneration
• mitochondrial recovery
• restoration of homeostasis

Pantothenic acid supports these physiological processes through its central role in CoA synthesis and cellular energy metabolism.

LIFT™

The follicular phase emphasizes:

• anabolic metabolism
• protein synthesis
• follicular growth
• mitochondrial activation

Pantothenic acid supports these biological priorities by facilitating ATP production and biosynthetic metabolism.

5. Dose Justification

Selected Dose: 5 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A daily dose of 5 mg corresponds to the Adequate Intake (AI) established for healthy adults and supports normal coenzyme A synthesis and cellular metabolism.

Human Clinical Evidence

Pantothenic acid deficiency is rare, and most research has focused on prevention of deficiency rather than supraphysiological supplementation. Current evidence indicates that meeting recommended intake supports normal energy metabolism and cellular physiology.

Safety

Pantothenic acid demonstrates an excellent safety profile.

No tolerable upper intake level has been established because toxicity has not been demonstrated at nutritional doses.

Formulation Compatibility

The selected dose:

• complements the B-complex
• supports mitochondrial metabolism
• supports energy production
• maintains physiological nutrient balance

HR+ Philosophy

Pantothenic acid demonstrates no known endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Pantothenic acid has been extensively characterized biochemically, although fewer clinical supplementation studies exist compared with other B vitamins.

Strong evidence supports its role in:

• coenzyme A synthesis
• energy metabolism
• fatty acid metabolism
• cellular physiology

Clinical evidence supporting benefits beyond correction of deficiency remains limited.

7. Safety Considerations

Pantothenic acid possesses an excellent safety profile.

Adequate Intake (Women): 5 mg/day

FEMSTATE Dose: 5 mg/day

Tolerable Upper Intake Level

No UL has been established because adverse effects have not been demonstrated at nutritional intakes.(2)

Very high supplemental doses may occasionally produce:

• mild gastrointestinal discomfort
• diarrhea (rare)

These effects occur at doses substantially exceeding those used in FEMSTATE™.

8. HR+ Safety Review

Pantothenic acid was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Pantothenic acid is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Thiamin (Vitamin B1)

Supports complementary carbohydrate metabolism -> Positive synergy

Riboflavin (Vitamin B2)

Supports oxidative energy metabolism -> Positive synergy

Niacin (Vitamin B3)

Works together in mitochondrial energy production -> Positive synergy

Magnesium

Supports numerous ATP-dependent enzymatic reactions involving CoA -> Strong physiological synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Vitamin D3
• Zinc
• Selenium

at FEMSTATE doses.

Known Considerations

No clinically significant nutrient interactions have been reported at nutritional doses.

10. Regulatory Status

Pantothenic acid is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an essential nutrient.
• Widely accepted for use in dietary supplements.
• Included in international nutritional recommendations.

11. Evidence Gaps & Future Research

Current evidence strongly supports pantothenic acid for:

• coenzyme A synthesis
• cellular energy metabolism
• fatty acid metabolism

Areas requiring further investigation include:

• Phase-specific coenzyme A metabolism during the menstrual cycle.
• Cellular energy requirements during regenerative versus anabolic physiology.
• Clinical evaluation of pantothenic acid within phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated pantothenic acid within a phase-aligned nutritional formulation.

12. Conclusion

Pantothenic acid, provided as calcium D-pantothenate, is a foundational metabolic nutrient within the FEMSTATE™ platform because of its essential role in coenzyme A synthesis, mitochondrial energy production, fatty acid metabolism, and cellular physiology. The selected dose of 5 mg/day aligns with the adult Adequate Intake and provides physiological support for the regenerative biology of RESET™ and the anabolic physiology of LIFT™. Rather than directly influencing reproductive hormones, pantothenic acid supports the metabolic infrastructure required for tissue repair, cellular growth, and energy production, making it an important component of the phase-aligned nutritional strategy.

References

• National Institutes of Health Office of Dietary Supplements. Pantothenic Acid Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on pantothenic acid and coenzyme A metabolism.
• Nutrients. Reviews on B vitamins and cellular metabolism.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on mitochondrial metabolism and endocrine physiology.

Ingredient Scientific Monograph

Thiamin (Vitamin B1)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Thiamin

Chemical Name: Vitamin B1

Ingredient Form: Thiamin Hydrochloride (Thiamin HCl)

FEMSTATE™ Daily Dose

Thiamin is included in RESET™ and LIFT™ because of its essential role in cellular energy metabolism, mitochondrial ATP production, carbohydrate utilization, and nervous system physiology. During the regenerative and anabolic phases of the menstrual cycle, efficient energy production is fundamental to tissue repair, cellular proliferation, and restoration of physiological homeostasis.

2. Physiological Role

Thiamin is an essential water-soluble B vitamin that functions as thiamin pyrophosphate (TPP), a coenzyme required for multiple enzymatic reactions involved in carbohydrate metabolism and mitochondrial energy production. Because humans cannot synthesize thiamin, adequate intake is required to support normal cellular metabolism.(1-4)

Thiamin contributes to:

• ATP production
• Carbohydrate metabolism
• Krebs (citric acid) cycle activity
• Pentose phosphate pathway
• Nervous system function
• Cardiac physiology
• Cellular energy homeostasis

These physiological functions are particularly relevant during the menstrual phase, when tissue regeneration requires substantial cellular energy, and during the follicular phase, when anabolic metabolism accelerates.

3. Mechanism of Action

Thiamin functions primarily through its active coenzyme form, thiamin pyrophosphate (TPP).

Mitochondrial Energy Production

TPP serves as a cofactor for:

• Pyruvate dehydrogenase
• α-Ketoglutarate dehydrogenase
• Branched-chain α-ketoacid dehydrogenase

These enzymes regulate:

Glucose -> Pyruvate -> Acetyl-CoA -> Citric Acid Cycle -> ATP Production

Consequently, thiamin is essential for efficient cellular energy production.

Carbohydrate Metabolism

Thiamin supports:

• glucose utilization
• oxidative metabolism
• ATP generation

This role is particularly important in tissues with high metabolic demand.

Nervous System Function

Thiamin contributes to:

• neuronal energy metabolism
• neurotransmission
• maintenance of normal nerve function

Because the nervous system depends heavily on glucose metabolism, adequate thiamin is critical for normal neurological physiology.

Pentose Phosphate Pathway

TPP is also required for transketolase, an enzyme involved in:

• nucleotide synthesis
• NADPH production
• antioxidant defense

This pathway supports tissue regeneration and cellular proliferation.

4. Why Included in FEMSTATE™

RESET™

During the menstrual phase, biological priorities include:

• tissue repair
• endometrial regeneration
• cellular recovery
• restoration of homeostasis

These regenerative processes require efficient ATP production.

Thiamin supports this physiology by facilitating carbohydrate metabolism and mitochondrial energy production.

LIFT™

During the follicular phase, anabolic physiology increases demand for:

• ATP
• cellular biosynthesis
• protein synthesis
• mitochondrial metabolism

Thiamin supports these processes by ensuring efficient conversion of glucose into cellular energy.

5. Dose Justification

Selected Dose: 5 mg

The selected dose was based on five scientific criteria.

Physiological Relevance

The dose provides approximately 400% of the Daily Value, ensuring sufficient availability of thiamin for mitochondrial energy metabolism during periods of increased physiological demand while remaining well within recognized safety margins.

Human Clinical Evidence

Clinical research consistently demonstrates that adequate thiamin is essential for:

• carbohydrate metabolism
• mitochondrial function
• neurological physiology

Although deficiency is uncommon in healthy populations, maintaining adequate thiamin status is essential for normal energy metabolism.

Safety

Thiamin has an excellent safety profile.

Because excess thiamin is readily excreted in urine, toxicity from oral supplementation has not been demonstrated at nutritional doses.

Formulation Compatibility

The selected dose:

• complements riboflavin
• complements niacin
• complements pantothenic acid
• supports mitochondrial physiology
• supports carbohydrate metabolism

HR+ Philosophy

Thiamin demonstrates no known endocrine activity and aligns fully with the FEMSTATE™ HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Thiamin has been extensively studied in relation to:

• energy metabolism
• neurological physiology
• cardiovascular function
• prevention of thiamin deficiency

Its biochemical role in ATP production is firmly established.

7. Safety Considerations

Thiamin possesses one of the strongest safety profiles among vitamins.

Recommended Dietary Allowance (Women): 1.1 mg/day

FEMSTATE Dose: 5 mg/day

Tolerable Upper Intake Level

No UL has been established because no adverse effects have been consistently associated with oral thiamin supplementation.(2)

Excess thiamin is rapidly eliminated through urinary excretion.

8. HR+ Safety Review

Thiamin was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Thiamin is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Riboflavin (Vitamin B2)

Supports complementary mitochondrial energy production -> Strong synergy

Niacin (Vitamin B3)

Supports oxidative metabolism through NAD/NADP pathways -> Positive synergy

Pantothenic Acid (Vitamin B5)

Supports Coenzyme A synthesis and ATP production -> Strong metabolic synergy

Magnesium

Magnesium is required for activation of thiamin into thiamin pyrophosphate -> Strong physiological synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Vitamin D3
• Zinc
• Selenium

at FEMSTATE doses.

Known Considerations

No clinically significant nutrient interactions have been reported at nutritional doses.

10. Regulatory Status

Thiamin is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an essential nutrient.
• Widely accepted for use in dietary supplements.
• Included in international nutritional recommendations.

11. Evidence Gaps & Future Research

Current evidence strongly supports thiamin for:

• mitochondrial energy production
• carbohydrate metabolism
• neurological physiology

Areas requiring further investigation include:

• Phase-specific thiamin utilization throughout the menstrual cycle.
• Mitochondrial metabolism during regenerative and anabolic physiology.
• Clinical evaluation of thiamin within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated thiamin within a phase-aligned nutritional formulation.

12. Conclusion

Thiamin (Vitamin B1), provided as thiamin hydrochloride, is a foundational metabolic nutrient within the FEMSTATE™ platform because of its indispensable role in mitochondrial ATP production, carbohydrate metabolism, and nervous system physiology. The selected dose of 5 mg/day provides robust physiological support while remaining well within established safety margins. Its inclusion in RESET™ and LIFT™ reflects the increased metabolic demands associated with tissue regeneration and anabolic growth. Rather than directly influencing endocrine function, thiamin supports the cellular energy systems that enable the regenerative and biosynthetic processes characteristic of these phases, making it a critical component of the phase-aligned nutritional strategy.

References

• National Institutes of Health Office of Dietary Supplements. Thiamin Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• Guyton and Hall Textbook of Medical Physiology.
• The American Journal of Clinical Nutrition. Reviews on thiamin metabolism and human physiology.
• Nutrients. Reviews on B vitamins, mitochondrial metabolism, and energy production.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on metabolism and women's physiology.

Ingredient Scientific Monograph

Riboflavin (Vitamin B2)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Riboflavin

Chemical Name: Vitamin B2

Ingredient Form: Riboflavin

FEMSTATE™ Daily Dose

Riboflavin is included in RESET™ and LIFT™ because of its essential role in mitochondrial energy production, oxidative metabolism, antioxidant defense, and cellular regeneration. As a precursor to flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), riboflavin is indispensable for ATP production and numerous oxidation-reduction reactions that support tissue repair and anabolic metabolism.

2. Physiological Role

Riboflavin is an essential water-soluble B vitamin that functions as the precursor of the coenzymes flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN). These flavin coenzymes participate in hundreds of enzymatic reactions involved in mitochondrial respiration, cellular energy production, fatty acid oxidation, antioxidant defense, and metabolism of other vitamins.(1-4)

Riboflavin contributes to:

• Mitochondrial ATP production
• Electron transport chain function
• Fatty acid oxidation
• Antioxidant enzyme activity
• Cellular growth
• Tissue repair
• Iron metabolism
• Conversion of vitamin B6 to its active form (P5P)

These physiological functions are particularly relevant during the regenerative biology of RESET™ and the anabolic physiology of LIFT™.

3. Mechanism of Action

Riboflavin functions through its active coenzymes FAD and FMN.

Mitochondrial Energy Production

FAD and FMN participate directly in:

• Electron Transport Chain Complex I
• Electron Transport Chain Complex II
• Oxidative phosphorylation
• ATP synthesis

These pathways generate the majority of cellular ATP.

Cellular Oxidation–Reduction

Riboflavin supports:

• electron transfer
• oxidative metabolism
• mitochondrial respiration
• fatty acid metabolism

Antioxidant Physiology

FAD is required for:

• glutathione reductase activity
• regeneration of reduced glutathione (GSH)
• maintenance of endogenous antioxidant systems

This mechanism supports normal redox homeostasis during tissue regeneration and anabolic growth.

Vitamin Metabolism

Riboflavin contributes to activation of several other vitamins including:

• Vitamin B6 (P5P)
• Folate metabolism
• Niacin synthesis from tryptophan

Thus, riboflavin supports the integrated function of the B-complex.

4. Why Included in FEMSTATE™

RESET™

During the menstrual phase, tissue repair requires:

• ATP production
• antioxidant regulation
• iron metabolism
• cellular regeneration

Riboflavin supports these physiological priorities through mitochondrial energy production and maintenance of endogenous antioxidant systems.

LIFT™

The follicular phase emphasizes:

• anabolic metabolism
• cellular proliferation
• mitochondrial activation
• connective tissue growth

Riboflavin supports these biological priorities through its central role in oxidative phosphorylation and biosynthetic metabolism.

5. Dose Justification

Selected Dose: 5 mg

The selected dose was based on five scientific criteria.

Physiological Relevance

A dose of 5 mg provides approximately 385% of the Daily Value, ensuring adequate flavin coenzyme availability during periods of increased metabolic activity while remaining within a conservative nutritional range.

Human Clinical Evidence

Human studies consistently demonstrate that riboflavin is essential for:

• mitochondrial energy metabolism
• prevention of riboflavin deficiency
• maintenance of glutathione metabolism
• support of normal cellular physiology

Although most research focuses on deficiency prevention, adequate riboflavin intake is fundamental for optimal mitochondrial function.

Safety

Riboflavin demonstrates an excellent safety profile.

Because absorption is regulated and excess riboflavin is readily excreted in urine, toxicity has not been demonstrated from oral supplementation.

Formulation Compatibility

The selected dose:

• complements thiamin
• complements niacin
• complements pantothenic acid
• supports vitamin B6 activation
• supports mitochondrial physiology

HR+ Philosophy

Riboflavin demonstrates no known endocrine activity and aligns fully with the FEMSTATE™ HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Riboflavin has been extensively studied in relation to:

• mitochondrial metabolism
• energy production
• antioxidant physiology
• neurological health
• prevention of riboflavin deficiency

Strong evidence supports its biochemical role in flavoprotein-dependent metabolism.

7. Safety Considerations

Riboflavin possesses an excellent safety profile.

Recommended Dietary Allowance (Women): 1.1 mg/day

FEMSTATE Dose: 5 mg/day

Tolerable Upper Intake Level

No UL has been established because no adverse effects have been consistently associated with oral riboflavin supplementation.(2)

The most common observation following supplementation is:

• bright yellow urine due to excretion of excess riboflavin

This effect is harmless and reflects normal physiological elimination.

8. HR+ Safety Review

Riboflavin was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Riboflavin is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Thiamin (Vitamin B1)

Supports complementary mitochondrial ATP production -> Strong metabolic synergy

Niacin (Vitamin B3)

Works together in oxidative metabolism through NAD/FAD-dependent pathways -> Strong synergy

Vitamin B6

Riboflavin is required for conversion of vitamin B6 into its active coenzyme form (P5P) -> Strong physiological synergy

Glutathione System

Supports glutathione reductase activity and endogenous antioxidant defenses -> Positive antioxidant synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Vitamin D3
• Magnesium
• Zinc

at FEMSTATE doses.

Known Considerations

No clinically significant nutrient interactions have been identified at nutritional doses.

10. Regulatory Status

Riboflavin is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an essential nutrient.
• Widely accepted for use in dietary supplements.
• Included in international nutritional recommendations.

11. Evidence Gaps & Future Research

Current evidence strongly supports riboflavin for:

• mitochondrial ATP production
• flavoprotein metabolism
• antioxidant physiology
• cellular energy production

Areas requiring further investigation include:

• Phase-specific riboflavin utilization throughout the menstrual cycle.
• Mitochondrial flavoprotein activity during regenerative and anabolic physiology.
• Clinical evaluation of riboflavin within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated riboflavin within a phase-aligned nutritional formulationOverall Scientific Confidence

12. Conclusion

Riboflavin (Vitamin B2) is a foundational metabolic nutrient within the FEMSTATE™ platform because of its indispensable role in mitochondrial respiration, ATP production, antioxidant defense, and cellular metabolism. The selected dose of 5 mg/day provides robust physiological support while remaining well within established safety parameters. Its inclusion in RESET™ and LIFT™ reflects the increased metabolic demands associated with tissue regeneration and anabolic growth. Through its roles in flavoprotein metabolism, activation of vitamin B6, and maintenance of glutathione physiology, riboflavin supports the energetic foundation required for the regenerative and biosynthetic priorities of these menstrual phases without directly influencing reproductive hormone physiology.

References

• National Institutes of Health Office of Dietary Supplements. Riboflavin Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• Guyton and Hall Textbook of Medical Physiology.
• The American Journal of Clinical Nutrition. Reviews on riboflavin metabolism and human physiology.
• Nutrients. Systematic reviews on riboflavin, flavoproteins, and mitochondrial metabolism.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on metabolism, oxidative physiology, and women's health.

Ingredient Scientific Monograph

Niacin (Vitamin B3)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Niacin

Chemical Name: Vitamin B3

Ingredient Forms:

• Niacin (Nicotinic Acid) - RESET™ and LIFT™
• Niacinamide (Nicotinamide) - SOOTHE™

FEMSTATE™ Daily Dose

FEMSTATE™ intentionally uses two different forms of vitamin B3 because they serve different physiological purposes. Small nutritional doses of niacin provide foundational support for mitochondrial metabolism and cellular energy production during the regenerative and anabolic phases, whereas niacinamide was selected for SOOTHE™ because it supports cellular metabolism without causing the vasodilatory "niacin flush" associated with nicotinic acid.

2. Physiological Role

Vitamin B3 is an essential water-soluble vitamin required for synthesis of nicotinamide adenine dinucleotide (NAD⁺) and nicotinamide adenine dinucleotide phosphate (NADP⁺), two of the most important coenzymes in human metabolism. NAD⁺ and NADP⁺ participate in hundreds of oxidation-reduction reactions regulating mitochondrial ATP production, carbohydrate metabolism, lipid metabolism, DNA repair, antioxidant defense, and cellular signaling.(1-4)

Vitamin B3 contributes to:

• Mitochondrial ATP production
• Oxidative phosphorylation
• Glucose metabolism
• Lipid metabolism
• DNA repair
• Cellular resilience
• Antioxidant systems
• Nervous system physiology

These functions are fundamental throughout the menstrual cycle and become particularly relevant during tissue regeneration (RESET™), anabolic metabolism (LIFT™), and neuroendocrine stabilization (SOOTHE™).

3. Mechanism of Action

Vitamin B3 functions primarily through formation of NAD⁺ and NADP⁺.

Cellular Energy Production

NAD⁺ participates in:

• Glycolysis
• Citric acid cycle
• Electron transport chain
• ATP production

These pathways are essential for efficient mitochondrial function.

Cellular Repair

NAD⁺ serves as a substrate for:

• PARP enzymes involved in DNA repair
• Sirtuins involved in cellular stress responses
• Multiple signaling pathways regulating cellular homeostasis

Antioxidant Physiology

NADPH participates in:

• glutathione regeneration
• reductive biosynthesis
• maintenance of cellular redox balance

Nervous System Function

Vitamin B3 contributes to:

• neuronal metabolism
• neurotransmitter physiology
• maintenance of cellular energy within the central nervous system

4. Why Included in FEMSTATE™

RESET™

During the menstrual phase:

• tissue repair
• mitochondrial recovery
• DNA repair
• cellular regeneration

require efficient NAD⁺-dependent metabolism.

A nutritional dose of niacin supports these physiological priorities.

LIFT™

The follicular phase emphasizes:

• anabolic metabolism
• cellular proliferation
• mitochondrial activation
• ATP production

Niacin supports these biological processes through its central role in oxidative metabolism.

SOOTHE™

The luteal phase emphasizes:

• neuroendocrine regulation
• cellular maintenance
• metabolic stability
• DNA repair

Niacinamide was selected because it supports NAD⁺ metabolism while avoiding the vasodilatory flushing effects of nicotinic acid, making it more appropriate for daily use at the higher dose included in SOOTHE™.

5. Dose Justification

RESET™ and LIFT™

Selected Dose: 5 mg Niacin Equivalents (NE)

Scientific Rationale

The selected dose:

• complements dietary intake
• supports mitochondrial metabolism
• contributes to NAD⁺ synthesis
• maintains nutritional balance within the B-complex

This dose emphasizes physiological support rather than pharmacological effects.

SOOTHE™

Selected Dose: 100 mg Niacinamide

Scientific Rationale

Niacinamide was selected because:

• it contributes directly to NAD⁺ metabolism
• it supports cellular energy production
• it avoids prostaglandin-mediated flushing
• it supports long-term daily tolerability

The dose remains well below levels commonly associated with clinically significant adverse effects while providing greater physiological exposure than nutritional maintenance doses.

6. Human Clinical Evidence

Vitamin B3 has been extensively studied in relation to:

• NAD⁺ metabolism
• energy production
• lipid metabolism
• cellular repair
• neurological physiology

Strong evidence supports its biochemical functions, while therapeutic benefits at pharmacological doses depend upon the clinical indication.

7. Safety Considerations

Vitamin B3 safety depends upon the chemical form.

Recommended Dietary Allowance (Women): 14 mg NE/day

FEMSTATE Doses

RESET™: 5 mg NE

LIFT™: 5 mg NE

SOOTHE™: 100 mg Niacinamide

Safety Profile

The low nutritional doses of niacin included in RESET™ and LIFT™ are not expected to produce flushing.

Niacinamide does not typically produce flushing because it does not activate the same prostaglandin-mediated pathway as nicotinic acid.

Potential adverse effects associated with very high intakes include:

• gastrointestinal discomfort
• liver toxicity (primarily pharmacological doses)
• insulin resistance at pharmacological doses

These effects occur at doses substantially higher than those used in FEMSTATE™.

8. HR+ Safety Review

Vitamin B3 was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Vitamin B3 is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Thiamin (Vitamin B1)

Supports complementary carbohydrate metabolism -> Strong metabolic synergy

Riboflavin (Vitamin B2)

Supports oxidative phosphorylation through FAD/NAD pathways -> Strong synergy

Pantothenic Acid (Vitamin B5)

Supports Coenzyme A synthesis and ATP production -> Strong metabolic synergy

Magnesium

Supports ATP-dependent reactions involving NAD⁺ -> Positive physiological synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Vitamin D3
• Zinc
• Selenium

at FEMSTATE doses.

Known Considerations

Individuals with severe liver disease should avoid high-dose pharmacological niacin without medical supervision. The doses used in FEMSTATE™ remain nutritional to moderate and are not intended for lipid-lowering therapy.

10. Regulatory Status

Vitamin B3 is:

• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an essential nutrient.
• Widely accepted for use in dietary supplements.
• Included in international nutritional recommendations.

11. Evidence Gaps & Future Research

Current evidence strongly supports vitamin B3 for:

• NAD⁺ metabolism
• mitochondrial physiology
• cellular energy production
• DNA repair

Areas requiring additional investigation include:

• Phase-specific NAD⁺ metabolism across the menstrual cycle.
• Neuroendocrine physiology during the luteal phase.
• Clinical evaluation of niacinamide within comprehensive phase-aligned nutritional systems.

No randomized controlled trials have specifically evaluated vitamin B3 within a phase-aligned formulation such as FEMSTATE™.

12. Conclusion

Vitamin B3 was strategically incorporated into the FEMSTATE™ platform using two complementary forms to match the physiological priorities of different menstrual phases. Low-dose niacin in RESET™ and LIFT™ provides foundational support for mitochondrial ATP production and anabolic metabolism, while niacinamide in SOOTHE™ supports NAD⁺-dependent cellular maintenance and neuroendocrine physiology without the flushing associated with nicotinic acid. This differentiated approach reflects the FEMSTATE™ philosophy of aligning nutrient form as well as dose with changing biological priorities throughout the menstrual cycle. Rather than targeting endocrine function directly, vitamin B3 supports the cellular energy systems that underpin tissue regeneration, anabolic growth, and physiological recovery.

References

• National Institutes of Health Office of Dietary Supplements. Niacin Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on niacin, NAD⁺ metabolism, and human physiology.
• Cell Metabolism. Reviews on NAD⁺ biology, cellular metabolism, and mitochondrial function.
• Nutrients. Systematic reviews on niacin, nicotinamide, and human health.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on metabolism, endocrine physiology, and women's health.

Ingredient Scientific Monograph

Magnesium (as Magnesium Glycinate)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Magnesium

Chemical Name: Magnesium Bisglycinate Chelate (Magnesium Glycinate)

Ingredient Form: Magnesium Glycinate

FEMSTATE™ Daily Dose

Magnesium glycinate was specifically selected for RESET™ because this phase emphasizes cellular regeneration, mitochondrial recovery, muscle relaxation, tissue repair, and restoration of physiological homeostasis. Glycinate was chosen over other magnesium salts because of its high bioavailability, excellent gastrointestinal tolerability, and minimal laxative effect, making it particularly appropriate during menstruation.

2. Physiological Role

Magnesium is the second most abundant intracellular cation and functions as an essential cofactor in more than 600 enzymatic reactions. It is indispensable for ATP production, protein synthesis, DNA repair, RNA transcription, muscle contraction, nerve conduction, glucose metabolism, and maintenance of cellular homeostasis.(1-4)

Magnesium contributes to:

• ATP production
• Mitochondrial function
• Protein synthesis
• DNA repair
• Muscle physiology
• Neuromuscular signaling
• Electrolyte balance
• Bone physiology
• Cellular stress responses

These physiological functions are particularly relevant during the regenerative biology of the menstrual phase.

3. Mechanism of Action

Magnesium exerts its physiological effects through multiple interconnected biochemical pathways.

ATP Production

Over 90% of intracellular ATP exists as Mg-ATP, meaning magnesium is required for virtually all ATP-dependent cellular reactions.

Magnesium supports:

Glucose -> ATP -> Cellular energy -> Tissue repair

Protein Synthesis

Magnesium is required for:

• ribosomal function
• translation
• protein assembly
• tissue regeneration

DNA Repair

Magnesium functions as a cofactor for enzymes involved in:

• DNA replication
• DNA repair
• RNA synthesis

These pathways are particularly active during tissue regeneration.

Muscle and Nervous System Physiology

Magnesium regulates:

• calcium transport
• neuromuscular signaling
• muscle relaxation
• membrane stability

This contributes to normal muscle physiology and cellular homeostasis.

4. Why Included in FEMSTATE™

RESET™

During the menstrual phase, biological priorities include:

• tissue repair
• mitochondrial recovery
• protein synthesis
• restoration of cellular homeostasis
• muscle physiology
• connective tissue regeneration

Magnesium glycinate supports these physiological processes through its central role in ATP production, enzymatic activity, and protein synthesis.

Unlike magnesium citrate, glycinate provides excellent absorption with minimal gastrointestinal effects, an important consideration during menstruation.

5. Dose Justification

Selected Dose: 250 mg elemental magnesium

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 250 mg elemental magnesium provides meaningful physiological support for ATP production, protein synthesis, mitochondrial metabolism, and cellular repair while contributing substantially toward the daily requirement.

Human Clinical Evidence

Human intervention studies evaluating magnesium have commonly investigated doses ranging from 200-400 mg/day of elemental magnesium for various physiological outcomes.

The selected dose falls squarely within this clinically studied range.

Safety

The selected dose remains within ranges widely used in clinical nutrition.

Although the adult UL for supplemental magnesium is 350 mg/day, this limit is based primarily on gastrointestinal effects (particularly diarrhea) rather than systemic toxicity. Magnesium glycinate is among the most well-tolerated supplemental forms because it produces fewer gastrointestinal symptoms than magnesium oxide or citrate.²

Formulation Compatibility

Magnesium glycinate was selected because it:

• provides high bioavailability
• minimizes gastrointestinal discomfort
• complements vitamin D
• complements vitamin B6
• supports ATP production
• fits comfortably within the formulation serving size

HR+ Philosophy

Magnesium demonstrates no endocrine activity and fully aligns with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Magnesium is one of the most extensively studied minerals in clinical nutrition.

Strong evidence supports its physiological roles in:

• ATP production
• neuromuscular physiology
• energy metabolism
• glucose metabolism
• enzyme activation

Evidence specific to menstrual physiology is strongest for maintenance of normal magnesium status and general physiological support rather than for phase-specific supplementation.

7. Safety Considerations

Magnesium glycinate has an excellent safety profile.

Recommended Dietary Allowance (Women): 310-320 mg/day

FEMSTATE Dose: 250 mg elemental magnesium

Tolerable Upper Intake Level

350 mg/day from supplemental sources (does not include dietary magnesium).(2)

Potential adverse effects:

• mild gastrointestinal discomfort (uncommon with glycinate)
• diarrhea (significantly less frequent than with magnesium citrate or oxide)

Systemic toxicity is extremely uncommon in healthy individuals with normal kidney function.

8. HR+ Safety Review

Magnesium glycinate was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Magnesium glycinate is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin D3

Magnesium is required for activation and metabolism of vitamin D -> Strong physiological synergy

Vitamin B6 (P5P)

Supports complementary enzymatic reactions involved in neurotransmitter synthesis and cellular metabolism -> Strong synergy

Thiamin, Riboflavin, Niacin, Pantothenic Acid

Together support mitochondrial ATP production -> Strong metabolic synergy

Vitamin K2

Supports coordinated skeletal physiology alongside vitamin D -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Selenium
• Chromium

at FEMSTATE doses.

Known Considerations

Magnesium may reduce absorption of certain medications, including:

• tetracycline antibiotics
• fluoroquinolone antibiotics
• bisphosphonates
• levothyroxine

When applicable, supplementation should be separated by several hours.

10. Regulatory Status

Magnesium glycinate is:

• Recognized as a dietary ingredient.
• Widely used in dietary supplements.
• Supported by the National Institutes of Health Office of Dietary Supplements.
• Considered one of the most bioavailable supplemental forms of magnesium.

11. Evidence Gaps & Future Research

Current evidence strongly supports magnesium for:

• ATP production
• mitochondrial physiology
• neuromuscular function
• enzyme activation

Areas requiring further investigation include:

• Phase-specific magnesium utilization across the menstrual cycle.
• Magnesium requirements during tissue regeneration.
• Clinical evaluation of magnesium glycinate within a complete phase-aligned nutritional system such as FEMSTATE™.

No randomized controlled trials have specifically evaluated magnesium glycinate within a phase-aligned formulation.

12. Conclusion

Magnesium glycinate is a cornerstone ingredient within the RESET™ formulation because of its central role in mitochondrial ATP production, protein synthesis, DNA repair, neuromuscular physiology, and cellular regeneration. The selected dose of 250 mg elemental magnesium reflects a balance between physiological relevance, robust human evidence, excellent tolerability, and long-term safety. The glycinate form was intentionally chosen because of its superior gastrointestinal tolerance and bioavailability compared with many other magnesium salts. Within the FEMSTATE™ platform, magnesium glycinate supports the regenerative physiology of the menstrual phase by helping maintain the cellular energy systems and enzymatic processes required for tissue repair and restoration of homeostasis, without directly influencing reproductive hormone production.

References

• National Institutes of Health Office of Dietary Supplements. Magnesium Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• Guyton and Hall Textbook of Medical Physiology.
• Nutrients. Systematic reviews on magnesium bioavailability, glycinate, and human physiology.
• The American Journal of Clinical Nutrition. Reviews on magnesium and mitochondrial metabolism.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on magnesium, endocrine physiology, and women's health.

FEMSTATE™ Phase Applications

RESET™

Dose: 250 mg elemental magnesium

Scientific Rationale

The menstrual phase is characterized by tissue regeneration, extracellular matrix remodeling, ATP production, and restoration of physiological homeostasis.

The higher dose was selected to support:

• mitochondrial ATP production
• tissue regeneration
• protein synthesis
• enzymatic activity
• cellular repair

LIFT™

Dose: 200 mg elemental magnesium

Scientific Rationale

During the follicular phase, physiological priorities shift toward:

• anabolic metabolism
• cellular proliferation
• protein synthesis
• mitochondrial activation

Because LIFT™ also contains 1 g of myo-inositol, collagen, hyaluronic acid, and other metabolically active ingredients, a 200 mg elemental magnesium dose provides sufficient physiological support while allowing greater formulation space for ingredients directly supporting follicular anabolic biology.

The slightly lower dose should not be interpreted as reduced importance of magnesium. Instead, it reflects optimization of the complete formulation according to the biological priorities of the follicular phase.

The difference between 250 mg and 200 mg is therefore a formulation engineering decision, not a difference in magnesium physiology.

Ingredient Scientific Monograph

Iron (as Ferrous Bisglycinate Chelate - Ferrochel®)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Iron

Chemical Name: Ferrous Bisglycinate Chelate

Branded Ingredient: Ferrochel®

Ingredient Form: Ferrous Bisglycinate Chelate

FEMSTATE™ Daily Dose

Iron is included exclusively in RESET™ because menstruation represents the only phase of the menstrual cycle associated with physiological blood loss. The formulation uses Ferrochel®, a patented ferrous bisglycinate chelate, selected for its superior bioavailability and gastrointestinal tolerability compared with many conventional iron salts. Unlike ferrous sulfate, Ferrochel® is less reactive within the gastrointestinal tract and has demonstrated efficient absorption in human studies while producing fewer gastrointestinal adverse effects.(1-5)

2. Physiological Role

Iron is an essential trace mineral required for oxygen transport, mitochondrial energy production, cellular respiration, DNA synthesis, immune function, and numerous enzymatic reactions. Approximately 65-70% of total body iron is contained within hemoglobin, while the remainder is distributed among myoglobin, ferritin, cytochromes, and other iron-containing proteins.(1-4)

Iron contributes to:

• Hemoglobin synthesis
• Oxygen transport
• Mitochondrial ATP production
• Cellular respiration
• DNA synthesis
• Cell proliferation
• Immune physiology
• Connective tissue repair

Because menstruation is the principal physiological mechanism of iron loss in reproductive-aged women, iron is uniquely relevant during the RESET™ phase.

3. Mechanism of Action

Iron participates in multiple physiological pathways.

Oxygen Transport

Iron is the central atom within hemoglobin.

Hemoglobin -> Oxygen transport -> Cellular respiration -> ATP production -> Tissue repair

This pathway is fundamental for regeneration of the endometrium following menstruation.

Mitochondrial Energy Production

Iron functions as a component of:

• cytochromes
• iron-sulfur proteins
• electron transport chain complexes

These proteins are essential for oxidative phosphorylation and ATP synthesis.

DNA Synthesis

Iron-dependent enzymes participate in:

• DNA replication
• cellular proliferation
• tissue regeneration

These processes become particularly active during endometrial repair.

Immune Physiology

Iron supports:

• lymphocyte proliferation
• macrophage physiology
• normal immune function

Adequate iron availability contributes to physiological tissue regeneration while maintaining immune homeostasis.

4. Why Included in FEMSTATE™

RESET™

Menstruation is associated with physiological iron loss through endometrial bleeding.

The menstrual phase simultaneously requires:

• tissue regeneration
• angiogenesis
• hemoglobin synthesis
• mitochondrial ATP production
• restoration of iron homeostasis

Iron therefore supports the biological priorities unique to the RESET™ phase.

Importantly, the formulation is not intended to treat iron deficiency anemia. Rather, it provides nutritional support aligned with the physiology of menstruation, particularly for women with normal menstrual blood loss.

5. Dose Justification

Selected Dose: 18 mg elemental iron

The selected dose was based on five scientific criteria.

Physiological Relevance

The dose corresponds to the Recommended Dietary Allowance (RDA) for premenopausal women in the United States.

It supports:

• maintenance of iron status
• hemoglobin synthesis
• physiological iron replacement following menstruation

Human Clinical Evidence

Numerous human studies have demonstrated that 18 mg/day effectively supports iron intake in women of reproductive age when dietary intake alone is insufficient to meet physiological requirements.

Ferrous bisglycinate has consistently demonstrated:

• excellent absorption
• high bioavailability
• improved gastrointestinal tolerability

relative to conventional ferrous salts.(3-5)

Safety

The selected dose remains well below the Tolerable Upper Intake Level (UL) of 45 mg/day established for healthy adults.(2)

Using the RDA rather than a pharmacologic dose minimizes gastrointestinal side effects while providing meaningful physiological support.

Formulation Compatibility

Ferrochel® was selected because it:

• demonstrates excellent bioavailability
• produces fewer gastrointestinal adverse effects than ferrous sulfate
• works synergistically with vitamin C
• is compatible with once-daily supplementation

HR+ Philosophy

Iron demonstrates no estrogenic or endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Iron is among the most extensively studied minerals in clinical nutrition.

Strong evidence supports its role in:

• maintenance of iron status
• prevention of iron deficiency
• hemoglobin synthesis
• oxygen transport
• mitochondrial metabolism

Ferrous bisglycinate has been evaluated in numerous randomized controlled trials demonstrating comparable or superior absorption with improved gastrointestinal tolerance compared with ferrous sulfate.(3-5)

7. Safety Considerations

Iron has an excellent safety profile when used at nutritional doses in appropriate populations.

Recommended Dietary Allowance (Premenopausal Women): 18 mg/day

FEMSTATE Dose: 18 mg/day

Tolerable Upper Intake Level: 45 mg/day

Potential adverse effects associated with excessive intake include:

• constipation
• nausea
• abdominal discomfort
• iron overload in susceptible individuals

These effects are less common with ferrous bisglycinate than with many conventional iron preparations.

Iron supplementation should not be used by individuals with:

• hereditary hemochromatosis
• iron overload disorders
• elevated ferritin without medical supervision

8. HR+ Safety Review

Ferrochel® was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Iron is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin C

Vitamin C enhances absorption of non-heme iron by reducing ferric iron to the more absorbable ferrous form -> Strong physiological synergy

Vitamin B12

Supports coordinated erythropoiesis -> Positive synergy

Folate

Supports DNA synthesis and red blood cell formation -> Positive synergy

Potential Negative Interactions

Absorption may be reduced by simultaneous intake of:

• calcium
• high-dose zinc
• phytates
• tannins (tea and coffee)

These interactions can be minimized by appropriate timing of supplementation.

Known Considerations

Individuals with diagnosed iron overload disorders or elevated ferritin concentrations should not supplement iron unless directed by a healthcare professional.

10. Regulatory Status

Ferrochel® is:

• An internationally recognized branded ingredient.
• Widely used in dietary supplements.
• Supported by multiple human bioavailability studies.
• Accepted for use in nutritional products worldwide.

Iron is recognized as an essential nutrient by:

• National Institutes of Health Office of Dietary Supplements.
• Dietary Reference Intakes.

11. Evidence Gaps & Future Research

Current evidence strongly supports iron for:

• maintenance of iron status
• hemoglobin synthesis
• oxygen transport
• erythropoiesis

Areas requiring additional investigation include:

• Phase-specific iron utilization throughout the menstrual cycle.
• Biomarker-guided phase-aligned iron supplementation.
• Clinical evaluation of RESET™ as an integrated formulation supporting menstrual physiology.

No randomized controlled trials have specifically evaluated Ferrochel® within a phase-aligned nutritional system.

12. Conclusion

Iron, provided as Ferrochel® (ferrous bisglycinate chelate), is one of the most physiologically targeted ingredients within the FEMSTATE™ platform. Its inclusion is limited to RESET™, reflecting the unique biology of menstruation as the only phase associated with physiological blood loss. The selected dose of 18 mg elemental iron corresponds to the Recommended Dietary Allowance for premenopausal women and was chosen based on biological relevance, extensive human clinical evidence, excellent gastrointestinal tolerability, and long-term safety. Ferrochel® was specifically selected because it combines high bioavailability with improved tolerability compared with conventional iron salts. Within the FEMSTATE™ formulation strategy, iron supports the physiological priorities of tissue regeneration, erythropoiesis, mitochondrial metabolism, and restoration of iron homeostasis without altering endocrine function or serving as a treatment for iron deficiency anemia.

References

• National Institutes of Health Office of Dietary Supplements. Iron Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• The American Journal of Clinical Nutrition. Reviews on iron metabolism and women's health.
• Nutrients. Systematic reviews on ferrous bisglycinate bioavailability and tolerability.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on iron physiology, erythropoiesis, and female nutrition.
• Williams Textbook of Endocrinology.

Ingredient Scientific Monograph

Zinc (as Zinc Picolinate)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Zinc

Chemical Name: Zinc

Ingredient Form: Zinc Picolinate

FEMSTATE™ Daily Dose

Zinc is included in RESET™ and LIFT™ because of its essential role in cellular repair, DNA synthesis, immune regulation, protein synthesis, antioxidant defense, and reproductive physiology. Zinc picolinate was selected because it is a highly bioavailable form that has demonstrated efficient intestinal absorption compared with several inorganic zinc salts.(1-4)

2. Physiological Role

Zinc is an essential trace mineral involved in the activity of more than 300 enzymes and over 2,000 transcription factors. It participates in virtually every aspect of cellular metabolism, including DNA synthesis, RNA transcription, protein synthesis, immune regulation, wound healing, antioxidant defense, reproductive physiology, and cell signaling.(1-4)

Zinc contributes to:

• DNA synthesis
• Cellular proliferation
• Protein synthesis
• Connective tissue remodeling
• Immune homeostasis
• Antioxidant defense
• Wound healing
• Skin physiology
• Reproductive tissue maintenance

These biological functions are particularly relevant during the regenerative physiology of RESET™ and the anabolic physiology of LIFT™.

Mechanism of Action

Zinc exerts its physiological effects through numerous biochemical pathways.

DNA and RNA Synthesis

Zinc functions as a structural and catalytic cofactor for enzymes involved in:

• DNA replication
• RNA transcription
• Cell division
• Tissue regeneration

These pathways are fundamental to endometrial repair and follicular growth.

Protein Synthesis

Zinc supports:

• ribosomal function
• translation
• enzyme synthesis
• connective tissue remodeling

This mechanism is particularly relevant during tissue regeneration and anabolic physiology.

Immune Regulation

Zinc contributes to:

• lymphocyte development
• neutrophil physiology
• macrophage function
• cytokine regulation

Rather than stimulating immunity, zinc supports maintenance of normal immune homeostasis.

Antioxidant Physiology

Zinc serves as a structural component of superoxide dismutase (Cu/Zn-SOD), one of the body’s principal endogenous antioxidant enzymes.

This pathway contributes to maintenance of physiological redox balance during tissue remodeling and cellular metabolism.

4. Why Included in FEMSTATE™

RESET™

The menstrual phase emphasizes:

• tissue regeneration
• wound repair
• immune homeostasis
• extracellular matrix remodeling

Zinc supports these biological priorities through its roles in DNA synthesis, protein synthesis, immune physiology, and antioxidant defense.

LIFT™

The follicular phase emphasizes:

• cellular proliferation
• anabolic metabolism
• connective tissue growth
• follicular development

Zinc supports these physiological priorities by facilitating DNA replication, protein synthesis, and cellular growth.

5. Dose Justification

Selected Dose: 10 mg elemental zinc

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 10 mg/day provides approximately 90% of the Daily Value, supporting normal cellular physiology while complementing dietary zinc intake.

This dose supports:

• tissue regeneration
• immune homeostasis
• protein synthesis
• cellular proliferation

without approaching excessive intake.

Human Clinical Evidence

Numerous randomized controlled trials have evaluated zinc supplementation across a range of physiological outcomes.

Human studies commonly use doses between 10-30 mg/day, with 10 mg representing an effective nutritional maintenance dose for healthy adults.

Safety

The selected dose remains well below the established Tolerable Upper Intake Level (UL) of 40 mg/day for adults.²

This minimizes the risk of long-term disturbances in copper metabolism while maintaining physiological efficacy.

Formulation Compatibility

Zinc picolinate was selected because it:

• demonstrates excellent bioavailability
• supports long-term daily supplementation
• complements vitamin C and selenium
• fits well within the formulation without excessive mineral competition

HR+ Philosophy

Zinc demonstrates no direct endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Zinc is among the most extensively studied trace minerals in human nutrition.

Strong evidence supports its role in:

• immune physiology
• wound healing
• DNA synthesis
• protein synthesis
• maintenance of normal zinc status

Evidence supporting female reproductive physiology primarily relates to normal ovarian function and reproductive health rather than phase-specific supplementation.

7. Safety Considerations

Zinc has an excellent safety profile at nutritional doses.

Recommended Dietary Allowance (Women): 8 mg/day

FEMSTATE Dose: 10 mg/day

Tolerable Upper Intake Level: 40 mg/day

Potential adverse effects associated with excessive intake include:

• nausea
• gastrointestinal discomfort
• impaired copper absorption
• reduced HDL cholesterol (with prolonged excessive intake)

These effects occur primarily with long-term intakes substantially exceeding the FEMSTATE dose.

8. HR+ Safety Review

Zinc was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor agonist activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Zinc is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin C

Supports complementary immune physiology and connective tissue repair -> Positive synergy

Vitamin A

Works together to maintain epithelial integrity and immune function -> Strong physiological synergy

Selenium

Supports complementary endogenous antioxidant systems -> Positive synergy

Potential Negative Interactions

High supplemental intakes of:

• iron
• calcium
• copper

may reduce zinc absorption when consumed simultaneously at pharmacological doses.

These interactions are minimal at the nutritional doses used within FEMSTATE™.

Known Considerations

Long-term zinc supplementation above the UL should be accompanied by appropriate copper intake.

The FEMSTATE dose does not approach levels associated with clinically meaningful copper depletion.

10. Regulatory Status

Zinc picolinate is:

• Widely accepted for use in dietary supplements.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an appropriate supplemental zinc form.
• Included in the U.S. Dietary Reference Intakes.
• Supported by international nutritional recommendations.

11. Evidence Gaps & Future Research

Current evidence strongly supports zinc for:

• immune physiology
• DNA synthesis
• wound healing
• cellular metabolism

Areas requiring further investigation include:

• Phase-specific zinc utilization during the menstrual cycle.
• Zinc requirements during regenerative versus anabolic physiology.
• Clinical evaluation of zinc picolinate within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated zinc picolinate within a phase-aligned formulation.

12. Conclusion

Zinc, provided as zinc picolinate, is a foundational trace mineral within the FEMSTATE™ platform because of its established roles in DNA synthesis, protein synthesis, immune regulation, wound healing, connective tissue biology, and antioxidant defense. The selected dose of 10 mg/day provides meaningful physiological support while remaining well below the established upper intake level for long-term supplementation. Zinc picolinate was intentionally selected because of its favorable bioavailability and compatibility with the formulation. Within FEMSTATE™, zinc supports the regenerative physiology of RESET™ and the anabolic biology of LIFT™, aligning with the biological priorities of tissue renewal and cellular growth without directly influencing reproductive hormone production.

References

• National Institutes of Health Office of Dietary Supplements. Zinc Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on zinc physiology and human metabolism.
• Nutrients. Systematic reviews on zinc supplementation, immune physiology, and wound healing.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on zinc, reproductive physiology, and endocrine health.
• Free Radical Biology and Medicine. Reviews on zinc and endogenous antioxidant systems.

Ingredient Scientific Monograph

Selenium (as L-Selenomethionine)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Selenium

Chemical Name: Selenium

Ingredient Form: L-Selenomethionine

FEMSTATE™ Daily Dose

Selenium is included in all four FEMSTATE™ formulations because of its essential role in antioxidant defense, thyroid hormone metabolism, immune regulation, mitochondrial function, and cellular protection. L-selenomethionine was selected because it demonstrates excellent oral bioavailability and efficiently supports physiological selenium status. Unlike phase-specific ingredients, selenium supports fundamental biological processes that remain active throughout the menstrual cycle.

2. Physiological Role

Selenium is an essential trace mineral incorporated into at least 25 human selenoproteins, many of which regulate antioxidant defense, thyroid hormone activation, redox homeostasis, immune function, and cellular metabolism. Selenium is unique among trace minerals because it is incorporated directly into proteins as the amino acid selenocysteine, allowing specialized biological functions.(1-4)

Selenium contributes to:

• Antioxidant defense
• Glutathione peroxidase activity
• Thyroid hormone metabolism
• Immune homeostasis
• Mitochondrial function
• DNA protection
• Cellular redox regulation
• Reproductive physiology

These physiological functions remain important throughout every phase of the menstrual cycle.

3. Mechanism of Action

Selenium functions primarily through incorporation into selenoproteins.

Antioxidant Physiology

Selenium is required for synthesis of:

• Glutathione peroxidase (GPx)
• Thioredoxin reductase
• Selenoprotein P

These enzymes protect cells from excessive oxidative damage while maintaining physiological redox signaling.

Unlike exogenous antioxidants, selenium supports the body's endogenous antioxidant systems.

Thyroid Hormone Metabolism

Selenium-dependent iodothyronine deiodinases convert:

T4 -> T3

maintaining normal thyroid physiology.

Because thyroid hormones regulate metabolism, selenium indirectly supports cellular energy production.

Immune Regulation

Selenium contributes to:

• lymphocyte proliferation
• natural killer cell function
• cytokine regulation
• maintenance of immune homeostasis

Its role is regulatory rather than stimulatory.

Mitochondrial Function

Selenium-dependent antioxidant enzymes help preserve:

• mitochondrial membrane integrity
• oxidative phosphorylation
• ATP production

particularly during periods of increased metabolic activity.

4. Why Included in FEMSTATE™

Unlike phase-specific nutrients, selenium supports physiological systems that remain active throughout the menstrual cycle.

RESET™

Supports:

• endogenous antioxidant defense
• tissue regeneration
• immune homeostasis

LIFT™

Supports:

• mitochondrial metabolism
• cellular proliferation
• antioxidant regulation

SHINE™

Supports:

• physiological oxidative balance
• mitochondrial resilience
• protection during ovulatory remodeling

SOOTHE™

Supports:

• immune regulation
• metabolic homeostasis
• thyroid physiology
• maintenance of cellular integrity

For these reasons, selenium is maintained at a constant dose across all four formulations.

5. Dose Justification

Selected Dose: 55 mcg

The selected dose was based on five scientific criteria.

Physiological Relevance

A dose of 55 mcg/day corresponds to the Recommended Dietary Allowance (RDA) for adult women and supports normal selenoprotein synthesis and antioxidant physiology.

Human Clinical Evidence

Human intervention studies demonstrate that selenium intake at recommended levels supports:

• glutathione peroxidase activity
• thyroid hormone metabolism
• maintenance of selenium status

Higher doses have not consistently demonstrated additional physiological benefit in selenium-replete individuals.

Safety

The selected dose remains well below the adult Tolerable Upper Intake Level (UL) of 400 mcg/day, providing an excellent safety margin.

Formulation Compatibility

The selected dose:

• complements vitamin E
• complements vitamin C
• complements CoQ10
• supports endogenous antioxidant systems
• avoids excessive selenium exposure when combined with dietary intake

HR+ Philosophy

Selenium demonstrates no known estrogenic or progesterone receptor activity and aligns fully with the FEMSTATE™ HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Selenium has been extensively studied in relation to:

• antioxidant physiology
• thyroid function
• immune regulation
• maintenance of selenium status

The strongest evidence supports maintenance of normal selenium nutrition and selenoprotein function rather than pharmacological supplementation.

7. Safety Considerations

Selenium has an excellent safety profile at nutritional doses.

Recommended Dietary Allowance (Women): 55 mcg/day

FEMSTATE Dose: 55 mcg/day

Tolerable Upper Intake Level: 400 mcg/day

Chronic excessive selenium intake may produce:

• brittle hair
• brittle nails
• gastrointestinal upset
• garlic odor on breath
• neurological symptoms (selenosis)

These effects occur at intakes substantially higher than the dose used in FEMSTATE™.

8. HR+ Safety Review

Selenium was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Current evidence does not support selenium supplementation as a treatment for hormone-sensitive cancers. Within nutritional doses, selenium is considered compatible with the HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin E

Selenium and vitamin E function synergistically within endogenous antioxidant systems -> Strong antioxidant synergy

Vitamin C

Supports complementary redox physiology -> Positive synergy

CoQ10

Supports mitochondrial antioxidant physiology -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Magnesium
• Zinc
• Vitamin D3
• Vitamin K2

at FEMSTATE doses.

Known Considerations

Individuals taking high-dose selenium supplements from multiple sources should monitor total intake to remain below the established UL.

10. Regulatory Status

L-selenomethionine is:

• Recognized as a dietary ingredient.
• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements as an appropriate selenium source.
• Widely accepted for use in dietary supplements worldwide.

11. Evidence Gaps & Future Research

Current evidence strongly supports selenium for:

• glutathione peroxidase activity
• thyroid hormone metabolism
• antioxidant physiology
• immune regulation

Areas requiring further investigation include:

• Phase-specific selenium metabolism across the menstrual cycle.
• Selenium requirements during ovulatory oxidative remodeling.
• Clinical evaluation of selenium within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated L-selenomethionine within a phase-aligned formulation.

12. Conclusion

Selenium, provided as L-selenomethionine, is a foundational micronutrient within the FEMSTATE™ platform because of its indispensable roles in endogenous antioxidant defense, thyroid hormone metabolism, immune regulation, mitochondrial physiology, and cellular protection. The selected dose of 55 mcg/day corresponds to the Recommended Dietary Allowance for adult women and provides physiological support while maintaining a wide safety margin below the established upper intake level. Its inclusion across RESET™, LIFT™, SHINE™, and SOOTHE™ reflects the continuous importance of selenoprotein function throughout the menstrual cycle rather than phase-specific endocrine changes. By supporting the body's own antioxidant enzyme systems rather than acting as a direct antioxidant itself, selenium contributes to the maintenance of normal cellular resilience across all physiological phases of the FEMSTATE™ platform.

References

• National Institutes of Health Office of Dietary Supplements. Selenium Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on selenium metabolism and human nutrition.
• Nutrients. Systematic reviews on selenium, glutathione peroxidase, and antioxidant physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on selenium, thyroid physiology, and reproductive endocrinology.
• Endocrine Reviews. Reviews on selenium biology and endocrine regulation.

Ingredient Scientific Monograph

Chromium (as Chromium Picolinate)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Chromium

Chemical Name: Trivalent Chromium

Ingredient Form: Chromium Picolinate

FEMSTATE™ Daily Dose

Chromium is included in all four FEMSTATE™ formulations because of its role in glucose metabolism, insulin signaling, cellular energy production, and metabolic homeostasis. Chromium picolinate was selected because it is one of the most extensively studied and bioavailable supplemental forms of chromium, with substantial human clinical literature supporting its physiological role in maintaining normal carbohydrate metabolism.(1-4)

Unlike ingredients that target a specific endocrine phase, chromium provides consistent metabolic support throughout the menstrual cycle.

2. Physiological Role

Chromium is an essential trace mineral involved in the regulation of glucose metabolism and insulin action. Although only very small amounts are required physiologically, chromium participates in maintaining normal carbohydrate, protein, and lipid metabolism by enhancing the efficiency of insulin signaling.(1-4)

Chromium contributes to:

• Normal insulin signaling
• Glucose utilization
• Cellular energy metabolism
• Carbohydrate metabolism
• Lipid metabolism
• Protein metabolism
• Maintenance of metabolic homeostasis

These physiological functions support cellular metabolism across all menstrual phases.

3. Mechanism of Action

Chromium functions primarily through modulation of insulin signaling.

Insulin Physiology

Current evidence suggests chromium enhances the activity of insulin after insulin binds to its receptor.

Insulin -> Insulin receptor activation -> Enhanced intracellular signaling -> Glucose uptake -> ATP production -> Cellular metabolism

Importantly, chromium does not stimulate insulin secretion. Instead, it supports normal insulin function.

Cellular Energy Production

By facilitating efficient glucose utilization, chromium indirectly supports:

• ATP synthesis
• mitochondrial metabolism
• cellular respiration

These pathways are fundamental throughout the menstrual cycle.

Macronutrient Metabolism

Chromium participates in:

• carbohydrate metabolism
• lipid metabolism
• amino acid metabolism

supporting overall metabolic homeostasis.

4. Why Included in FEMSTATE™

Chromium supports metabolic physiology throughout every endocrine phase.

RESET™

Supports:

• restoration of metabolic homeostasis
• cellular energy production
• glucose metabolism during tissue repair

LIFT™

Supports:

• anabolic metabolism
• efficient glucose utilization
• mitochondrial ATP production

SHINE™

Supports:

• increased cellular energy demand
• metabolic flexibility
• maintenance of physiological glucose metabolism

SOOTHE™

Supports:

• metabolic stability
• efficient energy utilization
• maintenance of normal insulin physiology

Because these biological functions remain important throughout the menstrual cycle, chromium is maintained at a constant dose across all four formulations.

5. Dose Justification

Selected Dose: 35 mcg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A daily intake of 35 mcg corresponds to the Daily Value used for dietary supplements and provides physiological support for normal insulin function and carbohydrate metabolism.

Human Clinical Evidence

Clinical studies investigating chromium picolinate have evaluated doses ranging from 35-1,000 mcg/day, depending on the population and clinical objective.

For healthy women without metabolic disease, a nutritional dose of 35 mcg/day supports normal chromium status while avoiding unnecessary pharmacologic exposure.

Safety

The selected dose provides nutritional support while remaining substantially below doses evaluated in therapeutic research.

Formulation Compatibility

The selected dose:

• complements magnesium
• complements B-complex vitamins
• supports mitochondrial metabolism
• supports long-term daily supplementation

HR+ Philosophy

Chromium demonstrates no direct endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Chromium picolinate has been extensively studied in relation to:

• glucose metabolism
• insulin physiology
• maintenance of chromium status
• carbohydrate metabolism

The strongest evidence supports chromium's role in maintaining normal glucose metabolism in individuals with inadequate chromium intake. Evidence for additional metabolic benefits in healthy chromium-replete populations is less consistent.

7. Safety Considerations

Chromium picolinate has an excellent safety profile at nutritional doses.

Adequate Intake (Women): 25 mcg/day

FEMSTATE Dose: 35 mcg/day - Tolerable Upper Intake Level

No UL has been established because adverse effects have not been consistently demonstrated from nutritional chromium intake.²

Rare reports of adverse events have generally involved prolonged consumption of doses hundreds of times greater than those used in FEMSTATE™.

8. HR+ Safety Review

Chromium picolinate was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Chromium picolinate is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Magnesium

Supports complementary insulin signaling and glucose metabolism -> Positive metabolic synergy

Vitamin B3

Supports carbohydrate metabolism and mitochondrial physiology -> Positive synergy

Vitamin B1

Supports glucose utilization and ATP production -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Vitamin D3
• Zinc
• Selenium

at FEMSTATE doses.

Known Considerations

Individuals using glucose-lowering medications should discuss chromium supplementation with their healthcare provider, as chromium may modestly influence glucose metabolism. The nutritional dose used in FEMSTATE™ is not intended to treat diabetes or alter medication requirements.

10. Regulatory Status

Chromium picolinate is:

• Recognized as a dietary ingredient.
• Included in the U.S. Dietary Reference Intakes through Adequate Intake recommendations.
• Recognized by the National Institutes of Health Office of Dietary Supplements.
• Widely accepted for use in dietary supplements internationally.

11. Evidence Gaps & Future Research

Current evidence strongly supports chromium for:

• maintenance of normal glucose metabolism
• insulin physiology
• carbohydrate metabolism

Areas requiring further investigation include:

• Phase-specific chromium utilization during the menstrual cycle.
• Metabolic flexibility across different endocrine environments.
• Clinical evaluation of chromium picolinate within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated chromium picolinate within a phase-aligned nutritional formulation.

12. Conclusion

Chromium, provided as chromium picolinate, serves as a foundational metabolic micronutrient within the FEMSTATE™ platform because of its established role in supporting normal insulin signaling, glucose utilization, and cellular energy metabolism. The selected dose of 35 mcg/day aligns with nutritional recommendations and provides physiological support while maintaining an excellent safety profile. Its inclusion across RESET™, LIFT™, SHINE™, and SOOTHE™ reflects the continuous importance of metabolic homeostasis throughout the menstrual cycle rather than phase-specific endocrine changes. Chromium does not alter reproductive hormone physiology; instead, it supports the efficient cellular metabolism that underpins tissue regeneration, anabolic growth, ovulatory transition, and physiological maintenance across all phases of the FEMSTATE™ system.

References

• National Institutes of Health Office of Dietary Supplements. Chromium Fact Sheet for Health Professionals.
• Institute of Medicine Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on chromium physiology and glucose metabolism.
• Nutrients. Systematic reviews on chromium picolinate and metabolic health.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on insulin physiology, metabolism, and micronutrients.
• Endocrine Society. Clinical guidance on metabolic physiology and endocrine health.

Ingredient Scientific Monograph

Potassium (as Potassium Citrate)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Potassium

Chemical Name: Potassium

Ingredient Form: Potassium Citrate

FEMSTATE™ Daily Dose

Potassium is included exclusively in SOOTHE™ because the luteal phase is characterized by physiological changes in fluid regulation, electrolyte balance, neuromuscular physiology, and cellular homeostasis under progesterone dominance. Potassium citrate was selected because it is highly bioavailable, well tolerated, and contributes to acid-base balance while supporting normal electrolyte physiology.

2. Physiological Role

Potassium is the principal intracellular cation and is essential for maintaining cell membrane potential, neuromuscular function, intracellular fluid balance, acid-base homeostasis, cardiovascular physiology, and cellular metabolism. Approximately 98% of total body potassium resides inside cells, where it plays a critical role in electrical signaling and ATP-dependent transport.(1-4)

Potassium contributes to:

• Cellular membrane potential
• Muscle contraction
• Nerve impulse transmission
• Fluid balance
• Acid-base regulation
• Cardiovascular physiology
• Cellular energy metabolism
• Electrolyte homeostasis

These physiological processes are continuously active but become particularly relevant during the luteal phase, when progesterone influences fluid distribution and metabolic regulation.

3. Mechanism of Action

Potassium functions primarily through maintenance of electrochemical gradients across cell membranes.

Cellular Electrical Activity

The sodium-potassium ATPase pump maintains:

High intracellular potassium -> Normal membrane potential -> Nerve conduction -> Muscle contraction -> Cellular homeostasis

This mechanism is fundamental to every excitable tissue in the body.

Fluid Regulation

Potassium contributes to:

• intracellular fluid balance
• osmotic regulation
• maintenance of normal cell volume

These processes complement the physiological adaptations occurring during the luteal phase.

Neuromuscular Physiology

Adequate potassium is required for:

• skeletal muscle function
• smooth muscle physiology
• cardiac electrical activity
• nervous system signaling

Acid-Base Homeostasis

Potassium citrate contributes citrate, which is metabolized to bicarbonate, supporting normal physiological acid-base balance.

4. Why Included in FEMSTATE™

SOOTHE™

The luteal phase emphasizes:

• physiological fluid regulation
• metabolic homeostasis
• neuromuscular physiology
• maintenance of cellular stability
• electrolyte balance

Progesterone influences renal handling of sodium and water and contributes to normal physiological changes in fluid distribution. Potassium supports these adaptive processes by maintaining intracellular electrolyte balance and normal neuromuscular function.

Importantly, potassium is not included to treat bloating or fluid retention, but rather to support the normal physiological regulation of electrolyte homeostasis during the luteal phase.

5. Dose Justification

Selected Dose: 200 mg elemental potassium

The selected dose was based on five scientific criteria.

Physiological Relevance

The dose provides meaningful supplemental potassium while recognizing that potassium requirements are primarily met through food. The formulation is intended to complement - not replace - dietary potassium intake.

Human Clinical Evidence

Clinical research demonstrates that adequate potassium intake supports:

• neuromuscular physiology
• cardiovascular health
• normal blood pressure regulation
• electrolyte balance

Most intervention studies use dietary approaches rather than supplementation because potassium is abundant in whole foods.

Safety

The selected dose remains modest relative to typical dietary potassium intake and is well tolerated in healthy individuals with normal kidney function.

Formulation Compatibility

The selected dose:

• complements magnesium
• supports neuromuscular physiology
• contributes to electrolyte balance
• fits safely within the overall formulation

HR+ Philosophy

Potassium demonstrates no endocrine activity and fully aligns with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Potassium has been extensively studied in relation to:

• cardiovascular physiology
• electrolyte balance
• neuromuscular function
• blood pressure regulation

The strongest evidence supports maintenance of adequate total potassium intake through diet. Supplemental potassium at nutritional doses contributes to overall potassium intake but is not generally intended as a therapeutic intervention in healthy individuals.

7. Safety Considerations

Potassium is safe at nutritional supplemental doses in healthy individuals.

Adequate Intake (Women): 2,600 mg/day (primarily from food)

FEMSTATE Dose: 200 mg/day - Tolerable Upper Intake Level

No formal UL has been established for potassium from food. Supplemental potassium requires caution in individuals with impaired renal function or those taking medications that increase serum potassium.

Potential adverse effects with excessive supplemental potassium include:

• gastrointestinal irritation
• hyperkalemia (primarily in susceptible individuals)
• cardiac rhythm disturbances in severe cases

The dose used in FEMSTATE is conservative and intended for healthy adults.

8. HR+ Safety Review

Potassium citrate was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Potassium citrate is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Magnesium

Potassium and magnesium work together to maintain:

• neuromuscular physiology
• electrolyte balance
• cellular membrane function

-> Strong physiological synergy

Sodium

Potassium complements sodium in maintaining fluid and electrolyte homeostasis -> Physiological balance

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Vitamin D3
• Selenium
• Zinc

at FEMSTATE doses.

Known Considerations. Individuals with:

• chronic kidney disease
• adrenal insufficiency
• hyperkalemia
• those taking potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs), or mineralocorticoid receptor antagonists

should consult a healthcare professional before potassium supplementation.

10. Regulatory Status

Potassium citrate is:

• Recognized as a dietary ingredient.
• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements.
• Widely accepted for use in dietary supplements.

11. Evidence Gaps & Future Research

Current evidence strongly supports potassium for:

• electrolyte homeostasis
• neuromuscular physiology
• cardiovascular health

Areas requiring additional investigation include:

• Electrolyte physiology across different menstrual phases.
• Luteal-phase adaptations in intracellular electrolyte regulation.
• Clinical evaluation of potassium citrate within phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated potassium citrate within a phase-aligned nutritional formulation.

12. Conclusion

Potassium, provided as potassium citrate, was specifically incorporated into SOOTHE™ because of its established role in maintaining electrolyte balance, neuromuscular physiology, intracellular fluid homeostasis, and cellular stability during the progesterone-dominant luteal phase. The selected dose of 200 mg elemental potassium provides meaningful supplemental support while recognizing that potassium requirements are primarily met through dietary intake. Rather than functioning as a treatment for fluid retention or premenstrual symptoms, potassium supports the normal physiological adaptations of the luteal phase by contributing to electrolyte homeostasis, neuromuscular function, and metabolic stability. Its inclusion reflects the FEMSTATE™ philosophy of aligning nutritional support with the biological priorities of each endocrine environment.

References

• National Institutes of Health Office of Dietary Supplements. Potassium Fact Sheet for Health Professionals.
• Dietary Reference Intakes.
• Williams Textbook of Endocrinology.
• Guyton and Hall Textbook of Medical Physiology.
• The American Journal of Clinical Nutrition. Reviews on potassium physiology and cardiovascular health.
• Nutrients. Systematic reviews on potassium intake, electrolyte physiology, and metabolic health.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on electrolyte physiology and endocrine regulation.

Ingredient Scientific Monograph

Sodium

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Sodium

Chemical Name: Sodium

Ingredient Form: Sodium (mineral salt)

FEMSTATE™ Daily Dose

Sodium is included in SHINE™ and SOOTHE™ as a physiological electrolyte rather than as a major dietary sodium source. The amounts included are intentionally small and are designed to complement potassium and magnesium in maintaining cellular hydration, neuromuscular function, and electrolyte balance during phases characterized by increased metabolic activity (SHINE™) and physiological stabilization (SOOTHE™).

2. Physiological Role

Sodium is the principal extracellular cation and is essential for maintaining extracellular fluid volume, nerve impulse transmission, muscle contraction, acid-base homeostasis, and nutrient transport across cell membranes. Together with potassium, sodium establishes the electrochemical gradients required for normal cellular physiology.(1-4)

Sodium contributes to:

• Extracellular fluid balance
• Cellular hydration
• Nerve conduction
• Skeletal muscle contraction
• Cardiac electrical activity
• Nutrient transport
• Acid-base regulation
• Maintenance of blood volume

Unlike potassium, which is predominantly intracellular, sodium functions primarily in the extracellular compartment and works continuously to maintain physiological homeostasis.

3. Mechanism of Action

Sodium functions through maintenance of extracellular electrochemical gradients.

Sodium-Potassium ATPase

The sodium-potassium pump continuously transports:

3 Sodium ions out of the cell -> 2 Potassium ions into the cell -> Maintenance of membrane potential -> Normal nerve transmission -> Muscle contraction -> Cellular homeostasis

This ATP-dependent mechanism is fundamental to every excitable tissue in the human body.

Fluid Homeostasis

Sodium regulates:

• extracellular osmolarity
• plasma volume
• tissue perfusion
• hydration status

These processes are tightly controlled by:

• aldosterone
• vasopressin (ADH)
• the renin-angiotensin-aldosterone system (RAAS)

Nutrient Transport

Sodium gradients drive absorption of:

• glucose
• amino acids
• certain vitamins

through sodium-dependent transport proteins within the gastrointestinal tract.

4. Why Included in FEMSTATE™

SHINE™

Ovulation is associated with:

• increased cellular metabolism
• heightened mitochondrial activity
• active tissue remodeling
• increased physiological demand for electrolyte homeostasis

The small amount of sodium supports normal extracellular electrolyte balance while complementing potassium and magnesium.

SOOTHE™

The luteal phase emphasizes:

• metabolic stability
• neuromuscular regulation
• maintenance of fluid homeostasis
• cellular equilibrium

Progesterone influences renal sodium handling through interactions with mineralocorticoid signaling, although the overall physiological response varies among individuals.

The small sodium contribution within SOOTHE™ complements the electrolyte profile without materially increasing total dietary sodium intake.

5. Dose Justification

Selected Dose

SHINE™ - 15 mg

SOOTHE™ - 10 mg

The selected doses were based upon five scientific criteria.

Physiological Relevance

The doses provide electrolyte balance within the formulation rather than serving as a significant dietary sodium source.

Average daily sodium intake from food typically exceeds 2,500–3,500 mg/day, making the sodium contribution from FEMSTATE nutritionally negligible but formulationally useful.

Human Clinical Evidence

Current evidence supports maintaining normal sodium homeostasis for:

• neuromuscular physiology
• extracellular fluid regulation
• nutrient transport

There is no evidence that women require phase-specific sodium supplementation during the menstrual cycle.

Accordingly, the sodium included in FEMSTATE is intended to support electrolyte balance within the formulation, not to alter sodium intake.

Safety

The selected doses are extremely small relative to normal dietary sodium consumption and have no meaningful impact on total sodium intake in healthy adults.

Formulation Compatibility

Low-dose sodium complements:

• potassium
• magnesium

to maintain physiological electrolyte balance without contributing materially to dietary sodium exposure.

HR+ Philosophy

Sodium demonstrates no endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Human evidence strongly supports sodium's role in:

• extracellular fluid balance
• nerve conduction
• muscle physiology
• cardiovascular regulation

However, there is no evidence supporting phase-specific sodium supplementation in healthy menstruating women.

For this reason, sodium was included solely to complement the formulation's electrolyte profile.

7. Safety Considerations

Adequate Intake (Women): Approximately 1,500 mg/day (varies by guideline and age)

FEMSTATE Dose: SHINE™: 15 mg / SOOTHE™: 10 mg

These represent less than 1% of typical daily sodium intake.

No safety concerns are anticipated from the amounts included in FEMSTATE.

8. HR+ Safety Review

Sodium was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

Findings

Current evidence demonstrates:

✔ No estrogen receptor activity

✔ No progesterone receptor activity

✔ No aromatase modulation

✔ No endocrine activity

✔ Favorable oncology safety profile

9. Ingredient Interactions

Positive Interactions

Potassium

Maintains physiological electrochemical gradients -> Strong physiological synergy

Magnesium

Supports neuromuscular physiology -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin C
• Vitamin D3
• Selenium
• Zinc

at FEMSTATE doses.

Known Considerations

Individuals following physician-prescribed sodium-restricted diets should continue following medical advice.

The sodium contribution from FEMSTATE is extremely small and is unlikely to meaningfully affect total sodium intake.

10. Regulatory Status

Sodium is:

• An essential dietary mineral.
• Included in the U.S. Dietary Reference Intakes.
• Recognized by the National Institutes of Health Office of Dietary Supplements.
• Universally accepted for use in foods and dietary supplements.

11. Evidence Gaps & Future Research

Current evidence strongly supports sodium for:

• fluid balance
• neuromuscular physiology
• electrolyte homeostasis

However:

• There is little evidence supporting menstrual phase-specific sodium requirements.
• No randomized controlled trials have evaluated low-dose sodium supplementation within a phase-aligned nutritional formulation.

Future research may explore electrolyte dynamics across menstrual phases, particularly during exercise and heat stress.

12. Conclusion

Sodium is included in SHINE™ (15 mg) and SOOTHE™ (10 mg) as a supportive electrolyte, not as a major source of dietary sodium. The amounts are intentionally minimal and are designed to complement potassium and magnesium in maintaining normal extracellular fluid balance, neuromuscular physiology, and cellular homeostasis. Because typical dietary sodium intake already greatly exceeds the quantities provided by FEMSTATE™, the rationale for inclusion is formulation balance rather than correction of sodium deficiency. Within the FEMSTATE™ platform, sodium supports the integrated electrolyte physiology of the ovulatory and luteal phases without influencing endocrine function or materially altering total sodium intake.

References

• National Institutes of Health Office of Dietary Supplements. Sodium and Electrolytes Guidance.
• Dietary Reference Intakes.
• Guyton and Hall Textbook of Medical Physiology.
• Williams Textbook of Endocrinology.
• The American Journal of Clinical Nutrition. Reviews on sodium physiology and electrolyte balance.
• Hypertension. Reviews on sodium homeostasis and cardiovascular physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on electrolyte physiology and endocrine regulation.

Ingredient Scientific Monograph

L-Theanine

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: L-Theanine

Chemical Name: γ-Glutamylethylamide

Ingredient Form: L-Theanine

Natural Source: Primarily found in the leaves of Green tea

FEMSTATE™ Daily Dose

L-Theanine is included exclusively in SOOTHE™ because the luteal phase is characterized by progesterone dominance, neuroendocrine regulation, GABAergic modulation, and physiological recovery. Unlike sedative compounds, L-theanine promotes a state of relaxed alertness, supporting normal brain physiology without impairing cognitive function. Its mechanism aligns closely with the biological priorities of the luteal phase, which emphasize neurophysiological stability rather than stimulation.

2. Physiological Role

L-Theanine is a naturally occurring non-protein amino acid that readily crosses the blood-brain barrier and influences several neurotransmitter systems involved in cognitive function, stress adaptation, and neuronal homeostasis. Human and mechanistic studies indicate that L-theanine modulates glutamatergic signaling while indirectly influencing GABA, dopamine, serotonin, and alpha-wave brain activity.(1-4)

L-Theanine contributes to:

• Neurophysiological regulation
• Maintenance of relaxed alertness
• Alpha brain wave activity
• GABAergic physiology
• Glutamate homeostasis
• Cognitive performance under stress
• Sleep quality support
• Neuroendocrine adaptation

These physiological functions are particularly relevant during the progesterone-dominant luteal phase.

3. Mechanism of Action

L-Theanine exerts multiple complementary neurophysiological actions.

Glutamatergic Regulation

L-Theanine is structurally similar to glutamate and interacts with glutamate receptors, contributing to regulation of excitatory neurotransmission without acting as a classical sedative.

GABA Physiology

Experimental evidence suggests L-theanine supports normal GABAergic signaling indirectly, contributing to balanced neuronal excitability and maintenance of physiological relaxation.

Alpha Brain Wave Activity

Electroencephalography (EEG) studies consistently demonstrate that L-theanine increases alpha-wave activity, a pattern associated with calm attention, mental relaxation, and preserved alertness.

Stress Physiology

Human studies suggest L-theanine may attenuate physiological responses to acute stress through modulation of autonomic nervous system activity and neuroendocrine signaling, while preserving cognitive performance.

Importantly, L-theanine does not induce sedation or impair cognition at nutritional doses.

4. Why Included in FEMSTATE™

SOOTHE™

The luteal phase is characterized by:

• Progesterone dominance
• Neuroendocrine adaptation
• Increased allopregnanolone production
• GABAergic modulation
• Physiological recovery
• Maintenance of neuronal homeostasis

L-Theanine complements this endocrine environment by supporting:

• physiological relaxation
• normal neurotransmitter regulation
• maintenance of cognitive function
• neuroendocrine stability

The formulation objective is not to sedate the user but to support the normal neurophysiological environment associated with the luteal phase.

5. Dose Justification

Selected Dose: 200 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 200 mg is one of the most frequently studied doses in randomized controlled trials evaluating:

• relaxation
• cognitive performance
• stress physiology
• sleep quality

Human Clinical Evidence

Multiple randomized controlled trials have demonstrated measurable physiological effects following single or repeated administration of 200 mg L-theanine.

This dose consistently supports:

• alpha-wave activity
• subjective relaxation
• cognitive performance under stress

without impairing alertness.

Safety

Clinical studies demonstrate excellent tolerability at doses considerably higher than those included in FEMSTATE™.

Formulation Compatibility

The selected dose:

• complements magnesium L-threonate
• complements GABA
• complements chamomile
• complements saffron
• supports the integrated neurophysiological objectives of SOOTHE™

HR+ Philosophy

L-Theanine demonstrates no direct endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

L-Theanine has been extensively investigated in randomized controlled trials evaluating:

• stress physiology
• relaxation
• sleep quality
• attention
• cognitive performance

The strongest evidence supports its ability to promote relaxed alertness rather than sedation.

7. Safety Considerations

L-Theanine possesses an excellent safety profile.

FEMSTATE Dose: 200 mg/day

Human studies have evaluated doses ranging from 50-400 mg/day, with several trials using even higher doses without serious adverse effects.

Reported adverse events are uncommon and generally mild, including:

• headache
• mild gastrointestinal discomfort
• transient dizziness (rare)

L-Theanine does not typically impair psychomotor performance or cause daytime sedation.

8. HR+ Safety Review

L-Theanine was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

L-Theanine is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Magnesium L-Threonate

Supports complementary neurophysiological regulation and synaptic function -> Strong neurophysiological synergy

GABA

Supports complementary regulation of neuronal excitability -> Positive synergy

Chamomile

Supports physiological relaxation through complementary mechanisms -> Positive synergy

Saffron

Supports neurophysiological homeostasis through distinct neurotransmitter pathways -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Vitamin B6
• Potassium
• Selenium

at FEMSTATE doses.

Known Considerations

L-Theanine may produce additive relaxation when combined with sedative medications or significant alcohol intake. Individuals using prescription anxiolytics or hypnotics should consult their healthcare provider before supplementation.

10. Regulatory Status

L-Theanine is:

• Widely accepted for use in dietary supplements.
• Generally recognized as safe (GRAS) for specified food uses in the United States.
• Supported by numerous human clinical trials evaluating cognitive and stress-related outcomes.

11. Evidence Gaps & Future Research

Current evidence strongly supports L-theanine for:

• relaxation
• stress physiology
• alpha-wave activity
• cognitive performance

Areas requiring additional investigation include:

• Neuroendocrine physiology during the luteal phase.
• Phase-specific application within menstrual physiology.
• Clinical evaluation of L-theanine as part of a comprehensive phase-aligned nutritional system such as FEMSTATE™.

No randomized controlled trials have specifically evaluated L-theanine within a phase-aligned formulation.

12. Conclusion

L-Theanine is a cornerstone neurophysiological ingredient within the SOOTHE™ formulation because of its established ability to promote relaxed alertness, support normal stress physiology, enhance alpha-wave activity, and contribute to neuroendocrine homeostasis without impairing cognitive performance. The selected dose of 200 mg reflects the most consistently studied amount in randomized controlled trials and aligns with the biological priorities of the luteal phase, which emphasize neuronal regulation, physiological recovery, and metabolic stability. Within the FEMSTATE™ platform, L-theanine supports the normal neurophysiological environment created by progesterone dominance rather than modifying reproductive hormone physiology, making it a key component of the phase-aligned strategy for SOOTHE™.

References

• Nutrients. Systematic reviews on L-theanine, stress physiology, and cognitive performance.
• Nutritional Neuroscience. Reviews on L-theanine and neurophysiology.
• Journal of Functional Foods. Human clinical studies evaluating L-theanine and relaxation.
• Nutritional Reviews. Reviews on amino acids and cognitive health.
• Williams Textbook of Endocrinology. Neuroendocrine physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on neuroendocrine regulation and women's physiology.

Ingredient Scientific Monograph

L-Tryptophan

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: L-Tryptophan

Chemical Name: L-Tryptophan

Ingredient Form: Pharmaceutical-grade L-Tryptophan

FEMSTATE™ Daily Dose

L-Tryptophan is included exclusively in SOOTHE™ because the luteal phase is characterized by progesterone dominance, neuroendocrine adaptation, neurotransmitter regulation, sleep physiology, and metabolic stabilization. As the essential amino acid precursor to serotonin and melatonin, L-tryptophan supports normal neurophysiology without directly altering reproductive hormone production.

2. Physiological Role

L-Tryptophan is an essential amino acid, meaning it cannot be synthesized by the human body and must be obtained from dietary sources. It serves as the precursor for several biologically important molecules, including:

• Serotonin
• Melatonin
• Niacin (Vitamin B3)
• Kynurenine pathway metabolites

Approximately 90-95% of dietary tryptophan is metabolized through the kynurenine pathway, while a smaller proportion is converted into serotonin and subsequently melatonin. These pathways contribute to normal nervous system physiology, immune regulation, sleep-wake cycles, and cellular metabolism.(1-4)

L-Tryptophan contributes to:

• Serotonin synthesis
• Melatonin synthesis
• Sleep physiology
• Neurotransmitter regulation
• Protein synthesis
• Immune physiology
• Cellular metabolism

These biological functions align closely with the physiological priorities of the luteal phase.

3. Mechanism of Action

L-Tryptophan functions primarily as a metabolic precursor.

Serotonin Synthesis

L-Tryptophan -> 5-Hydroxytryptophan (5-HTP) -> Serotonin -> Normal neurotransmission -> Neurophysiological homeostasis

The conversion of tryptophan to serotonin requires vitamin B6 (P5P) as a cofactor, creating an intentional synergy within the SOOTHE™ formulation.

Melatonin Synthesis

Serotonin -> N-acetylserotonin -> Melatonin -> Sleep-wake regulation

This pathway supports normal circadian physiology rather than acting as a direct sedative.

Protein Synthesis

As an essential amino acid, tryptophan also contributes to:

• structural protein synthesis
• tissue maintenance
• cellular repair

Kynurenine Pathway

The majority of dietary tryptophan is metabolized through the kynurenine pathway, contributing to:

• NAD⁺ synthesis
• immune regulation
• cellular energy metabolism

4. Why Included in FEMSTATE™

SOOTHE™

The luteal phase is characterized by:

• progesterone dominance
• neuroendocrine adaptation
• GABAergic regulation
• maintenance of physiological homeostasis
• preparation for the next endocrine transition

L-Tryptophan supports these biological priorities by providing the physiological precursor required for normal serotonin and melatonin synthesis.

Importantly, the formulation does not aim to increase serotonin pharmacologically, but rather to support the normal biochemical pathways involved in neurotransmitter production.

5. Dose Justification

Selected Dose: 150 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

The dose supports normal precursor availability for serotonin synthesis while complementing dietary protein intake.

Unlike therapeutic doses historically used in sleep research (typically 500-2,000 mg), 150 mg was selected as a physiological nutritional dose within a multi-ingredient formulation.

Human Clinical Evidence

Human intervention studies evaluating L-tryptophan have used a broad range of doses depending on study objectives.

The selected dose was chosen because it:

• contributes to precursor availability
• complements vitamin B6
• integrates well with L-theanine and GABA
• maintains excellent tolerability

Safety

The selected dose remains substantially below doses commonly used in clinical sleep studies and has an excellent safety profile.

Formulation Compatibility

150 mg allows:

• synergistic interaction with vitamin B6
• complementary activity with L-theanine
• complementary physiology with GABA
• maintenance of serving size

HR+ Philosophy

L-Tryptophan demonstrates no known endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

L-Tryptophan has been investigated in relation to:

• sleep physiology
• serotonin metabolism
• mood regulation
• stress physiology
• cognitive function

The strongest evidence supports its role as the physiological precursor of serotonin and melatonin.

Evidence supporting supplementation effects is strongest at higher doses than those used in FEMSTATE™, whereas the FEMSTATE dose is intended to provide nutritional support within an integrated formulation rather than therapeutic intervention.

7. Safety Considerations

L-Tryptophan has an excellent safety profile at nutritional doses.

FEMSTATE Dose: 150 mg/day

Clinical studies have commonly evaluated doses between: 500-2,000 mg/day

The FEMSTATE dose is substantially lower.

Potential adverse effects associated with much higher doses include:

• gastrointestinal discomfort
• drowsiness
• headache

Rare historical safety concerns related to eosinophilia-myalgia syndrome were linked to contaminated manufacturing batches in the late 1980s rather than to L-tryptophan itself.

8. HR+ Safety Review

L-Tryptophan was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

L-Tryptophan is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Vitamin B6 (P5P)

Required for conversion of tryptophan into serotonin -> Strong physiological synergy

L-Theanine

Supports complementary neurophysiological regulation -> Positive synergy

GABA

Supports complementary regulation of neuronal excitability -> Positive synergy

Magnesium L-Threonate

Supports normal nervous system physiology -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Selenium
• Potassium

at FEMSTATE doses.

Known Considerations

Individuals taking:

• Selective serotonin reuptake inhibitor
• Monoamine oxidase inhibitor
• other serotonergic medications

should consult their healthcare provider before using supplemental L-tryptophan because of the theoretical risk of excessive serotonergic activity.

10. Regulatory Status

L-Tryptophan is:

• Widely accepted for use in dietary supplements.
• Recognized as an amino acid ingredient in nutritional products.
• Supported by numerous human clinical studies evaluating neurophysiology and sleep.

11. Evidence Gaps & Future Research

Current evidence strongly supports L-tryptophan as:

• the physiological precursor of serotonin
• the physiological precursor of melatonin

Areas requiring further investigation include:

• Phase-specific tryptophan metabolism during the menstrual cycle.
• Neuroendocrine adaptation during the luteal phase.
• Clinical evaluation of L-tryptophan within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated L-tryptophan within a phase-aligned nutritional formulation.

12. Conclusion

L-Tryptophan is a foundational neurophysiological ingredient within SOOTHE™ because it serves as the natural precursor for serotonin and melatonin synthesis while also contributing to protein metabolism and NAD⁺ biosynthesis. The selected dose of 150 mg was intentionally chosen as a physiological nutritional dose that complements vitamin B6, L-theanine, GABA, and magnesium L-threonate within the integrated SOOTHE™ formulation. Rather than functioning as a pharmacological sleep aid or mood intervention, L-tryptophan supports the normal biochemical pathways underlying neuroendocrine regulation during the progesterone-dominant luteal phase, making it an integral component of the FEMSTATE™ phase-aligned nutritional strategy.

References

• Nutrients. Reviews on tryptophan metabolism, serotonin physiology, and human nutrition.
• Nutritional Neuroscience. Reviews on tryptophan, neurotransmitters, and cognition.
• The American Journal of Clinical Nutrition. Reviews on amino acid metabolism and tryptophan physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on neuroendocrine regulation and women's physiology.
• Williams Textbook of Endocrinology.
• Sleep Medicine Reviews. Reviews on tryptophan, serotonin, melatonin, and sleep physiology.

Ingredient Scientific Monograph

Gamma-Aminobutyric Acid (GABA)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: GABA

Chemical Name: Gamma-Aminobutyric Acid

Ingredient Form: Pharmaceutical-grade Gamma-Aminobutyric Acid (GABA)

FEMSTATE™ Daily Dose

Gamma-aminobutyric acid (GABA) is included exclusively in SOOTHE™ because the luteal phase is characterized by progesterone dominance, neuroendocrine adaptation, GABAergic modulation, physiological recovery, and maintenance of neuronal homeostasis. GABA was selected to complement the natural neurophysiological environment established during the luteal phase rather than to function as a sedative or pharmacologic anxiolytic.

2. Physiological Role

GABA is the primary inhibitory neurotransmitter in the mammalian central nervous system. It regulates neuronal excitability, maintains the balance between excitatory and inhibitory signaling, and contributes to normal sleep physiology, stress adaptation, motor control, autonomic regulation, and cognitive function.(1-4)

Approximately one-third of all synapses in the brain utilize GABAergic signaling.

GABA contributes to:

• Regulation of neuronal excitability
• Maintenance of physiological relaxation
• Sleep physiology
• Stress adaptation
• Motor coordination
• Autonomic nervous system regulation
• Neuroendocrine homeostasis

These physiological functions closely align with the biological priorities of the luteal phase.

3. Mechanism of Action

GABA exerts its effects through activation of:

• GABA-A receptors
• GABA-B receptors

Neuronal Regulation

GABA binds to inhibitory receptors -> Reduced neuronal firing -> Balanced neuronal activity -> Maintenance of physiological homeostasis

Unlike sedative medications, nutritional GABA supplementation is intended to support normal neurophysiology rather than suppress central nervous system activity.

Neuroendocrine Physiology

During the luteal phase:

Progesterone -> Allopregnanolone -> Positive modulation of GABA-A receptors -> Physiological neuroendocrine adaptation

The inclusion of GABA in SOOTHE™ complements this naturally occurring endocrine environment.

Autonomic Regulation

Experimental evidence suggests GABA participates in:

• parasympathetic regulation
• stress physiology
• autonomic balance

although the clinical significance of orally administered GABA remains an active area of investigation.

4. Why Included in FEMSTATE™

SOOTHE™

The luteal phase emphasizes:

• progesterone dominance
• neuroendocrine adaptation
• GABAergic physiology
• physiological recovery
• maintenance of neuronal homeostasis

SOOTHE™ includes GABA to complement this biological environment.

Importantly, the formulation is not intended to pharmacologically increase GABA activity or function as a treatment for anxiety or insomnia.

Instead, GABA was selected because it aligns conceptually with the normal neurophysiological priorities of the progesterone-dominant phase.

5. Dose Justification

Selected Dose: 150 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 150 mg represents a moderate nutritional dose commonly used in dietary supplement formulations and clinical research investigating relaxation and stress physiology.

Human Clinical Evidence

Human studies evaluating oral GABA have generally investigated doses ranging from:

100–300 mg/day

The selected dose falls comfortably within this clinically investigated range.

Safety

Human studies demonstrate excellent tolerability at doses substantially higher than those used in FEMSTATE™.

Formulation Compatibility

The selected dose:

• complements L-theanine
• complements magnesium L-threonate
• complements L-tryptophan
• complements chamomile

allowing an integrated neurophysiological formulation without excessive serving size.

HR+ Philosophy

GABA demonstrates no endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

The human evidence supporting oral GABA is moderate.

The strongest findings involve:

• subjective relaxation
• stress physiology
• sleep quality
• autonomic nervous system responses

However, an important scientific consideration is that the extent to which orally administered GABA crosses the blood-brain barrier remains uncertain. Some studies suggest limited central penetration, while others propose that observed effects may occur through peripheral nervous system pathways or gut–brain communication. Consequently, although clinical trials have reported favorable outcomes, the precise mechanism by which oral GABA exerts physiological effects remains under investigation.

7. Safety Considerations

GABA demonstrates an excellent safety profile at nutritional doses.

FEMSTATE Dose: 150 mg/day

Human studies have evaluated doses ranging from: 100–750 mg/day with excellent tolerability.

Reported adverse effects are uncommon and generally mild:

• transient drowsiness
• mild gastrointestinal discomfort
• headache (rare)

8. HR+ Safety Review

GABA was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

GABA is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

L-Theanine

Supports complementary neurophysiological regulation.

↓

Strong synergy

Magnesium L-Threonate

Supports neuronal signaling and synaptic physiology -> Strong synergy

L-Tryptophan

Supports complementary neurotransmitter physiology -> Positive synergy

Chamomile

Supports physiological relaxation through complementary pathways -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Potassium
• Selenium

at FEMSTATE doses.

Known Considerations

Individuals using:

• benzodiazepines
• barbiturates
• prescription sedative medications

should consult their healthcare provider before using GABA-containing supplements because additive central nervous system effects are theoretically possible, although evidence at nutritional doses remains limited.

10. Regulatory Status

GABA is:

• Widely accepted for use in dietary supplements.
• Supported by multiple human clinical studies.
• Commercially available in numerous international markets.

11. Evidence Gaps & Future Research

Current evidence supports GABA for:

• relaxation
• stress physiology
• sleep quality

However, important research questions remain.

Future investigation should address:

• Blood-brain barrier transport of oral GABA.
• Peripheral versus central mechanisms of action.
• Neuroendocrine physiology during the luteal phase.
• Clinical evaluation within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have evaluated oral GABA as part of a phase-aligned nutritional formulation.

12. Conclusion

Gamma-aminobutyric acid (GABA) was incorporated exclusively into SOOTHE™ because its physiological role closely mirrors the neuroendocrine priorities of the progesterone-dominant luteal phase. The selected dose of 150 mg reflects commonly studied nutritional doses and integrates effectively with L-theanine, magnesium L-threonate, L-tryptophan, and chamomile to create a formulation focused on neuronal homeostasis rather than sedation. Current evidence supports oral GABA as a safe ingredient with moderate human evidence for relaxation and stress physiology, while recognizing ongoing scientific uncertainty regarding its mechanism of action after oral administration. Within the FEMSTATE™ platform, GABA is included not to alter endocrine function but to complement the natural neurophysiological environment established during the luteal phase.

References

• Nutrients. Systematic reviews on oral GABA supplementation and human physiology.
• Frontiers in Neuroscience. Reviews on GABA physiology, neurotransmission, and neuroendocrine regulation.
• Nutritional Neuroscience. Human studies evaluating oral GABA and stress physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on neuroendocrine physiology and women's health.
• Williams Textbook of Endocrinology.
• Neuroscience & Biobehavioral Reviews. Reviews on GABAergic signaling and central nervous system physiology.Bottom of Form

Ingredient Scientific Monograph

Myo-Inositol

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Myo-Inositol

Chemical Name: Myo-Inositol

Ingredient Form: Myo-Inositol

FEMSTATE™ Daily Dose

Myo-inositol is included exclusively in LIFT™ because the follicular phase is characterized by follicular growth, increasing insulin sensitivity, mitochondrial activation, cellular proliferation, and ovarian metabolic activity. Myo-inositol was selected to support the physiological environment of the follicular phase rather than to treat endocrine disorders. Although myo-inositol has been extensively studied in women with Polycystic Ovary Syndrome, its inclusion in FEMSTATE™ is based on its established role in normal cellular signaling and ovarian physiology.

2. Physiological Role

Myo-inositol is a naturally occurring carbohydrate-like molecule that functions as a structural component of cell membranes and as a precursor for inositol phosphates and phosphatidylinositol, key intracellular signaling molecules. It plays a central role in insulin signaling, calcium signaling, follicular physiology, glucose metabolism, and cellular communication.(1-4)

Myo-inositol contributes to:

• Intracellular signal transduction
• Insulin signaling
• Glucose metabolism
• Calcium signaling
• Ovarian follicular physiology
• Mitochondrial metabolism
• Cellular proliferation
• Membrane integrity

Because these biological processes become particularly active during the follicular phase, myo-inositol aligns closely with the biological priorities of LIFT™.

3. Mechanism of Action

Myo-inositol functions primarily as a precursor of intracellular second messengers.

Cellular Signaling

Myo-inositol -> Phosphatidylinositol -> Inositol triphosphate (IP₃) -> Calcium signaling -> Cellular communication

This signaling pathway regulates numerous physiological processes throughout the body.

Insulin Physiology

Myo-inositol participates in intracellular insulin signaling.

Normal insulin binding -> Intracellular inositol signaling -> Glucose uptake -> Cellular metabolism

Importantly, myo-inositol does not stimulate insulin secretion but contributes to normal intracellular signaling.

Ovarian Physiology

Within the ovary, myo-inositol contributes to:

• granulosa cell physiology
• follicular maturation
• intracellular calcium signaling
• mitochondrial function

These mechanisms have been extensively investigated in reproductive endocrinology.

Mitochondrial Function

Through its effects on cellular signaling, myo-inositol supports:

• ATP production
• metabolic regulation
• cellular proliferation

during anabolic physiology.

4. Why Included in FEMSTATE™

LIFT™

The follicular phase is characterized by:

• follicular growth
• increasing estradiol
• cellular proliferation
• mitochondrial activation
• anabolic metabolism

Myo-inositol supports these biological priorities by contributing to:

• intracellular signaling
• glucose metabolism
• ovarian cellular physiology
• metabolic homeostasis

Importantly, FEMSTATE™ does not include myo-inositol to treat PCOS or induce ovulation. Instead, it is incorporated because intracellular signaling and ovarian metabolism are fundamental components of normal follicular physiology.

5. Dose Justification

Selected Dose: 1,000 mg

The selected dose was based on five scientific criteria.

Physiological Relevance

A dose of 1,000 mg/day provides meaningful physiological exposure while fitting within a multi-ingredient formulation designed for healthy women.

This dose supports:

• intracellular signaling
• ovarian physiology
• glucose metabolism
• mitochondrial function

without approaching pharmacological dosing strategies commonly used in clinical management of PCOS.

Human Clinical Evidence

Clinical trials in reproductive endocrinology frequently use 2-4 g/day of myo-inositol in women with PCOS. However, these doses are intended to address a pathological metabolic condition.

For FEMSTATE™, a lower dose of 1 g/day was intentionally selected because the objective is to support normal follicular physiology, not to treat insulin resistance or endocrine disease.

Safety

Myo-inositol has demonstrated excellent tolerability in human studies, including trials using substantially higher doses than those incorporated into FEMSTATE™.

Formulation Compatibility

The selected dose:

• complements magnesium
• complements collagen
• complements hyaluronic acid
• supports the anabolic physiology of LIFT™
• allows sufficient formulation space for additional phase-specific nutrients

HR+ Philosophy

Myo-inositol demonstrates no estrogenic activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Myo-inositol has been extensively investigated in women with PCOS, insulin resistance, and reproductive disorders.

The strongest human evidence supports:

• insulin signaling
• ovarian physiology
• follicular development
• metabolic regulation

However, most clinical evidence comes from women with metabolic or reproductive disorders rather than healthy cycling women. Therefore, extrapolation to phase-aligned nutrition should be made cautiously.

7. Safety Considerations

Myo-inositol demonstrates an excellent safety profile.

FEMSTATE Dose

1,000 mg/day

Clinical studies have safely evaluated doses up to 12 g/day, although reproductive studies most commonly use 2–4 g/day.

Reported adverse effects are generally mild and may include:

• transient gastrointestinal discomfort
• mild nausea
• abdominal bloating (uncommon)

The FEMSTATE™ dose remains well below amounts commonly evaluated in therapeutic studies.

Overall Safety Rating

★★★★★ Excellent

8. HR+ Safety Review

Myo-inositol was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Although myo-inositol influences intracellular signaling involved in ovarian physiology, it does not directly stimulate estrogen production or function as a hormone.

9. Ingredient Interactions

Positive Interactions

Magnesium

Supports intracellular signaling and ATP production -> Strong physiological synergy

Chromium

Supports complementary glucose metabolism and insulin signaling -> Positive metabolic synergy

Vitamin B Complex

Supports mitochondrial metabolism and cellular energy production -> Positive synergy

Collagen & Hyaluronic Acid

Complement the anabolic physiology of the follicular phase -> Positive formulation synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Zinc
• Selenium

at FEMSTATE™ doses.

Known Considerations

Individuals taking glucose-lowering medications should consult their healthcare provider before combining high-dose myo-inositol with prescription therapy. The 1 g dose in FEMSTATE™ is nutritional and not intended for treatment of insulin resistance.

10. Regulatory Status

Myo-inositol is:

• Widely accepted for use in dietary supplements.
• Extensively investigated in reproductive endocrinology.
• Commonly used in nutritional products supporting women's health.
• Recognized internationally as a nutritional ingredient.

11. Evidence Gaps & Future Research

Current evidence strongly supports myo-inositol for:

• intracellular signaling
• ovarian physiology
• insulin signaling
• follicular biology

Areas requiring further investigation include:

• Phase-specific application in healthy menstruating women.
• Optimal nutritional dosing outside PCOS populations.
• Clinical evaluation within phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated 1 g/day myo-inositol within a phase-aligned nutritional formulation for healthy women.

12. Conclusion

Myo-inositol is a key metabolic ingredient within LIFT™ because of its established roles in intracellular signaling, ovarian physiology, glucose metabolism, and cellular communication. The selected dose of 1,000 mg reflects a deliberate distinction between physiological nutritional support and therapeutic dosing commonly used in women with PCOS. Rather than targeting endocrine dysfunction, the FEMSTATE™ formulation uses myo-inositol to support the normal anabolic and metabolic environment of the follicular phase, aligning with the platform's physiology-first philosophy. Its excellent safety profile, strong mechanistic rationale, and extensive reproductive endocrinology literature make it one of the strongest evidence-based ingredients within the LIFT™ formulation.

References

• International Journal of Endocrinology. Reviews on myo-inositol and reproductive endocrinology.
• Nutrients. Systematic reviews on myo-inositol, insulin signaling, and ovarian physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on myo-inositol and female reproductive physiology.
• Gynecological Endocrinology. Clinical studies of myo-inositol in ovarian function.
• Williams Textbook of Endocrinology.
• Yen and Jaffe's Reproductive Endocrinology.

Ingredient Scientific Monograph

Ginger (Zingiber officinale) Root Extract

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Ginger

Scientific Name: Ginger

Botanical Source: Zingiber officinale Roscoe

Ingredient Form: Standardized Ginger Root Extract

Primary Bioactive Compounds:

• 6-Gingerol
• 8-Gingerol
• 10-Gingerol
• 6-Shogaol
• Zingerone

FEMSTATE™ Daily Dose

Ginger is included exclusively in RESET™ because the menstrual phase is characterized by physiological inflammatory remodeling, uterine tissue regeneration, oxidative metabolism, and gastrointestinal adaptation. Ginger was selected because of its well-established roles in supporting normal inflammatory physiology, antioxidant defense, gastrointestinal function, and comfort during menstruation. Importantly, the rationale for inclusion extends beyond symptom management and is based on its participation in the biological processes active during menstrual tissue repair.

2. Physiological Role

Ginger is one of the most extensively studied medicinal botanicals in human nutrition. Its biological activity is primarily attributed to gingerols and shogaols, which influence inflammatory signaling pathways, oxidative balance, gastrointestinal motility, and cellular stress responses.(1-4)

Experimental and human studies demonstrate that ginger contributes to:

• Physiological inflammatory regulation
• Endogenous antioxidant defense
• Gastrointestinal physiology
• Cellular redox balance
• Smooth muscle physiology
• Mitochondrial protection

Within the FEMSTATE™ platform, these physiological functions align closely with the regenerative biology of the menstrual phase.

3. Mechanism of Action

Ginger exerts multiple complementary biological effects.

Physiological Inflammatory Regulation

Gingerols and shogaols influence several inflammatory signaling pathways, including modulation of:

• Cyclooxygenase (COX)
• Lipoxygenase (LOX)
• Nuclear factor-kappa B (NF-κB)

Rather than suppressing normal inflammation, ginger helps maintain balanced inflammatory signaling during physiological tissue remodeling.

Antioxidant Physiology

Ginger contributes to:

• maintenance of endogenous antioxidant enzyme activity
• regulation of reactive oxygen species
• preservation of cellular redox homeostasis

These mechanisms complement the oxidative physiology associated with endometrial regeneration.

Gastrointestinal Physiology

Human studies consistently demonstrate that ginger supports:

• normal gastric emptying
• gastrointestinal motility
• digestive comfort

These actions may be particularly relevant during menstruation when gastrointestinal physiology can be influenced by prostaglandin signaling.

Smooth Muscle Physiology

Experimental evidence suggests ginger may influence smooth muscle activity through multiple biochemical pathways. While these mechanisms have been investigated extensively, the clinical significance in healthy menstruating women remains an area of active research.

4. Why Included in FEMSTATE™

RESET™

The menstrual phase is characterized by:

• controlled inflammatory remodeling
• endometrial regeneration
• oxidative metabolism
• tissue repair
• physiological gastrointestinal adaptation

Ginger supports these biological priorities through:

• regulation of inflammatory signaling
• endogenous antioxidant physiology
• gastrointestinal homeostasis
• cellular resilience

The ingredient was not selected solely for menstrual comfort, but because its physiological actions complement the regenerative environment created during menstruation.

5. Dose Justification

Selected Dose: 250 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 250 mg/day provides meaningful exposure to ginger bioactive compounds while integrating effectively within a multi-ingredient formulation.

Human Clinical Evidence

Randomized controlled trials evaluating ginger for women's health and gastrointestinal physiology commonly use doses between 250 mg and 2,000 mg/day, depending on the study objective.

The selected dose represents the lower end of clinically investigated ranges while maintaining excellent tolerability.

Safety

The selected dose provides physiological support while remaining substantially below doses associated with gastrointestinal intolerance.

Formulation Compatibility

The selected dose:

• complements vitamin C
• complements magnesium
• complements tart cherry
• supports the regenerative objectives of RESET™

without contributing excessive botanical load.

HR+ Philosophy

Ginger demonstrates no clinically meaningful estrogenic activity and aligns with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Ginger is supported by numerous randomized controlled trials and systematic reviews.

The strongest evidence supports:

• gastrointestinal physiology
• maintenance of normal inflammatory responses
• menstrual comfort
• antioxidant physiology

Several meta-analyses have reported that ginger supplementation can reduce primary dysmenorrhea pain intensity compared with placebo, although FEMSTATE™ does not position ginger as a treatment for menstrual pain. Instead, these findings provide supportive evidence for ginger's role in menstrual physiology.¹,³

7. Safety Considerations

Ginger has an excellent safety profile.

FEMSTATE Dose: 250 mg/day

Clinical studies have safely evaluated doses ranging from: 250-2,000 mg/day

Reported adverse effects are generally mild:

• heartburn
• mild gastrointestinal discomfort
• belching

These effects are uncommon at the dose used in FEMSTATE™.

8. HR+ Safety Review

Ginger was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• phytoestrogen activity
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No clinically meaningful estrogen receptor agonist activity

✔ No progesterone receptor agonist activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Current evidence does not support classification of ginger as a hormonally active botanical.

9. Ingredient Interactions

Positive Interactions

Vitamin C

Supports complementary antioxidant physiology -> Positive synergy

Tart Cherry Extract

Supports complementary regulation of physiological inflammatory pathways -> Positive synergy

Magnesium

Supports complementary smooth muscle and neuromuscular physiology -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Iron
• Zinc
• Selenium

at FEMSTATE doses.

Known Considerations

Ginger may have mild antiplatelet activity. Individuals taking anticoagulant or antiplatelet medications, or those with bleeding disorders, should consult a healthcare professional before using concentrated ginger supplements, particularly before surgery.

10. Regulatory Status

Ginger is:

• Widely accepted for use in dietary supplements.
• Recognized as a traditional food and botanical ingredient.
• Supported by numerous human clinical trials.
• Generally recognized as safe (GRAS) for use in foods in the United States.

11. Evidence Gaps & Future Research

Current evidence strongly supports ginger for:

• gastrointestinal physiology
• menstrual comfort
• physiological inflammatory regulation
• antioxidant biology

Areas requiring further investigation include:

• Mechanistic studies examining ginger during normal menstrual tissue regeneration.
• Phase-specific application within physiology-based nutritional systems.
• Clinical evaluation of ginger as part of the complete RESET™ formulation.

No randomized controlled trials have specifically evaluated ginger within a phase-aligned nutritional system such as FEMSTATE™.

12. Conclusion

Ginger (Zingiber officinale) is a key botanical ingredient within RESET™ because its physiological activities closely align with the biological priorities of the menstrual phase. The selected dose of 250 mg is supported by extensive human clinical research demonstrating favorable effects on gastrointestinal physiology, normal inflammatory regulation, antioxidant biology, and menstrual comfort. Within the FEMSTATE™ platform, ginger is incorporated not as a symptomatic intervention, but as a botanical that complements the coordinated tissue remodeling, oxidative balance, and regenerative physiology characteristic of menstruation. Its excellent safety profile, strong human evidence, and compatibility with the HR+-conscious formulation philosophy make it one of the highest-confidence botanical ingredients in the RESET™ formulation.

References

• Pain Medicine. Systematic reviews and meta-analyses of ginger for primary dysmenorrhea.
• Nutrients. Reviews on ginger phytochemistry, antioxidant activity, and human health.
• Phytotherapy Research. Clinical trials of ginger in women's health and gastrointestinal physiology.
• Journal of Ethnopharmacology. Reviews on ginger pharmacology and inflammatory signaling.
• Williams Textbook of Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on menstrual physiology, inflammation, and reproductive biology.

Ingredient Scientific Monograph

Tart Cherry (Montmorency Cherry) Fruit Extract

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Tart Cherry

Scientific Name: Montmorency tart cherry

Botanical Source: Prunus cerasus L.

Ingredient Form: Standardized Tart Cherry Fruit Extract

Primary Bioactive Compounds:

• Anthocyanins
• Cyanidin glycosides
• Flavonoids
• Phenolic acids
• Melatonin (naturally occurring, trace amounts)

FEMSTATE™ Daily Dose

Tart cherry extract is included exclusively in RESET™ because the menstrual phase is characterized by physiological inflammatory remodeling, oxidative metabolism, connective tissue regeneration, and cellular recovery. Tart cherry was selected as an HR+-compatible alternative to botanical ingredients with potential endocrine concerns (such as curcumin), providing support for normal recovery physiology through antioxidant and polyphenol pathways rather than hormonal mechanisms.

2. Physiological Role

Tart cherry is naturally rich in polyphenols, particularly anthocyanins, which contribute to endogenous antioxidant physiology and regulation of normal inflammatory signaling. Human studies have investigated tart cherry primarily in the context of exercise recovery, muscle physiology, oxidative stress, sleep, and inflammatory biomarkers.(1-4)

Its principal physiological functions include:

• Endogenous antioxidant support
• Maintenance of physiological inflammatory balance
• Recovery following tissue stress
• Cellular redox homeostasis
• Connective tissue physiology
• Vascular function
• Muscle recovery

Within the FEMSTATE™ platform, these biological activities align closely with the regenerative physiology of the menstrual phase.

3. Mechanism of Action

Tart cherry exerts its physiological effects primarily through its polyphenol content.

Antioxidant Physiology

Anthocyanins support endogenous antioxidant systems by:

• scavenging reactive oxygen species (ROS)
• supporting glutathione-dependent pathways
• maintaining physiological redox homeostasis

Importantly, tart cherry supports normal oxidative balance rather than eliminating physiologic ROS required for tissue repair.

Physiological Inflammatory Regulation

Experimental studies suggest tart cherry polyphenols influence:

• cyclooxygenase (COX) pathways
• nuclear factor-kappa B (NF-κB)
• cytokine signaling

These actions support normal inflammatory regulation during tissue remodeling.

Connective Tissue Recovery

By supporting physiological inflammatory resolution and antioxidant balance, tart cherry contributes to the normal recovery of connective tissues following physiological stress.

Vascular Physiology

Polyphenols may support endothelial nitric oxide bioavailability and vascular function, although these effects are modest and remain under investigation.

4. Why Included in FEMSTATE™

RESET™

The menstrual phase emphasizes:

• endometrial regeneration
• connective tissue remodeling
• physiological inflammatory repair
• oxidative metabolism
• restoration of tissue homeostasis

Tart cherry supports these biological priorities through:

• endogenous antioxidant physiology
• regulation of physiological inflammatory signaling
• maintenance of cellular resilience
• support of tissue recovery

The ingredient was intentionally selected to complement the regenerative biology of menstruation while maintaining compatibility with the HR+-conscious formulation philosophy.

5. Dose Justification

Selected Dose: 300 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 300 mg provides meaningful exposure to tart cherry polyphenols while fitting within a comprehensive multi-ingredient formulation.

Human Clinical Evidence

Human intervention studies have commonly evaluated standardized tart cherry extracts in doses ranging from 240-600 mg/day, depending on extract standardization and study objectives.

The selected dose falls comfortably within the lower-to-middle portion of clinically investigated ranges.

Safety

The selected dose provides physiological support while maintaining excellent gastrointestinal tolerability and long-term safety.

Formulation Compatibility

The selected dose:

• complements vitamin C
• complements ginger
• complements magnesium
• complements selenium

creating an integrated regenerative formulation without excessive botanical loading.

HR+ Philosophy

Tart cherry was selected because it demonstrates no clinically meaningful estrogenic activity and provides a conservative botanical option consistent with the FEMSTATE™ HR+ safety strategy.

6. Human Clinical Evidence

Human clinical studies have investigated tart cherry in relation to:

• exercise recovery
• muscle soreness
• oxidative stress biomarkers
• inflammatory biomarkers
• sleep quality

The strongest evidence supports its ability to support normal recovery physiology and reduce exercise-induced oxidative and inflammatory responses.

Direct evidence in menstrual physiology remains limited.

7. Safety Considerations

Tart cherry extract has an excellent safety profile.

FEMSTATE Dose: 300 mg/day

Human clinical studies have evaluated similar and substantially higher doses without serious adverse effects.

Reported adverse events are uncommon and generally mild:

• transient gastrointestinal discomfort
• mild bloating (rare)

8. HR+ Safety Review

Tart cherry extract was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• phytoestrogen content
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No clinically meaningful estrogen receptor agonist activity

✔ No progesterone receptor agonist activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Unlike certain botanical extracts commonly marketed for inflammation, tart cherry has no evidence of clinically relevant hormonal activity.

9. Ingredient Interactions

Positive Interactions

Vitamin C

Supports complementary antioxidant physiology -> Strong antioxidant synergy

Ginger

Supports complementary physiological inflammatory regulation -> Positive synergy

Selenium

Supports endogenous antioxidant enzyme systems -> Positive synergy

Vitamin E

Provides complementary lipid and water-soluble antioxidant support -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Iron
• Magnesium
• Zinc

at FEMSTATE™ doses.

Known Considerations

Individuals with allergies to cherries or other stone fruits should avoid supplementation.

Because tart cherry contains naturally occurring polyphenols, theoretical interactions with anticoagulant medications have been discussed but have not been demonstrated at nutritional doses.

10. Regulatory Status

Tart cherry extract is:

• Widely accepted for use in dietary supplements.
• Commonly used in sports nutrition and recovery products.
• Supported by multiple randomized controlled trials evaluating recovery physiology.
• Generally recognized as safe (GRAS) as a food ingredient.

11. Evidence Gaps & Future Research

Current evidence strongly supports tart cherry for:

• antioxidant physiology
• recovery biology
• exercise-induced inflammatory responses

Areas requiring further investigation include:

• Menstrual tissue regeneration.
• Physiological inflammatory remodeling during menstruation.
• Clinical evaluation within phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated tart cherry within a menstrual phase-aligned nutritional formulation.

12. Conclusion

Tart cherry (Prunus cerasus) was selected as a key botanical ingredient within RESET™ because its physiological activities closely align with the biological priorities of the menstrual phase. Rich in anthocyanins and other polyphenols, tart cherry supports endogenous antioxidant systems, physiological inflammatory regulation, connective tissue recovery, and cellular resilience without demonstrating clinically meaningful endocrine activity. The selected dose of 300 mgreflects clinically investigated ranges while maintaining excellent tolerability and compatibility with the overall formulation. Importantly, tart cherry was intentionally chosen as an HR+-conscious botanical alternative to ingredients with greater endocrine uncertainty, reinforcing the FEMSTATE™ philosophy of supporting normal regenerative physiology through evidence-based nutritional strategies rather than hormonal modulation.

References

• Nutrients. Systematic reviews on tart cherry, recovery physiology, and antioxidant biology.
• Scandinavian Journal of Medicine & Science in Sports. Randomized controlled trials evaluating tart cherry and exercise recovery.
• Journal of the International Society of Sports Nutrition. Reviews on tart cherry supplementation and recovery.
• Antioxidants. Reviews on anthocyanins, oxidative physiology, and polyphenols.
• Williams Textbook of Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on oxidative physiology and women's health.

Ingredient Scientific Monograph

Broccoli Sprout Extract (Source of Sulforaphane)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Broccoli Sprout Extract

Scientific Name: Broccoli

Botanical Source: Young broccoli sprouts (Brassica oleracea var. italica)

Primary Bioactive Compound: Sulforaphane (generated from glucoraphanin by the enzyme myrosinase)

Ingredient Form: Broccoli Sprout Extract

FEMSTATE™ Daily Dose

Broccoli sprout extract is included in RESET™ and LIFT™ because of its role in supporting cellular defense systems, endogenous antioxidant pathways, detoxification enzymes, mitochondrial resilience, and normal inflammatory regulation. Rather than functioning as a direct antioxidant, sulforaphane activates the body's own cytoprotective mechanisms through regulation of the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway.

Importantly, broccoli sprout extract was intentionally selected as an HR+-conscious alternative to botanicals with potential endocrine activity.

2. Physiological Role

Sulforaphane is one of the most extensively studied dietary isothiocyanates.

Unlike conventional antioxidants that directly neutralize reactive oxygen species, sulforaphane functions primarily by activating endogenous cellular defense systems.

Physiological functions include:

• Activation of Nrf2 signaling
• Induction of Phase II detoxification enzymes
• Maintenance of cellular redox homeostasis
• Mitochondrial protection
• Regulation of oxidative stress responses
• Cellular resilience
• Support of normal inflammatory regulation

These biological processes are particularly relevant during:

• tissue regeneration (RESET™)
• anabolic cellular growth (LIFT™)

3. Mechanism of Action

Sulforaphane functions primarily through activation of the Nrf2-Keap1 signaling pathway.

Nrf2 Activation

Sulforaphane -> Modification of Keap1 -> Release of Nrf2 -> Nuclear translocation -> Activation of Antioxidant Response Elements (ARE) -> Increased expression of cytoprotective genes -> Enhanced endogenous cellular defense

This pathway regulates expression of numerous protective enzymes including:

• Glutathione S-transferases
• NAD(P)H quinone oxidoreductase-1 (NQO1)
• Heme oxygenase-1 (HO-1)
• Glutamate-cysteine ligase

Cellular Redox Homeostasis

Sulforaphane supports:

• glutathione synthesis
• oxidative stress adaptation
• mitochondrial resilience

Unlike direct antioxidants, it enhances the body’s own antioxidant capacity.

Detoxification Physiology

Sulforaphane induces Phase II detoxification enzymes involved in normal metabolism of endogenous and exogenous compounds.

Importantly, this should not be interpreted as “detoxifying the body,” but rather as supporting normal hepatic and cellular detoxification pathways.

Cellular Stress Adaptation

Sulforaphane promotes cellular resilience during:

• oxidative metabolism
• tissue regeneration
• physiological inflammatory remodeling

4. Why Included in FEMSTATE™

RESET™

The menstrual phase is characterized by:

• tissue regeneration
• physiological inflammatory remodeling
• oxidative metabolism
• extracellular matrix repair

Sulforaphane supports these biological priorities by activating endogenous antioxidant defenses and maintaining cellular resilience during regeneration.

LIFT™

The follicular phase emphasizes:

• cellular proliferation
• mitochondrial activation
• anabolic metabolism
• connective tissue synthesis

Sulforaphane supports these processes by maintaining redox homeostasis during increased cellular activity.

Importantly, the ingredient was selected to support normal cellular physiology, not to influence reproductive hormone production.

5. Dose Justification

Selected Dose: 10 mg Broccoli Sprout Extract

The selected dose was based on five scientific criteria.

Physiological Relevance

The selected amount contributes sulforaphane precursors while fitting within a multi-ingredient formulation designed for long-term daily use.

Because broccoli sprout extracts differ considerably in glucoraphanin concentration and myrosinase activity, the physiologically relevant dose is ultimately determined by standardized sulforaphane yield rather than extract weight alone.

Human Clinical Evidence

Clinical studies have evaluated a wide range of broccoli sprout preparations.

Rather than attempting to reproduce pharmacological doses used in disease-focused trials, FEMSTATE uses a nutritional dose intended to complement endogenous antioxidant physiology.

Safety

Broccoli sprout extracts demonstrate excellent tolerability in human studies.

Formulation Compatibility

The selected dose:

• complements vitamin C
• complements selenium
• complements tart cherry
• complements antioxidant physiology

while maintaining formulation balance.

HR+ Philosophy

Broccoli sprout extract was selected because it demonstrates a favorable endocrine safety profile while supporting cellular defense pathways.

6. Human Clinical Evidence

Sulforaphane has been investigated in hundreds of human studies.

The strongest evidence supports:

• activation of Nrf2
• induction of Phase II enzymes
• glutathione metabolism
• antioxidant physiology
• cellular protection

Evidence for clinical disease outcomes remains variable and depends on study population, formulation, and dose.

7. Safety Considerations

Broccoli sprout extract possesses an excellent safety profile.

FEMSTATE Dose: 10 mg/day

Human intervention studies have evaluated substantially larger amounts of standardized broccoli sprout preparations without major safety concerns.

Reported adverse effects are uncommon:

• mild gastrointestinal discomfort
• bloating
• transient digestive symptoms

8. HR+ Safety Review

This is one of the most important ingredients within the FEMSTATE™ HR+ framework.

Broccoli sprout extract was independently evaluated for:

• estrogen receptor agonism
• progesterone receptor activity
• aromatase modulation
• phytoestrogen properties
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor agonist activity

✔ No phytoestrogen properties

✔ No evidence of direct endocrine stimulation

Importantly, sulforaphane has been extensively investigated in laboratory and translational oncology research because of its effects on Nrf2 signaling and cellular defense pathways. However, these findings should not be interpreted as evidence that broccoli sprout extract prevents, treats, or reduces the risk of cancer. Within FEMSTATE™, the ingredient is included solely to support normal cellular physiology and endogenous antioxidant mechanisms.

9. Ingredient Interactions

Positive Interactions

Vitamin C

Supports complementary antioxidant physiology -> Strong synergy

Selenium

Supports glutathione-dependent antioxidant systems -> Strong synergy

Tart Cherry

Supports complementary regulation of oxidative physiology -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Iron
• Magnesium
• Zinc
• Vitamin D

at FEMSTATE doses.

Known Considerations

Individuals taking anticoagulant medications or with thyroid disorders consuming very high amounts of cruciferous vegetables should follow standard dietary guidance. The amount included in FEMSTATE™ is nutritional and not expected to meaningfully affect thyroid function in iodine-replete individuals.

10. Regulatory Status

Broccoli sprout extract is:

• Widely accepted for use in dietary supplements.
• Extensively investigated in nutritional science.
• Recognized as a food-derived botanical ingredient.

11. Evidence Gaps & Future Research

Current evidence strongly supports sulforaphane for:

• Nrf2 activation
• endogenous antioxidant defense
• cellular resilience

Areas requiring further investigation include:

• Phase-specific application during menstrual physiology.
• Cellular adaptation during tissue regeneration.
• Clinical evaluation within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated broccoli sprout extract within a phase-aligned formulation.

12. Conclusion

Broccoli sprout extract, as a source of sulforaphane, is one of the most scientifically distinctive ingredients within the FEMSTATE™ platform. Its inclusion in RESET™ and LIFT™ is based on its ability to activate endogenous cellular defense pathways rather than acting as a direct antioxidant. Through regulation of the Nrf2 pathway, sulforaphane supports physiological antioxidant responses, mitochondrial resilience, and cellular adaptation during tissue regeneration and anabolic growth. The selected dose reflects a physiology-based approach focused on long-term nutritional support rather than pharmacological intervention. Its excellent safety profile and favorable HR+ assessment make broccoli sprout extract a highly compatible ingredient within the FEMSTATE™ philosophy of supporting normal cellular biology without directly influencing endocrine function.

References

• Nutrients. Systematic reviews on sulforaphane, Nrf2 activation, and human health.
• Cancer Prevention Research. Human studies on broccoli sprout extracts and sulforaphane biomarkers.
• Free Radical Biology and Medicine. Reviews on Nrf2 signaling and endogenous antioxidant systems.
• Molecular Nutrition & Food Research. Reviews on sulforaphane metabolism and cellular defense.
• Williams Textbook of Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on oxidative physiology and endocrine regulation.

Ingredient Scientific Monograph

Chamomile Flower Extract (Matricaria chamomilla L.)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Chamomile

Scientific Name: Chamomile (German Chamomile)

Botanical Source: Matricaria chamomilla L.

Ingredient Form: Standardized Chamomile Flower Extract

Primary Bioactive Compounds:

• Apigenin
• Bisabolol
• Chamazulene
• Flavonoids
• Terpenoids

FEMSTATE™ Daily Dose

Chamomile is included exclusively in SOOTHE™ because the luteal phase is characterized by progesterone dominance, neuroendocrine adaptation, physiological recovery, immune regulation, and maintenance of homeostasis. Chamomile was selected for its well-characterized effects on relaxation physiology, GABAergic signaling, and inflammatory regulation, which complement the biological priorities of the luteal phase without directly influencing reproductive hormone production.

2. Physiological Role

Chamomile is one of the most extensively studied medicinal botanicals in traditional and modern phytotherapy. Its biological activity is attributed primarily to flavonoids - particularly apigenin - along with sesquiterpenes such as bisabolol and chamazulene.

Experimental and clinical research indicates that chamomile contributes to:

• Neurophysiological regulation
• GABAergic signaling
• Physiological relaxation
• Sleep physiology
• Immune homeostasis
• Antioxidant physiology
• Normal inflammatory regulation

These biological functions align closely with the physiological priorities of the luteal phase.

3. Mechanism of Action

Chamomile exerts multiple complementary physiological actions.

GABAergic Physiology

Apigenin has been shown experimentally to bind to the benzodiazepine site of the GABA-A receptor, where it may positively modulate inhibitory neurotransmission.

Unlike benzodiazepines, chamomile does not produce clinically significant central nervous system depression at nutritional doses.

Instead, it supports normal neurophysiological relaxation.

Physiological Relaxation

Human studies suggest chamomile contributes to:

• physiological relaxation
• maintenance of sleep quality
• neuroendocrine adaptation

These effects are believed to result from combined flavonoid activity rather than a single bioactive compound.

Physiological Inflammatory Regulation

Chamomile constituents influence several inflammatory signaling pathways, including:

• Cyclooxygenase (COX)
• Lipoxygenase (LOX)
• NF-κB signaling

These actions support normal inflammatory homeostasis rather than suppression of physiological inflammation.

Antioxidant Physiology

Chamomile flavonoids contribute to endogenous antioxidant physiology through regulation of oxidative signaling and maintenance of cellular redox balance.

4. Why Included in FEMSTATE™

SOOTHE™

The luteal phase emphasizes:

• neuroendocrine regulation
• physiological recovery
• GABAergic physiology
• metabolic stability
• immune homeostasis

Chamomile supports these biological priorities through:

• maintenance of physiological relaxation
• complementary GABAergic regulation
• antioxidant physiology
• normal inflammatory signaling

The ingredient was selected to complement progesterone-mediated neurophysiology rather than to function as a sedative or sleep medication.

5. Dose Justification

Selected Dose: 150 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 150 mg provides meaningful exposure to chamomile flavonoids while integrating effectively within a comprehensive multi-ingredient formulation.

Human Clinical Evidence

Clinical studies evaluating standardized chamomile extracts have commonly investigated doses ranging from 150-1,500 mg/day, depending on extract composition and study objectives.

The selected dose represents a conservative nutritional dose that complements the broader SOOTHE™ formulation.

Safety

The selected dose provides physiological support while maintaining excellent long-term tolerability.

Formulation Compatibility

The selected dose:

• complements L-theanine
• complements GABA
• complements magnesium L-threonate
• complements saffron
• complements L-tryptophan

creating an integrated neurophysiological formulation.

HR+ Philosophy

Chamomile demonstrates minimal endocrine activity and aligns with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Chamomile has been investigated in numerous randomized controlled trials evaluating:

• relaxation
• generalized anxiety symptoms
• sleep quality
• inflammatory physiology
• gastrointestinal function

The strongest evidence supports:

• physiological relaxation
• sleep quality
• stress adaptation

Evidence for reproductive physiology remains limited.

7. Safety Considerations

Chamomile possesses an excellent safety profile.

FEMSTATE Dose: 150 mg/day

Human clinical trials have safely evaluated substantially larger doses than those used in FEMSTATE™.

Reported adverse effects are uncommon and generally mild:

• gastrointestinal discomfort
• mild drowsiness
• allergic reactions in individuals sensitive to plants in the Asteraceae (ragweed) family

8. HR+ Safety Review

Chamomile was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• phytoestrogen activity
• endocrine disruption
• oncology safety

Findings

Current evidence indicates:

✔ No clinically meaningful estrogen receptor agonist activity at nutritional doses

✔ No progesterone receptor agonist activity

✔ No aromatase stimulation

✔ No evidence supporting clinically relevant hormonal effects

Although isolated laboratory studies have reported weak flavonoid interactions with estrogen receptors, these findings have not translated into clinically meaningful endocrine effects at typical dietary or supplemental intakes.

Accordingly, chamomile is considered compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

L-Theanine

Supports complementary physiological relaxation -> Strong synergy

GABA

Supports complementary GABAergic physiology -> Strong synergy

L-Tryptophan

Supports complementary neurophysiology and sleep regulation -> Positive synergy

Magnesium L-Threonate

Supports neuronal physiology and neuromuscular homeostasis -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Selenium
• Potassium

at FEMSTATE™ doses.

Known Considerations

Individuals with allergies to ragweed or other Asteraceae plants may experience hypersensitivity reactions.

Chamomile may have mild additive effects when combined with sedative medications.

10. Regulatory Status

Chamomile is:

• Widely accepted for use in dietary supplements.
• Commonly used in herbal medicine worldwide.
• Generally recognized as safe (GRAS) as a food ingredient in the United States.
• Supported by numerous human clinical studies.

11. Evidence Gaps & Future Research

Current evidence strongly supports chamomile for:

• relaxation physiology
• sleep quality
• stress physiology

Areas requiring further investigation include:

• Neuroendocrine adaptation during the luteal phase.
• Phase-specific application within menstrual physiology.
• Clinical evaluation within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated chamomile within a phase-aligned formulation.

12. Conclusion

Chamomile (Matricaria chamomilla) is a key botanical ingredient within SOOTHE™ because its physiological activities closely align with the neuroendocrine and recovery-oriented biology of the luteal phase. The selected dose of 150 mg supports normal GABAergic physiology, physiological relaxation, antioxidant defense, and inflammatory homeostasis while maintaining an excellent safety profile. Importantly, chamomile was selected as a supportive neurophysiological botanical rather than as a sedative or hormone-modulating ingredient. Within the FEMSTATE™ platform, it complements progesterone-driven physiology by supporting the natural transition toward physiological stability and recovery during the luteal phase.

References

• Phytomedicine. Reviews on chamomile pharmacology and clinical applications.
• Journal of Clinical Psychopharmacology. Randomized controlled trials of chamomile and anxiety.
• Nutrients. Reviews on chamomile, flavonoids, and human health.
• Journal of Ethnopharmacology. Reviews on chamomile phytochemistry and mechanisms of action.
• Williams Textbook of Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on neuroendocrine physiology and women's health.

Ingredient Scientific Monograph

Saffron Extract (Crocus sativus L.)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Saffron

Scientific Name: Saffron

Botanical Source: Crocus sativus L.

Ingredient Form: Standardized Saffron Stigma Extract

Primary Bioactive Compounds:

• Crocin
• Crocetin
• Safranal
• Picrocrocin

FEMSTATE™ Daily Dose

Saffron is included exclusively in SOOTHE™ because the luteal phase is characterized by progesterone dominance, neuroendocrine adaptation, neurotransmitter regulation, oxidative balance, and physiological recovery. Standardized saffron extract was selected because it is one of the best-studied botanicals for supporting normal mood physiology and emotional well-being in healthy adults, with multiple randomized controlled trials using 30 mg/day.

Importantly, saffron is included to support normal neurophysiology, not to treat depression, anxiety, or premenstrual disorders.

2. Physiological Role

Saffron contains a unique combination of carotenoid-derived compounds that influence multiple biological pathways involved in neurophysiology, antioxidant defense, and cellular signaling.

Human and experimental studies suggest that saffron contributes to:

• Neurotransmitter regulation
• Oxidative balance
• Neuroprotection
• Cellular resilience
• Emotional well-being
• Cognitive physiology
• Endogenous antioxidant systems

These biological activities align with the neuroendocrine priorities of the luteal phase.

3. Mechanism of Action

The biological activity of saffron is attributed primarily to crocin, crocetin, and safranal.

Neurotransmitter Regulation

Experimental evidence suggests saffron influences:

• serotonin signaling
• dopamine signaling
• norepinephrine signaling

Unlike pharmaceutical antidepressants, saffron does not function through potent inhibition of neurotransmitter reuptake. Instead, it appears to support normal neurotransmitter physiology through multiple complementary mechanisms.

Antioxidant Physiology

Crocin and crocetin contribute to:

• endogenous antioxidant defense
• reduction of oxidative stress biomarkers
• maintenance of neuronal redox balance

These actions support cellular resilience during the progesterone-dominant phase.

Neuroprotection

Experimental studies suggest saffron supports:

• neuronal survival
• mitochondrial integrity
• synaptic physiology

Although promising, these mechanisms remain primarily supported by preclinical and translational research.

Neuroendocrine Adaptation

Emerging evidence suggests saffron may influence stress physiology through modulation of the hypothalamic–pituitary–adrenal (HPA) axis, although these mechanisms require additional investigation.

4. Why Included in FEMSTATE™

SOOTHE™

The luteal phase emphasizes:

• neuroendocrine regulation
• physiological recovery
• GABAergic adaptation
• neurotransmitter homeostasis
• oxidative balance

Saffron supports these biological priorities through:

• maintenance of normal neurotransmitter physiology
• endogenous antioxidant support
• cellular resilience
• neurophysiological homeostasis

Importantly, saffron was selected to complement the biological environment established by progesterone rather than to modify endocrine function.

5. Dose Justification

Selected Dose: 30 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 30 mg/day represents the most extensively studied dose in human randomized controlled trials evaluating saffron.

Human Clinical Evidence

The overwhelming majority of clinical trials investigating saffron for emotional well-being, mood, and cognitive outcomes have used 30 mg/day, making this the best-supported evidence-based dose.

Safety

Human studies consistently demonstrate excellent tolerability at 30 mg/day.

This dose remains far below amounts associated with toxicity.

Formulation Compatibility

The selected dose:

• complements L-theanine
• complements GABA
• complements chamomile
• complements magnesium L-threonate

creating an integrated neurophysiological formulation.

HR+ Philosophy

Saffron demonstrates no clinically meaningful estrogenic activity and aligns with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Saffron possesses one of the strongest human evidence bases among botanical ingredients used for neurophysiological support.

Numerous randomized controlled trials and meta-analyses have investigated saffron in relation to:

• emotional well-being
• mood
• stress physiology
• sleep quality
• cognitive function

Importantly, several randomized controlled trials have also evaluated saffron in women experiencing premenstrual symptoms, demonstrating improvements in emotional and physical symptom scores compared with placebo. While these findings are encouraging, FEMSTATE™ does not position saffron as a treatment for PMS. Rather, these data support its inclusion as a botanical that aligns with the neurophysiological priorities of the luteal phase.

7. Safety Considerations

Saffron demonstrates an excellent safety profile at nutritional doses.

FEMSTATE Dose: 30 mg/day

Human clinical trials have safely evaluated 30 mg/day for periods extending up to several months.

Reported adverse effects are uncommon and generally mild:

• headache
• nausea
• dry mouth
• dizziness

Toxicity has been reported only at doses many times higher than those used in dietary supplements.

8. HR+ Safety Review

Saffron was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• phytoestrogen properties
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No clinically meaningful estrogen receptor agonist activity

✔ No progesterone receptor agonist activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Although saffron has been investigated in reproductive health, current evidence does not support classification as a hormonally active botanical.

9. Ingredient Interactions

Positive Interactions

L-Theanine

Supports complementary neurophysiological regulation -> Strong synergy

GABA

Supports complementary neuronal homeostasis -> Positive synergy

Chamomile

Supports complementary physiological relaxation -> Positive synergy

Magnesium L-Threonate

Supports neuronal physiology and synaptic function -> Strong physiological synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Potassium
• Selenium

at FEMSTATE doses.

Known Considerations

Individuals taking:

• antidepressant medications
• serotonergic drugs
• anticoagulants

should consult a healthcare professional before using concentrated saffron supplements.

10. Regulatory Status

Saffron extract is:

• Widely accepted for use in dietary supplements.
• Supported by numerous randomized controlled trials.
• Commonly used in nutritional products targeting emotional well-being and cognitive health.

11. Evidence Gaps & Future Research

Current evidence strongly supports saffron for:

• mood physiology
• emotional well-being
• stress physiology

Areas requiring further investigation include:

• Neuroendocrine adaptation during the luteal phase.
• Mechanistic interaction with progesterone physiology.
• Clinical evaluation within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have evaluated saffron within a complete phase-aligned nutritional formulation.

12. Conclusion

Saffron (Crocus sativus L.) is one of the most scientifically supported botanical ingredients within the SOOTHE™ formulation. The selected dose of 30 mg/day reflects the dose most consistently validated in randomized controlled trials evaluating emotional well-being, neurophysiology, and stress adaptation. Within the FEMSTATE™ platform, saffron is incorporated not as a treatment for depression or premenstrual syndrome, but as a botanical whose physiological activities align with the neuroendocrine priorities of the progesterone-dominant luteal phase. Its excellent safety profile, strong human clinical evidence, and favorable HR+ assessment make saffron one of the highest-confidence botanical ingredients in the entire formulation.

References

• Journal of Affective Disorders. Randomized controlled trials and meta-analyses of saffron for mood and emotional well-being.
• Phytotherapy Research. Clinical studies evaluating saffron in women's health and neurophysiology.
• Nutrients. Systematic reviews on saffron, crocin, and human health.
• Journal of Ethnopharmacology. Reviews on saffron phytochemistry and mechanisms of action.
• Williams Textbook of Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on neuroendocrine physiology and women's health.

Ingredient Scientific Monograph

Resveratrol (from Japanese Knotweed Root Extract)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Resveratrol

Chemical Name: trans-Resveratrol

Botanical Source: Japanese knotweed (formerly Polygonum cuspidatum)

Ingredient Form: Standardized trans-Resveratrol

Primary Bioactive Compound:

• trans-Resveratrol

FEMSTATE™ Daily Dose

Resveratrol is included exclusively in SHINE™ because the ovulatory phase is characterized by increased mitochondrial activity, physiological oxidative metabolism, endothelial adaptation, extracellular matrix remodeling, and cellular resilience. Resveratrol was selected because of its well-characterized effects on cellular stress-response pathways, mitochondrial physiology, endothelial function, and endogenous antioxidant systems.

Importantly, resveratrol is included to support normal cellular physiology, not to influence estrogen signaling or reproductive hormone production.

2. Physiological Role

Resveratrol is a naturally occurring polyphenol found in grapes, berries, peanuts, and Japanese knotweed. It has been extensively investigated for its effects on cellular resilience, mitochondrial biology, oxidative physiology, endothelial function, and healthy aging.(1-5)

Resveratrol contributes to:

• Cellular stress adaptation
• Mitochondrial physiology
• Endothelial function
• Nitric oxide signaling
• Endogenous antioxidant defense
• Cellular energy metabolism
• Healthy inflammatory regulation
• Vascular homeostasis

Within FEMSTATE™, these physiological activities align with the biological priorities of the ovulatory phase.

3. Mechanism of Action

Resveratrol influences multiple cellular signaling pathways.

SIRT1 Activation

Experimental evidence suggests resveratrol may activate Sirtuin-1 (SIRT1).

SIRT1 -> Mitochondrial biogenesis -> Cellular stress adaptation -> Metabolic regulation -> Cellular resilience

Although the physiological significance of SIRT1 activation in humans continues to be investigated, this pathway represents one of the principal mechanisms associated with resveratrol biology.

AMPK Signaling

Resveratrol has been shown experimentally to influence:

AMP-activated protein kinase (AMPK) -> Cellular energy sensing -> Mitochondrial function -> ATP homeostasis

Endothelial Physiology

Resveratrol supports:

• nitric oxide bioavailability
• endothelial function
• vascular physiology

These actions complement the increased vascular activity associated with ovulation.

Antioxidant Physiology

Resveratrol contributes to endogenous antioxidant defense through regulation of:

• Nrf2 signaling
• antioxidant enzyme expression
• mitochondrial oxidative balance

Unlike direct antioxidants, resveratrol primarily influences cellular signaling pathways involved in oxidative adaptation.

4. Why Included in FEMSTATE™

SHINE™

The ovulatory phase emphasizes:

• mitochondrial activation
• endothelial adaptation
• extracellular matrix remodeling
• physiological oxidative metabolism
• cellular resilience

Resveratrol supports these biological priorities through:

• mitochondrial physiology
• vascular biology
• endogenous antioxidant regulation
• cellular stress adaptation

The formulation objective is to support the physiological demands of ovulation rather than modify endocrine function.

5. Dose Justification

Selected Dose: 100 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 100 mg/day provides meaningful exposure to trans-resveratrol while remaining appropriate for long-term nutritional supplementation.

Human Clinical Evidence

Human intervention studies have evaluated doses ranging from:

50–1,000 mg/day

The 100 mg dose represents one of the most commonly studied nutritional doses and demonstrates favorable tolerability while supporting cellular physiology.

Safety

The selected dose remains well below doses associated with gastrointestinal intolerance in clinical studies.

Formulation Compatibility

The selected dose:

• complements CoQ10
• complements astaxanthin
• complements quercetin
• complements vitamin C
• complements vitamin E

creating an integrated formulation supporting mitochondrial physiology and cellular resilience.

HR+ Philosophy

Resveratrol required one of the most comprehensive HR+ evaluations within the FEMSTATE™ formulation because of its extensive literature in reproductive biology and oncology.

6. Human Clinical Evidence

Resveratrol has been extensively investigated in relation to:

• cardiovascular physiology
• endothelial function
• oxidative stress
• mitochondrial metabolism
• healthy aging

The strongest human evidence supports improvements in vascular function and oxidative physiology.

Evidence regarding female reproductive physiology remains mixed and should be interpreted cautiously.

7. Safety Considerations

Resveratrol demonstrates an excellent safety profile at nutritional doses.

FEMSTATE Dose: 100 mg/day

Human clinical studies have safely evaluated doses substantially higher than 100 mg/day.

Reported adverse effects are generally mild:

• gastrointestinal discomfort
• nausea
• diarrhea (primarily at much higher doses)

8. HR+ Safety Review

Resveratrol underwent an extensive HR+ safety review because it has been investigated in laboratory models of hormone-sensitive cancers.

The literature was reviewed for:

• estrogen receptor agonism
• estrogen receptor antagonism
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence indicates:

✔ No evidence that nutritional doses of 100 mg/day produce clinically meaningful estrogenic stimulation.

✔ Laboratory studies demonstrate complex interactions with estrogen receptors that are dose-dependent, tissue-specific, and often contradictory.

✔ Human clinical evidence does not support classification of resveratrol as an estrogenic botanical at nutritional doses.

Accordingly, the FEMSTATE™ Scientific Advisory Framework considers 100 mg/day compatible with the HR+-conscious formulation strategy, while recognizing that higher pharmacological doses investigated in experimental oncology should not be extrapolated to nutritional supplementation.

9. Ingredient Interactions

Positive Interactions

Quercetin

Supports complementary polyphenol physiology -> Strong synergy

Astaxanthin

Supports complementary antioxidant physiology -> Positive synergy

CoQ10

Supports mitochondrial function through complementary mechanisms -> Strong synergy

Vitamin C

Supports endogenous antioxidant systems -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Magnesium
• Zinc
• Selenium

at FEMSTATE doses.

Known Considerations

Resveratrol may exhibit mild antiplatelet activity.

Individuals using:

• anticoagulants
• antiplatelet medications

should consult their healthcare provider before supplementation.

10. Regulatory Status

Resveratrol is:

• Widely accepted for use in dietary supplements.
• Commonly derived from Japanese knotweed.
• Extensively investigated in human clinical trials.
• Recognized internationally as a nutritional polyphenol.

11. Evidence Gaps & Future Research

Current evidence strongly supports resveratrol for:

• endothelial physiology
• antioxidant biology
• mitochondrial function

Areas requiring additional investigation include:

• Phase-specific physiology during ovulation.
• Cellular adaptation during reproductive tissue remodeling.
• Long-term studies evaluating nutritional-dose resveratrol in healthy reproductive-aged women.
• Clinical evaluation within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated 100 mg/day resveratrol within a phase-aligned formulation.

12. Conclusion

Resveratrol is one of the most scientifically sophisticated polyphenols within the SHINE™ formulation. The selected dose of 100 mg/day supports the physiological priorities of the ovulatory phase by contributing to mitochondrial biology, endothelial function, cellular resilience, and endogenous antioxidant regulation. Its inclusion is based on systems physiology rather than symptom management. Because resveratrol has been extensively investigated in hormone-related research, it underwent an expanded HR+ safety evaluation. Current evidence supports the compatibility of nutritional-dose resveratrol with the FEMSTATE™ HR+-conscious formulation philosophy while recognizing the need for continued surveillance as the scientific literature evolves. Within FEMSTATE™, resveratrol serves as a cellular resilience ingredient supporting the dynamic biology of ovulation rather than modifying endocrine function.

References

• Nature Reviews Drug Discovery. Reviews on resveratrol biology and therapeutic potential.
• Nutrients. Systematic reviews on resveratrol, mitochondrial physiology, and human health.
• The American Journal of Clinical Nutrition. Reviews on resveratrol and cardiovascular physiology.
• Free Radical Biology and Medicine. Reviews on resveratrol, oxidative signaling, and cellular stress adaptation.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on resveratrol, endocrine physiology, and women's health.
• Williams Textbook of Endocrinology.

Ingredient Scientific Monograph

Quercetin (as Quercetin Dihydrate)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Quercetin

Chemical Name: Quercetin Dihydrate

Ingredient Form: Quercetin Dihydrate

Natural Sources: Apples, onions, berries, capers, leafy vegetables, and tea

FEMSTATE™ Daily Dose

Quercetin is included exclusively in SHINE™ because the ovulatory phase is characterized by physiological oxidative signaling, localized inflammatory remodeling, vascular adaptation, extracellular matrix turnover, and cellular resilience. Quercetin was selected as a polyphenol that supports endogenous antioxidant systems, mast cell stability, endothelial physiology, and normal inflammatory signaling during this highly dynamic endocrine transition.

2. Physiological Role

Quercetin is a naturally occurring flavonol widely present in plant foods. It has been extensively studied for its roles in redox physiology, endothelial function, cellular signaling, immune regulation, and inflammatory homeostasis.

Quercetin contributes to:

• Endogenous antioxidant defense
• Physiological inflammatory regulation
• Mast cell stabilization
• Endothelial function
• Nitric oxide bioavailability
• Cellular resilience
• Mitochondrial physiology
• Immune homeostasis

Within FEMSTATE™, these functions align most closely with the biological priorities of SHINE™, where ovulation requires controlled tissue remodeling and redox balance.

3. Mechanism of Action

Quercetin acts through multiple complementary pathways.

Antioxidant and Redox Physiology

Quercetin supports redox homeostasis by:

• scavenging reactive oxygen species
• supporting endogenous antioxidant enzyme activity
• influencing Nrf2-related cellular defense pathways
• reducing lipid peroxidation markers in some human studies

This is relevant during ovulation, when physiological ROS signaling participates in follicular rupture and tissue remodeling.

Physiological Inflammatory Regulation

Quercetin has been shown experimentally to influence:

• NF-κB signaling
• cyclooxygenase pathways
• lipoxygenase pathways
• cytokine signaling

These actions support normal inflammatory regulation without suppressing the physiological inflammatory remodeling required for ovulation.

Endothelial and Vascular Physiology

Quercetin may support:

• endothelial function
• nitric oxide bioavailability
• vascular responsiveness
• microcirculatory physiology

This aligns with the vascular remodeling and increased ovarian blood flow associated with the ovulatory transition.

Mast Cell and Immune Regulation

Quercetin is often studied for mast cell stabilization and histamine-related pathways. Within FEMSTATE™, this is framed conservatively as support for normal immune homeostasis, not as treatment of allergy or inflammatory disease.

4. Why Included in FEMSTATE™

SHINE™

The ovulatory phase emphasizes:

• LH-driven follicular rupture
• localized inflammatory remodeling
• transient oxidative metabolism
• angiogenesis
• endothelial adaptation
• extracellular matrix remodeling
• cellular resilience

Quercetin supports these biological priorities through its effects on redox balance, inflammatory signaling, endothelial physiology, and immune homeostasis.

Importantly, quercetin is not included to alter ovulation, suppress inflammation, or modify reproductive hormones. It is included to support normal cellular physiology during a phase of heightened biological activity.

5. Dose Justification

Selected Dose: 250 mg

The selected dose was based on five scientific criteria.

Physiological Relevance

A dose of 250 mg/day provides meaningful polyphenol exposure while remaining appropriate for long-term nutritional supplementation.

Human Clinical Evidence

Human trials commonly evaluate quercetin doses ranging from 250-1,000 mg/day, depending on the outcome studied. The selected dose represents the lower end of clinically investigated supplemental ranges and was chosen to support cellular physiology without excessive polyphenol loading.

Safety

Quercetin has demonstrated good tolerability at doses substantially higher than 250 mg/day in human studies.

Formulation Compatibility

The selected dose:

• complements resveratrol
• complements vitamin C
• complements vitamin E
• complements astaxanthin
• complements CoQ10

creating an integrated SHINE™ formulation focused on mitochondrial function, antioxidant physiology, vascular biology, and cellular resilience.

HR+ Philosophy

Quercetin underwent HR+ review because flavonoids can demonstrate receptor activity in some in vitro systems. At nutritional doses, current human evidence does not support clinically meaningful estrogenic activity.

6. Human Clinical Evidence

Quercetin has been evaluated in randomized controlled trials and systematic reviews for:

• antioxidant biomarkers
• inflammatory markers
• endothelial function
• blood pressure physiology
• immune-related outcomes

The strongest human evidence supports roles in oxidative physiology and cardiovascular biomarkers. Direct evidence in ovulatory or menstrual phase-specific physiology remains limited.

7. Safety Considerations

Quercetin has a favorable safety profile at nutritional supplemental doses.

FEMSTATE Dose: 250 mg/day

Human studies have commonly evaluated doses up to 1,000 mg/day with good tolerability.

Potential adverse effects are uncommon and may include:

• mild gastrointestinal discomfort
• headache
• nausea

At very high doses or in susceptible individuals, caution is appropriate due to potential effects on drug metabolism.

8. HR+ Safety Review

Quercetin was evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor agonism
• estrogen receptor antagonism
• progesterone receptor activity
• aromatase modulation
• phytoestrogen properties
• oncology safety

Findings

Current evidence indicates:

✔ Quercetin is a dietary flavonoid with some in vitro receptor-related findings.

✔ Human evidence does not support clinically meaningful estrogenic activity at nutritional supplemental doses.

✔ No evidence supports quercetin as a progesterone receptor agonist.

✔ No evidence supports clinically meaningful aromatase stimulation at the FEMSTATE™ dose.

Because quercetin has complex cell-signaling effects in laboratory models, FEMSTATE™ classifies it as HR+ compatible with ongoing literature surveillance.

9. Ingredient Interactions

Positive Interactions

Resveratrol

Supports complementary polyphenol signaling and cellular resilience -> Strong synergy

Vitamin C

Supports antioxidant network function and may help preserve flavonoid redox activity -> Positive synergy

Vitamin E

Supports complementary lipid-phase antioxidant physiology -> Positive synergy

CoQ10

Supports mitochondrial physiology through complementary mechanisms -> Positive synergy

Astaxanthin

Supports cellular and membrane antioxidant physiology -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Selenium
• Zinc
• Magnesium
• Vitamin D3

at FEMSTATE doses.

Known Considerations

Quercetin may interact with certain medications through effects on drug transporters or cytochrome P450 enzymes. Individuals taking prescription medications with narrow therapeutic windows, anticoagulants, or immunosuppressants should consult a healthcare professional before using concentrated quercetin supplements.

10. Regulatory Status

Quercetin is:

• Widely accepted for use in dietary supplements.
• Naturally present in commonly consumed foods.
• Supported by numerous human clinical studies.
• Commonly used in nutritional products focused on antioxidant and immune physiology.

11. Evidence Gaps & Future Research

Current evidence supports quercetin for:

• redox physiology
• endothelial function
• inflammatory biomarker modulation
• immune homeostasis

Areas requiring further investigation include:

• Ovulatory phase-specific redox biology.
• Quercetin pharmacokinetics within a multi-polyphenol formulation.
• Clinical evaluation within phase-aligned systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated quercetin within an ovulation-aligned nutritional formulation.

12. Conclusion

Quercetin dihydrate is included in SHINE™ because its biological profile aligns with the ovulatory phase’s needs for cellular resilience, endothelial support, antioxidant regulation, and controlled inflammatory remodeling. The selected dose of 250 mg sits within clinically studied supplemental ranges while remaining conservative for long-term nutritional use. Within FEMSTATE™, quercetin is positioned as a polyphenol support ingredient for normal ovulatory physiology, not as a hormone modulator, anti-inflammatory drug, or fertility intervention. Its strongest role is as part of the integrated SHINE™ polyphenol-antioxidant network alongside resveratrol, vitamin C, vitamin E, astaxanthin, selenium, and CoQ10.

References

• Boots AW, Haenen GRMM, Bast A. Health effects of quercetin: From antioxidant to nutraceutical. Health effects of quercetin: From antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2-3):325-337.
• Li Y, Yao J, Han C, et al. Quercetin, Inflammation and Immunity. Quercetin, inflammation and immunity. Nutrients.2016;8(3):167.
• Brito AF, Ribeiro M, Abrantes AM, et al. Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?. Quercetin in cancer treatment, alone or in combination with conventional therapeutics? Curr Med Chem. 2015;22(26):3025-3039.
• D'Andrea G. Quercetin: A flavonol with multifaceted therapeutic applications?. Quercetin: A flavonol with multifaceted therapeutic applications? Fitoterapia. 2015;106:256-271.
• Serban MC, Sahebkar A, Zanchetti A, et al. Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-analysis. Effects of quercetin on blood pressure: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;5:e002713.
• Xu D, Hu MJ, Wang YQ, Cui YL. Antioxidant Activities of Quercetin and Its Complexes. Antioxidant activities of quercetin and its complexes. Food Chem. 2019;279:56-63.
• Ulusoy HG, Sanlier N. A Minireview of Quercetin: From Its Metabolism to Possible Mechanisms of Its Biological Activities. A minireview of quercetin: From its metabolism to possible mechanisms of its biological activities. Crit Rev Food Sci Nutr. 2020.
• Andres S, Pevny S, Ziegenhagen R, et al. Safety Aspects of the Use of Quercetin as a Dietary Supplement. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res. 2018;62:e1700447.
• Williams Textbook of Endocrinology. Chapter on oxidative stress, inflammation, and endocrine physiology.
• Guyton and Hall Textbook of Medical Physiology. Chapters on endothelial physiology, oxidative metabolism, and cellular homeostasis.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on oxidative physiology, endothelial biology, and female endocrine physiology.
• Nutrients. Reviews on flavonoids, polyphenols, and women's health.

Ingredient Scientific Monograph

Coenzyme Q10 (CoQ10)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Coenzyme Q10

Chemical Name: Ubiquinone-10

Common Abbreviation: CoQ10

Ingredient Form: Coenzyme Q10 (Ubiquinone)

FEMSTATE™ Daily Dose

Coenzyme Q10 (CoQ10) is included exclusively in SHINE™ because the ovulatory phase is characterized by peak mitochondrial activity, increased ATP demand, steroidogenesis, extracellular matrix remodeling, endothelial adaptation, and physiological oxidative metabolism. CoQ10 was selected because it plays a central role in mitochondrial energy production while simultaneously functioning as an endogenous lipid-soluble antioxidant.

Unlike stimulant ingredients, CoQ10 supports the body's natural bioenergetic systems, making it highly compatible with the physiological priorities of ovulation.

2. Physiological Role

Coenzyme Q10 is a naturally occurring lipid-soluble quinone synthesized in virtually every human cell. It is highly concentrated in tissues with elevated metabolic activity, including:

• Heart
• Brain
• Liver
• Skeletal muscle
• Ovaries

CoQ10 serves two principal physiological functions:

• Mitochondrial ATP production
• Endogenous antioxidant protection

It contributes to:

• Electron transport chain activity
• Cellular energy production
• Membrane stabilization
• Oxidative balance
• Endothelial physiology
• Cellular resilience
• Mitochondrial integrity

These biological functions closely align with the increased metabolic demands of the ovulatory phase.

3. Mechanism of Action

CoQ10 functions primarily within mitochondria.

Mitochondrial ATP Production

CoQ10 serves as an electron carrier within the electron transport chain.

NADH -> Complex I -> CoQ10 -> Complex III -> ATP Production

Without CoQ10, efficient oxidative phosphorylation cannot occur.

Antioxidant Physiology

Reduced CoQ10 (ubiquinol) protects:

• mitochondrial membranes
• phospholipid membranes
• lipoproteins

from oxidative damage.

Unlike direct antioxidants, CoQ10 participates continuously in mitochondrial redox cycling.

Cellular Bioenergetics

CoQ10 contributes to:

• mitochondrial efficiency
• ATP availability
• cellular resilience
• metabolic homeostasis

These mechanisms become particularly relevant during ovulation, when ovarian energy demand increases substantially.

Endothelial Function

Human studies suggest CoQ10 supports:

• endothelial physiology
• nitric oxide bioavailability
• vascular homeostasis

These actions complement the vascular remodeling associated with ovulation.

4. Why Included in FEMSTATE™

SHINE™

The ovulatory phase is characterized by:

• LH surge
• follicular rupture
• steroid hormone synthesis
• angiogenesis
• extracellular matrix remodeling
• mitochondrial activation

These biological processes require substantial ATP production.

CoQ10 supports:

• mitochondrial bioenergetics
• cellular resilience
• oxidative balance
• endothelial physiology

Importantly, CoQ10 is not included to improve fertility or ovarian reserve, but rather to support the increased cellular energy demands associated with normal ovulatory physiology.

5. Dose Justification

Selected Dose: 100 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 100 mg/day provides meaningful physiological exposure while remaining appropriate for long-term nutritional supplementation.

Human Clinical Evidence

Human intervention studies have commonly investigated CoQ10 doses ranging from:

100–300 mg/day

The selected dose of 100 mg is among the most frequently studied nutritional doses and has demonstrated favorable effects on mitochondrial physiology and endothelial function.

Safety

The selected dose provides physiological support while remaining substantially below doses associated with adverse effects.

Formulation Compatibility

The selected dose:

• complements resveratrol
• complements quercetin
• complements vitamin E
• complements vitamin C
• complements astaxanthin

creating an integrated formulation focused on mitochondrial function and cellular resilience.

HR+ Philosophy

CoQ10 demonstrates no endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

CoQ10 has been extensively investigated in randomized controlled trials evaluating:

• mitochondrial physiology
• cardiovascular health
• endothelial function
• exercise physiology
• healthy aging

Evidence supporting ovarian physiology primarily comes from women with diminished ovarian reserve or infertility, often using doses of 200-600 mg/day. These therapeutic studies should not be extrapolated to healthy reproductive-aged women or to the dose used in FEMSTATE™.

Within FEMSTATE™, CoQ10 is included for cellular bioenergetics, not fertility enhancement.

7. Safety Considerations

CoQ10 demonstrates an excellent safety profile.

FEMSTATE Dose: 100 mg/day

Human studies have safely evaluated doses exceeding: 1,200 mg/day

Reported adverse effects are uncommon:

• mild gastrointestinal discomfort
• nausea
• headache

These events are generally mild and infrequent.

8. HR+ Safety Review

CoQ10 was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

CoQ10 is fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Resveratrol

Supports complementary mitochondrial physiology -> Strong synergy

Quercetin

Supports complementary cellular resilience -> Positive synergy

Vitamin E

Supports lipid membrane antioxidant protection -> Strong synergy

Vitamin C

Supports regeneration of antioxidant systems -> Positive synergy

Astaxanthin

Supports complementary mitochondrial and membrane antioxidant physiology -> Strong synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Magnesium
• Selenium
• Zinc

at FEMSTATE doses.

Known Considerations

CoQ10 may modestly reduce the anticoagulant effect of Warfarin in some individuals. Patients taking vitamin K antagonists should consult their healthcare provider before supplementation.

10. Regulatory Status

Coenzyme Q10 is:

• Widely accepted for use in dietary supplements.
• Extensively studied in human clinical trials.
• Commonly used in cardiovascular and mitochondrial health formulations.
• Recognized internationally as a nutritional ingredient.

11. Evidence Gaps & Future Research

Current evidence strongly supports CoQ10 for:

• mitochondrial ATP production
• endothelial physiology
• cellular bioenergetics
• antioxidant physiology

Areas requiring additional investigation include:

• Mitochondrial adaptation during normal ovulation.
• Phase-specific ATP requirements throughout the menstrual cycle.
• Clinical evaluation of CoQ10 within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated 100 mg/day CoQ10 within a phase-aligned nutritional formulation.

12. Conclusion

Coenzyme Q10 is one of the cornerstone ingredients of the SHINE™ formulation because it directly supports the increased mitochondrial energy production required during ovulation. The selected dose of 100 mg/day is one of the most extensively studied nutritional doses and aligns with the physiological priorities of the ovulatory phase, including ATP production, endothelial adaptation, oxidative balance, and cellular resilience. Unlike therapeutic fertility protocols that employ much higher doses, FEMSTATE™ incorporates CoQ10 to support normal mitochondrial physiology during the body's most metabolically active endocrine transition. Its exceptional safety profile, robust human evidence, and complete compatibility with the HR+-conscious formulation philosophy make CoQ10 one of the highest-confidence ingredients within the SHINE™ formulation.

References

• BioFactors. Reviews on coenzyme Q10 physiology, mitochondrial function, and human health.
• Mitochondrion. Reviews on CoQ10, oxidative phosphorylation, and bioenergetics.
• Nutrients. Systematic reviews on CoQ10 supplementation and clinical outcomes.
• The American Journal of Clinical Nutrition. Reviews on CoQ10 metabolism and cardiovascular physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on mitochondrial physiology, ovarian metabolism, and endocrine health.
• Williams Textbook of Endocrinology.
• Fertility and Sterility. Clinical studies evaluating CoQ10 in ovarian physiology and reproductive medicine.

Ingredient Scientific Monograph

Hyaluronic Acid (as Sodium Hyaluronate)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Hyaluronic Acid

Chemical Name: Hyaluronan

Ingredient Form: Sodium Hyaluronate

FEMSTATE™ Daily Dose

Hyaluronic acid is included exclusively in LIFT™ because the follicular phase is characterized by cellular proliferation, extracellular matrix synthesis, connective tissue remodeling, angiogenesis, and anabolic physiology. Sodium hyaluronate was selected because of its excellent stability, bioavailability, and extensive clinical evidence supporting connective tissue, skin, and joint physiology.

Within the FEMSTATE™ platform, hyaluronic acid is not included as a cosmetic ingredient, but as a structural component supporting the connective tissue biology and extracellular matrix remodeling that naturally occur during the estrogen-dominant follicular phase.

2. Physiological Role

Hyaluronic acid is a naturally occurring glycosaminogly can present throughout the extracellular matrix of nearly every connective tissue in the body.

Highest concentrations are found in:

• Skin
• Synovial fluid
• Cartilage
• Connective tissue
• Eyes
• Umbilical cord
• Ovarian follicles
• Endometrium

Hyaluronic acid contributes to:

• Extracellular matrix organization
• Tissue hydration
• Cellular migration
• Connective tissue integrity
• Angiogenesis
• Wound healing
• Joint lubrication
• Skin physiology

These biological functions closely align with the regenerative and anabolic physiology of the follicular phase.

3. Mechanism of Action

Hyaluronic acid functions primarily as a structural molecule within the extracellular matrix.

Extracellular Matrix Organization

Hyaluronic acid -> Water binding -> Extracellular matrix expansion -> Cell migration -> Tissue remodeling -> Connective tissue physiology

Its extraordinary water-binding capacity contributes to tissue elasticity and structural organization.

Cellular Signaling

Hyaluronic acid interacts with receptors including:

• CD44
• RHAMM

These receptors regulate:

• cell migration
• proliferation
• wound repair
• extracellular matrix remodeling

Tissue Hydration

Hyaluronic acid binds large quantities of water, contributing to:

• tissue hydration
• connective tissue flexibility
• extracellular matrix viscosity

This role is especially important in tissues undergoing active remodeling.

Ovarian Physiology

Within the ovary, hyaluronic acid contributes to:

• follicular extracellular matrix
• cumulus-oocyte complex expansion
• ovulatory tissue remodeling

These physiological roles support its inclusion during the follicular phase.

4. Why Included in FEMSTATE™

LIFT™

The follicular phase is characterized by:

• increasing estradiol
• connective tissue remodeling
• angiogenesis
• extracellular matrix synthesis
• follicular maturation
• anabolic physiology

Hyaluronic acid supports these biological priorities through:

• extracellular matrix organization
• connective tissue physiology
• tissue hydration
• cellular migration

Importantly, FEMSTATE™ includes hyaluronic acid to support normal connective tissue biology, not for cosmetic skin enhancement.

5. Dose Justification

Selected Dose: 120 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 120 mg/day supports connective tissue physiology while fitting appropriately within a comprehensive multi-ingredient formulation.

Human Clinical Evidence

Randomized controlled trials evaluating oral sodium hyaluronate have commonly investigated doses ranging from: 120-240 mg/day

The selected dose represents one of the most frequently studied nutritional doses for connective tissue physiology.

Safety

The selected dose demonstrates excellent long-term tolerability.

Formulation Compatibility

The selected dose:

• complements collagen peptides
• complements vitamin C
• complements magnesium
• complements myo-inositol

creating an integrated anabolic formulation supporting extracellular matrix biology.

HR+ Philosophy

Hyaluronic acid demonstrates no endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Human clinical studies have investigated oral hyaluronic acid in relation to:

• skin hydration
• connective tissue physiology
• joint function
• extracellular matrix biology

The strongest evidence supports improvements in skin hydration and joint comfort. While these outcomes are not the primary objective of FEMSTATE™, they support hyaluronic acid's established physiological role in connective tissue biology.

Evidence regarding ovarian physiology is primarily mechanistic.

7. Safety Considerations

Hyaluronic acid demonstrates an excellent safety profile.

FEMSTATE Dose: 120 mg/day

Human studies have safely evaluated doses exceeding: 240 mg/day

Reported adverse effects are uncommon:

• mild gastrointestinal discomfort
• bloating (rare)

8. HR+ Safety Review

Hyaluronic acid was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Although hyaluronic acid participates in ovarian extracellular matrix physiology, it does not influence endocrine signaling.

9. Ingredient Interactions

Positive Interactions

Collagen Peptides

Supports complementary extracellular matrix biology -> Strong connective tissue synergy

Vitamin C

Supports collagen synthesis while hyaluronic acid supports extracellular matrix hydration -> Strong synergy

Myo-Inositol

Supports follicular physiology through complementary mechanisms -> Positive synergy

Magnesium

Supports ATP-dependent connective tissue metabolism -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Selenium
• Zinc

at FEMSTATE doses.

Known Considerations

No clinically significant nutrient interactions have been reported at nutritional doses.

Individuals with severe allergies to the manufacturing source (if fermentation-derived or animal-derived) should verify product sourcing, although most modern sodium hyaluronate is produced through microbial fermentation.

10. Regulatory Status

Sodium hyaluronate is:

• Widely accepted for use in dietary supplements.
• Extensively studied in human clinical trials.
• Commonly used in nutritional products supporting connective tissue and skin physiology.
• Recognized internationally as a safe nutritional ingredient.

11. Evidence Gaps & Future Research

Current evidence strongly supports hyaluronic acid for:

• connective tissue physiology
• extracellular matrix biology
• tissue hydration

Areas requiring further investigation include:

• Ovarian extracellular matrix remodeling during the follicular phase.
• Endometrial connective tissue physiology.
• Clinical evaluation within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated hyaluronic acid within a phase-aligned nutritional formulation.

13. Conclusion

Hyaluronic acid, provided as sodium hyaluronate, is a foundational connective tissue ingredient within LIFT™ because of its central role in extracellular matrix organization, tissue hydration, angiogenesis, and cellular migration. The selected dose of 120 mg/day reflects one of the most extensively studied oral doses and aligns with the anabolic physiology of the follicular phase, during which connective tissue remodeling and extracellular matrix synthesis are naturally increased. Rather than functioning as a cosmetic ingredient, hyaluronic acid supports the structural biology of tissue growth and regeneration that accompanies rising estrogen. Its excellent safety profile, strong human clinical evidence, and complete compatibility with the HR+-conscious formulation philosophy make it one of the highest-confidence structural ingredients within the FEMSTATE™ platform.

References

• Nutrients. Systematic reviews on oral hyaluronic acid, connective tissue physiology, and skin health.
• Nutrients. Reviews of randomized controlled trials evaluating oral sodium hyaluronate.
• International Journal of Biological Macromolecules. Reviews on hyaluronic acid biology and extracellular matrix physiology.
• Matrix Biology. Reviews on hyaluronan, connective tissue remodeling, and cell signaling.
• Williams Textbook of Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on ovarian physiology, extracellular matrix remodeling, and reproductive biology.

Ingredient Scientific Monograph

Astaxanthin

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Astaxanthin

Chemical Name: Astaxanthin

Ingredient Form: Natural Astaxanthin

Primary Source: Haematococcus pluvialis microalgae

Primary Bioactive Compound:

• Astaxanthin (xanthophyll carotenoid)

FEMSTATE™ Daily Dose

Astaxanthin is included exclusively in SHINE™ because the ovulatory phase represents the period of greatest physiological oxidative metabolism, requiring efficient endogenous antioxidant regulation, mitochondrial resilience, membrane stability, and cellular protection. Astaxanthin was selected because it is one of the most potent naturally occurring carotenoid antioxidants and demonstrates excellent biological activity in mitochondrial and membrane physiology.

Unlike conventional antioxidants, astaxanthin integrates into lipid membranes, allowing protection of both membrane surfaces while preserving normal physiological oxidative signaling.

2. Physiological Role

Astaxanthin is a naturally occurring xanthophyll carotenoid synthesized primarily by Haematococcus pluvialis. It accumulates in marine organisms such as salmon, trout, shrimp, lobster, and krill.

Within human physiology, astaxanthin contributes to:

• Cellular antioxidant defense
• Mitochondrial protection
• Membrane stability
• Endothelial physiology
• Immune homeostasis
• Skin physiology
• Muscle recovery
• Cellular resilience

These biological functions closely align with the increased oxidative metabolism associated with ovulation.

3. Mechanism of Action

Astaxanthin functions through multiple complementary mechanisms.

Membrane Antioxidant Protection

Astaxanthin spans the phospholipid bilayer.

Unlike vitamin C (water-soluble) or vitamin E (lipid-soluble), astaxanthin protects:

• inner membrane surface
• lipid membrane core
• outer membrane surface

-> Improved membrane stability -> Cellular resilience

Mitochondrial Physiology

Astaxanthin contributes to:

• maintenance of mitochondrial membrane integrity
• reduction of oxidative injury
• preservation of ATP production

These functions become particularly relevant during ovulation, when mitochondrial activity increases substantially.

Oxidative Balance

Astaxanthin supports:

• endogenous antioxidant systems
• maintenance of physiological redox balance
• regulation of oxidative metabolism

Importantly, it does not eliminate physiological reactive oxygen species required for ovulation.

Endothelial Function

Human studies suggest astaxanthin supports:

• endothelial physiology
• nitric oxide bioavailability
• vascular function

These mechanisms complement the vascular remodeling that accompanies ovulation.

4. Why Included in FEMSTATE™

SHINE™

The ovulatory phase is characterized by:

• LH surge
• extracellular matrix remodeling
• angiogenesis
• mitochondrial activation
• physiological oxidative metabolism
• increased ATP demand

Astaxanthin supports these biological priorities through:

• membrane protection
• mitochondrial physiology
• endogenous antioxidant regulation
• cellular resilience

Within FEMSTATE™, astaxanthin is included to support normal cellular adaptation during ovulation rather than to suppress oxidative physiology.

5. Dose Justification

Selected Dose: 6 mg

The selected dose was based upon five scientific criteria.

Physiological Relevance

A daily dose of 6 mg provides meaningful physiological exposure while remaining practical for long-term supplementation.

Human Clinical Evidence

Human intervention studies evaluating astaxanthin have commonly investigated doses ranging from:

4-12 mg/day

The selected dose of 6 mg falls within the most frequently studied range for antioxidant physiology and mitochondrial support.

Safety

Clinical trials consistently demonstrate excellent tolerability at doses considerably higher than 6 mg/day.

Formulation Compatibility

The selected dose:

• complements CoQ10
• complements vitamin E
• complements vitamin C
• complements quercetin
• complements resveratrol

creating an integrated mitochondrial and antioxidant network within SHINE™.

HR+ Philosophy

Astaxanthin demonstrates no endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Astaxanthin has been investigated in randomized controlled trials evaluating:

• oxidative stress biomarkers
• exercise physiology
• skin physiology
• endothelial function
• mitochondrial physiology

The strongest evidence supports improvements in biomarkers of oxidative stress and cellular resilience.

Evidence directly relating to ovulatory physiology remains limited.

7. Safety Considerations

Astaxanthin demonstrates an excellent safety profile.

FEMSTATE Dose

6 mg/day

Human studies have safely evaluated doses ranging from:

4-40 mg/day

Reported adverse effects are uncommon and generally mild:

• orange discoloration of stool (rare)
• mild gastrointestinal discomfort
• headache (rare)

No serious safety concerns have been consistently reported at nutritional doses.

8. HR+ Safety Review

Astaxanthin was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Astaxanthin is considered fully compatible with the FEMSTATE™ HR+-conscious formulation philosophy.

9. Ingredient Interactions

Positive Interactions

Coenzyme Q10

Supports complementary mitochondrial physiology -> Strong synergy

Vitamin E

Supports membrane antioxidant protection -> Strong synergy

Vitamin C

Regenerates antioxidant systems -> Positive synergy

Resveratrol

Supports complementary cellular resilience pathways -> Positive synergy

Quercetin

Supports complementary polyphenol-mediated antioxidant physiology -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Selenium
• Zinc
• Magnesium

at FEMSTATE doses.

Known Considerations

No clinically significant nutrient interactions have been consistently reported.

Individuals taking anticoagulant medications should consult a healthcare provider before initiating concentrated carotenoid supplementation, although current evidence suggests minimal interaction at nutritional doses.

10. Regulatory Status

Astaxanthin is:

• Widely accepted for use in dietary supplements.
• Commonly derived from Haematococcus pluvialis microalgae.
• Supported by numerous randomized controlled trials.
• Recognized internationally as a nutritional carotenoid.

11. Evidence Gaps & Future Research

Current evidence strongly supports astaxanthin for:

• antioxidant physiology
• mitochondrial function
• membrane protection
• endothelial physiology

Areas requiring further investigation include:

• Physiological oxidative metabolism during ovulation.
• Phase-specific application in healthy reproductive-aged women.
• Clinical evaluation within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated astaxanthin within a phase-aligned nutritional formulation.

12. Conclusion

Astaxanthin is one of the cornerstone antioxidant ingredients within SHINE™ because of its exceptional ability to support mitochondrial integrity, membrane stability, endothelial physiology, and endogenous antioxidant defense during the metabolically demanding ovulatory phase. The selected dose of 6 mg/day aligns with the most consistently studied range in human clinical trials and complements the integrated mitochondrial network formed by CoQ10, vitamin C, vitamin E, quercetin, and resveratrol. Rather than suppressing physiological oxidative signaling, astaxanthin supports the body's natural antioxidant systems while preserving the oxidative processes required for normal ovulation. Its excellent safety profile, robust human evidence, and complete HR+ compatibility make it one of the highest-confidence ingredients within the SHINE™ formulation.

References

• Marine Drugs. Reviews on astaxanthin pharmacology, bioavailability, and human health.
• Nutrients. Systematic reviews on astaxanthin supplementation and antioxidant physiology.
• Antioxidants. Reviews on astaxanthin, mitochondrial function, and oxidative stress.
• The American Journal of Clinical Nutrition. Reviews on carotenoids, endothelial physiology, and human metabolism.
• Journal of Clinical Biochemistry and Nutrition. Randomized controlled trials evaluating astaxanthin in healthy adults.
• Williams Textbook of Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on oxidative physiology, mitochondrial metabolism, and women's health.

Ingredient Scientific Monograph

Ceramides (as CeraLOK® Rice Bran Extract)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Ceramides

Ingredient Form: Plant-Derived Glucosylceramides

Branded Ingredient: CeraLOK®

Source: Rice Bran Extract

Primary Bioactive Components:

• Glucosylceramides
• Plant Ceramides

FEMSTATE™ Daily Dose

CeraLOK® is included exclusively in RESET™ because the menstrual phase is characterized by epithelial renewal, connective tissue repair, extracellular matrix remodeling, and restoration of barrier integrity. Rather than serving as a cosmetic ingredient, plant ceramides support the physiological regeneration of epithelial tissues and maintenance of skin barrier function during the body's primary regenerative phase.

2. Physiological Role

Ceramides are sphingolipids that constitute approximately 50% of the lipid matrix of the stratum corneum, the outermost layer of the skin. They are also present in cell membranes throughout the body, where they contribute to membrane organization, cellular signaling, and barrier integrity.(1-4)

Ceramides contribute to:

• Epidermal barrier function
• Skin hydration
• Cellular membrane integrity
• Extracellular lipid organization
• Water retention
• Cellular signaling
• Tissue resilience

Although best known for their role in skin physiology, ceramides are fundamental structural molecules involved in maintenance of epithelial tissues.

3. Mechanism of Action

Plant-derived glucosylceramides support epidermal physiology through multiple mechanisms.

Epidermal Barrier Function

Ceramides form organized lipid lamellae within the stratum corneum.

Ceramides -> Lipid bilayer organization -> Reduced transepidermal water loss -> Improved barrier integrity -> Maintenance of tissue hydration

Cellular Membrane Structure

Ceramides contribute to:

• membrane stability
• lipid organization
• cellular resilience

Skin Hydration

Human studies demonstrate oral plant ceramides support:

• skin moisture
• barrier function
• epidermal integrity

These physiological effects appear to result from modulation of epidermal lipid metabolism rather than direct incorporation into skin.

Tissue Recovery

By supporting epithelial integrity and barrier physiology, ceramides complement the regenerative biology of the menstrual phase.

4. Why Included in FEMSTATE™

RESET™

The menstrual phase is characterized by:

• tissue regeneration
• epithelial renewal
• extracellular matrix remodeling
• connective tissue repair

Ceramides support these biological priorities by helping maintain:

• epithelial barrier integrity
• tissue hydration
• cellular resilience
• connective tissue physiology

Within FEMSTATE™, CeraLOK® is positioned as a structural support ingredient, reflecting the body’s regenerative priorities rather than cosmetic goals.

5. Dose Justification

Selected Dose: 0.6 mg glucosylceramides

The selected dose was based upon five scientific criteria.

Physiological Relevance

CeraLOK® is a highly standardized ingredient with demonstrated biological activity at relatively low doses because the active glucosylceramide fraction is concentrated.

The selected dose supports epithelial physiology while maintaining efficient formulation design.

Human Clinical Evidence

Human clinical trials evaluating plant-derived ceramides have commonly investigated doses between 0.6 mg and 3.5 mg/day, depending on ingredient standardization.

The selected dose corresponds to the clinically investigated range for CeraLOK®.

Safety

Plant-derived ceramides demonstrate excellent tolerability and are appropriate for long-term daily use.

Formulation Compatibility

The selected dose:

• complements vitamin C
• complements collagen-supportive physiology
• complements vitamin A
• complements zinc

creating an integrated regenerative formulation.

HR+ Philosophy

Rice-derived ceramides demonstrate no endocrine activity and align fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Human clinical studies have investigated oral plant ceramides in relation to:

• skin hydration
• barrier function
• transepidermal water loss
• epidermal physiology

The strongest evidence supports improvements in objective measures of skin barrier function.

Although these studies primarily evaluate dermatological outcomes, they support ceramides' physiological role as structural lipids.

7. Safety Considerations

Plant-derived ceramides have an excellent safety profile.

FEMSTATE Dose: 0.6 mg/day

Human studies have safely evaluated substantially higher doses.

Reported adverse effects are rare and generally limited to mild gastrointestinal discomfort.

No serious adverse effects have been consistently reported.

8. HR+ Safety Review

CeraLOK® was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Rice-derived glucosylceramides function as structural lipids and have no known hormonal activity.

9. Ingredient Interactions

Positive Interactions

Vitamin C

Supports connective tissue physiology while ceramides support epithelial barrier integrity -> Strong structural synergy

Vitamin A

Supports epithelial differentiation -> Complementary epithelial physiology

Zinc

Supports tissue repair and epithelial regeneration -> Positive synergy

Collagen-supportive nutrients

Complement extracellular matrix biology -> Positive structural synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Magnesium
• Selenium
• Iron

at FEMSTATE doses.

Known Considerations

Individuals with rice allergy should verify ingredient suitability, although purified glucosylceramide extracts generally contain minimal allergenic proteins.

10. Regulatory Status

CeraLOK® rice bran extract is:

• Widely accepted for use in dietary supplements.
• Supported by multiple randomized controlled trials.
• Commonly used in nutritional products supporting skin barrier physiology.
• Derived from food-grade rice bran.

11. Evidence Gaps & Future Research

Current evidence strongly supports plant ceramides for:

• skin hydration
• epithelial barrier function
• transepidermal water loss

Areas requiring additional investigation include:

• Connective tissue regeneration during menstruation.
• Epithelial biology beyond dermatological outcomes.
• Clinical evaluation within phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated CeraLOK® within a phase-aligned nutritional formulation.

12. Conclusion

CeraLOK® rice-derived glucosylceramides were incorporated into RESET™ because they support one of the central biological priorities of the menstrual phase: epithelial regeneration and restoration of tissue integrity. The selected dose of 0.6 mg reflects clinically investigated amounts shown to improve skin barrier function and hydration while maintaining excellent long-term safety. Within the FEMSTATE™ platform, ceramides are positioned as structural lipids that complement connective tissue repair, extracellular matrix remodeling, and epithelial recovery during menstruation. Their inclusion broadens the concept of tissue regeneration beyond the endometrium to encompass whole-body epithelial physiology, reinforcing FEMSTATE's systems biology approach to phase-aligned nutrition.

References

• Nutrients. Systematic reviews on oral ceramides, skin barrier function, and human physiology.
• Journal of Cosmetic Dermatology. Randomized controlled trials evaluating plant-derived ceramides and skin hydration.
• International Journal of Molecular Sciences. Reviews on ceramide biology, epidermal barrier function, and lipid metabolism.
• Experimental Dermatology. Reviews on ceramides and epidermal physiology.
• Williams Textbook of Endocrinology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on tissue remodeling and epithelial physiology.

Ingredient Scientific Monograph

Inulin (Prebiotic Dietary Fiber)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Inulin

Chemical Name: Fructan (β-2,1-linked Fructooligosaccharide)

Ingredient Form: Chicory Root–Derived Inulin

Botanical Source: Chicory Root

Ingredient Class: Soluble Prebiotic Dietary Fiber

FEMSTATE™ Daily Dose

Inulin is included exclusively in SOOTHE™ because the luteal phase is characterized by metabolic stabilization, gastrointestinal adaptation, neuroendocrine regulation, immune homeostasis, and preparation for the transition into the next menstrual cycle. Inulin was selected because it is one of the most extensively studied prebiotic fibers, supporting the gut microbiota, production of short-chain fatty acids (SCFAs), intestinal barrier integrity, and the gut-brain axis.

Within FEMSTATE™, inulin is included to support normal gastrointestinal and metabolic physiology, not as a laxative or digestive treatment.

2. Physiological Role

Inulin is a naturally occurring soluble dietary fiber that resists digestion in the upper gastrointestinal tract and is selectively fermented by beneficial gut microorganisms in the colon. This fermentation produces short-chain fatty acids (SCFAs) - primarily acetate, propionate, and butyrate - which contribute to gastrointestinal physiology, immune regulation, metabolic homeostasis, and gut barrier function.(1-5)

Inulin contributes to:

• Gut microbiome diversity
• Short-chain fatty acid production
• Intestinal barrier integrity
• Gastrointestinal physiology
• Immune homeostasis
• Mineral absorption
• Gut–brain communication
• Metabolic regulation

These biological functions align closely with the physiological priorities of the luteal phase.

3. Mechanism of Action

Inulin functions primarily as a prebiotic substrate.

Prebiotic Fermentation

Inulin -> Fermentation by beneficial bacteria -> Short-chain fatty acids -> Gut barrier support -> Immune homeostasis -> Metabolic regulation

Unlike probiotics, inulin does not introduce microorganisms but provides nourishment for existing beneficial bacteria.

Short-Chain Fatty Acid Production

SCFAs contribute to:

• maintenance of intestinal epithelial cells
• regulation of immune signaling
• maintenance of gut barrier integrity
• metabolic physiology

Gut-Brain Axis

Emerging evidence suggests that alterations in gut microbial activity influence communication between the gastrointestinal tract and central nervous system through:

• microbial metabolites
• immune signaling
• vagal pathways
• endocrine mediators

Although this field is rapidly evolving, these mechanisms provide a biological rationale for including a prebiotic during the neuroendocrine-focused SOOTHE™ phase.

Mineral Absorption

Inulin may modestly enhance absorption of certain minerals, particularly calcium and magnesium, through fermentation-related reductions in colonic pH.

4. Why Included in FEMSTATE™

SOOTHE™

The luteal phase emphasizes:

• metabolic stability
• gastrointestinal physiology
• neuroendocrine regulation
• immune homeostasis
• physiological recovery

During this phase, progesterone can influence gastrointestinal motility and digestive physiology.

Inulin supports these biological priorities by:

• maintaining gut microbiome activity
• supporting gut barrier function
• contributing to SCFA production
• supporting metabolic homeostasis

Importantly, FEMSTATE™ does not position inulin as a treatment for constipation, irritable bowel syndrome, or gastrointestinal disease.

5. Dose Justification

Selected Dose: 3 g

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 3 g/day represents one of the most widely studied nutritional doses for prebiotic activity and consistently demonstrates measurable effects on the gut microbiota and SCFA production.

Human Clinical Evidence

Randomized controlled trials evaluating inulin have commonly investigated doses ranging from:

3-10 g/day

The selected dose represents the minimum effective dose for consistent prebiotic activity while minimizing gastrointestinal intolerance.

Safety

Higher doses may increase bloating and gastrointestinal discomfort.

The selected dose provides meaningful prebiotic activity while maintaining excellent tolerability.

Formulation Compatibility

The selected dose:

• complements the probiotic blend
• complements magnesium L-threonate
• complements L-theanine
• complements GABA

creating an integrated gut–brain support system.

HR+ Philosophy

Inulin demonstrates no endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Inulin is among the most extensively studied prebiotic fibers.

Strong evidence supports:

• increased Bifidobacterium abundance
• SCFA production
• gut microbiome modulation
• bowel regularity
• gastrointestinal physiology

Emerging evidence supports roles in:

• metabolic physiology
• gut–brain communication
• immune regulation

However, evidence specifically evaluating menstrual physiology remains limited.

7. Safety Considerations

Inulin has an excellent safety profile.

FEMSTATE Dose: 3 g/day

Human studies have safely evaluated doses exceeding: 10-20 g/day

The most common adverse effects are dose-dependent and include:

• bloating
• flatulence
• mild abdominal discomfort

These symptoms occur more frequently at doses substantially higher than 3 g/day.

8. HR+ Safety Review

Inulin was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Although the gut microbiome contributes to estrogen metabolism through the estrobolome, there is no evidence that nutritional inulin supplementation directly increases circulating estrogen concentrations in healthy women.

9. Ingredient Interactions

Positive Interactions

Probiotic Blend

Provides fermentable substrate supporting probiotic survival and activity -> Strong synbiotic synergy

Magnesium

May modestly enhance magnesium absorption through SCFA-mediated effects on the colon -> Positive synergy

Calcium

Supports physiological calcium absorption -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Selenium
• Zinc
• L-Theanine

at FEMSTATE doses.

Known Considerations

Individuals with:

• irritable bowel syndrome (IBS)
• FODMAP sensitivity
• severe gastrointestinal disorders

may experience increased bloating when introducing prebiotic fibers. Gradual adaptation generally improves tolerance.

10. Regulatory Status

Inulin is:

• Widely accepted for use in foods and dietary supplements.
• Recognized as a dietary fiber.
• Generally recognized as safe (GRAS) in the United States.
• Supported by numerous international nutrition organizations as a prebiotic fiber.

11. Evidence Gaps & Future Research

Current evidence strongly supports inulin for:

• gut microbiome modulation
• prebiotic activity
• gastrointestinal physiology
• SCFA production

Areas requiring further investigation include:

• Gut microbiome dynamics across the menstrual cycle.
• Gut-brain interactions during the luteal phase.
• Clinical evaluation of synbiotic formulations within phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated 3 g/day inulin within a phase-aligned nutritional formulation.

12. Conclusion

Inulin is a cornerstone prebiotic ingredient within SOOTHE™ because it supports one of the most rapidly advancing areas of women's physiology: the interaction between the gut microbiome, immune system, metabolism, and neuroendocrine function. The selected dose of 3 g/day represents one of the best-supported nutritional doses for promoting beneficial microbial fermentation while maintaining excellent gastrointestinal tolerability. Within the FEMSTATE™ platform, inulin is included not to treat gastrointestinal symptoms, but to support the normal gut physiology, microbial activity, and metabolic stability that characterize the progesterone-dominant luteal phase. Its robust human evidence, exceptional safety profile, and complete HR+ compatibility make it one of the strongest evidence-based prebiotic ingredients in the entire formulation.

References

• International Scientific Association for Probiotics and Prebiotics. Scientific Consensus Statement on Prebiotics.
• Nature Reviews Gastroenterology & Hepatology. Reviews on prebiotics, gut microbiota, and human health.
• Gut. Reviews on dietary fiber, SCFAs, and intestinal physiology.
• Nutrients. Systematic reviews on inulin supplementation, gut microbiota, and metabolic health.
• The American Journal of Clinical Nutrition. Reviews on prebiotic fibers, mineral absorption, and gastrointestinal physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on the gut microbiome, endocrine physiology, and women's health.
• Williams Textbook of Endocrinology.

Ingredient Scientific Monograph

Inulin (Prebiotic Dietary Fiber)

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Inulin

Chemical Name: Fructan (β-2,1-linked Fructooligosaccharide)

Ingredient Form: Chicory Root–Derived Inulin

Botanical Source: Chicory Root

Ingredient Class: Soluble Prebiotic Dietary Fiber

FEMSTATE™ Daily Dose

Inulin is included exclusively in SOOTHE™ because the luteal phase is characterized by metabolic stabilization, gastrointestinal adaptation, neuroendocrine regulation, immune homeostasis, and preparation for the transition into the next menstrual cycle. Inulin was selected because it is one of the most extensively studied prebiotic fibers, supporting the gut microbiota, production of short-chain fatty acids (SCFAs), intestinal barrier integrity, and the gut-brain axis.

Within FEMSTATE™, inulin is included to support normal gastrointestinal and metabolic physiology, not as a laxative or digestive treatment.

2. Physiological Role

Inulin is a naturally occurring soluble dietary fiber that resists digestion in the upper gastrointestinal tract and is selectively fermented by beneficial gut microorganisms in the colon. This fermentation produces short-chain fatty acids (SCFAs) - primarily acetate, propionate, and butyrate - which contribute to gastrointestinal physiology, immune regulation, metabolic homeostasis, and gut barrier function.(1-5)

Inulin contributes to:

• Gut microbiome diversity
• Short-chain fatty acid production
• Intestinal barrier integrity
• Gastrointestinal physiology
• Immune homeostasis
• Mineral absorption
• Gut–brain communication
• Metabolic regulation

These biological functions align closely with the physiological priorities of the luteal phase.

3. Mechanism of Action

Inulin functions primarily as a prebiotic substrate.

Prebiotic Fermentation

Inulin -> Fermentation by beneficial bacteria -> Short-chain fatty acids -> Gut barrier support -> Immune homeostasis -> Metabolic regulation

Unlike probiotics, inulin does not introduce microorganisms but provides nourishment for existing beneficial bacteria.

Short-Chain Fatty Acid Production

SCFAs contribute to:

• maintenance of intestinal epithelial cells
• regulation of immune signaling
• maintenance of gut barrier integrity
• metabolic physiology

Gut-Brain Axis

Emerging evidence suggests that alterations in gut microbial activity influence communication between the gastrointestinal tract and central nervous system through:

• microbial metabolites
• immune signaling
• vagal pathways
• endocrine mediators

Although this field is rapidly evolving, these mechanisms provide a biological rationale for including a prebiotic during the neuroendocrine-focused SOOTHE™ phase.

Mineral Absorption

Inulin may modestly enhance absorption of certain minerals, particularly calcium and magnesium, through fermentation-related reductions in colonic pH.

4. Why Included in FEMSTATE™

SOOTHE™

The luteal phase emphasizes:

• metabolic stability
• gastrointestinal physiology
• neuroendocrine regulation
• immune homeostasis
• physiological recovery

During this phase, progesterone can influence gastrointestinal motility and digestive physiology.

Inulin supports these biological priorities by:

• maintaining gut microbiome activity
• supporting gut barrier function
• contributing to SCFA production
• supporting metabolic homeostasis

Importantly, FEMSTATE™ does not position inulin as a treatment for constipation, irritable bowel syndrome, or gastrointestinal disease.

5. Dose Justification

Selected Dose: 3 g

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 3 g/day represents one of the most widely studied nutritional doses for prebiotic activity and consistently demonstrates measurable effects on the gut microbiota and SCFA production.

Human Clinical Evidence

Randomized controlled trials evaluating inulin have commonly investigated doses ranging from:

3–10 g/day

The selected dose represents the minimum effective dose for consistent prebiotic activity while minimizing gastrointestinal intolerance.

Safety

Higher doses may increase bloating and gastrointestinal discomfort.

The selected dose provides meaningful prebiotic activity while maintaining excellent tolerability.

Formulation Compatibility

The selected dose:

• complements the probiotic blend
• complements magnesium L-threonate
• complements L-theanine
• complements GABA

creating an integrated gut–brain support system.

HR+ Philosophy

Inulin demonstrates no endocrine activity and aligns fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Inulin is among the most extensively studied prebiotic fibers.

Strong evidence supports:

• increased Bifidobacterium abundance
• SCFA production
• gut microbiome modulation
• bowel regularity
• gastrointestinal physiology

Emerging evidence supports roles in:

• metabolic physiology
• gut-brain communication
• immune regulation

However, evidence specifically evaluating menstrual physiology remains limited.

7. Safety Considerations

Inulin has an excellent safety profile.

FEMSTATE Dose: 3 g/day

Human studies have safely evaluated doses exceeding: 10-20 g/day

The most common adverse effects are dose-dependent and include:

• bloating
• flatulence
• mild abdominal discomfort

These symptoms occur more frequently at doses substantially higher than 3 g/day.

8. HR+ Safety Review

Inulin was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

✔ Favorable endocrine safety profile

Although the gut microbiome contributes to estrogen metabolism through the estrobolome, there is no evidence that nutritional inulin supplementation directly increases circulating estrogen concentrations in healthy women.

9. Ingredient Interactions

Positive Interactions

Probiotic Blend

Provides fermentable substrate supporting probiotic survival and activity -> Strong synbiotic synergy

Magnesium

May modestly enhance magnesium absorption through SCFA-mediated effects on the colon -> Positive synergy

Calcium

Supports physiological calcium absorption -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Vitamin D3
• Selenium
• Zinc
• L-Theanine

at FEMSTATE doses.

Known Considerations

Individuals with:

• irritable bowel syndrome (IBS)
• FODMAP sensitivity
• severe gastrointestinal disorders

may experience increased bloating when introducing prebiotic fibers. Gradual adaptation generally improves tolerance.

10. Regulatory Status

Inulin is:

• Widely accepted for use in foods and dietary supplements.
• Recognized as a dietary fiber.
• Generally recognized as safe (GRAS) in the United States.
• Supported by numerous international nutrition organizations as a prebiotic fiber.

11. Evidence Gaps & Future Research

Current evidence strongly supports inulin for:

• gut microbiome modulation
• prebiotic activity
• gastrointestinal physiology
• SCFA production

Areas requiring further investigation include:

• Gut microbiome dynamics across the menstrual cycle.
• Gut–brain interactions during the luteal phase.
• Clinical evaluation of synbiotic formulations within phase-aligned nutritional systems such as FEMSTATE™.

No randomized controlled trials have specifically evaluated 3 g/day inulin within a phase-aligned nutritional formulation.

12. Conclusion

Inulin is a cornerstone prebiotic ingredient within SOOTHE™ because it supports one of the most rapidly advancing areas of women's physiology: the interaction between the gut microbiome, immune system, metabolism, and neuroendocrine function. The selected dose of 3 g/day represents one of the best-supported nutritional doses for promoting beneficial microbial fermentation while maintaining excellent gastrointestinal tolerability. Within the FEMSTATE™ platform, inulin is included not to treat gastrointestinal symptoms, but to support the normal gut physiology, microbial activity, and metabolic stability that characterize the progesterone-dominant luteal phase. Its robust human evidence, exceptional safety profile, and complete HR+ compatibility make it one of the strongest evidence-based prebiotic ingredients in the entire formulation.

References

• International Scientific Association for Probiotics and Prebiotics. Scientific Consensus Statement on Prebiotics.
• Nature Reviews Gastroenterology & Hepatology. Reviews on prebiotics, gut microbiota, and human health.
• Gut. Reviews on dietary fiber, SCFAs, and intestinal physiology.
• Nutrients. Systematic reviews on inulin supplementation, gut microbiota, and metabolic health.
• The American Journal of Clinical Nutrition. Reviews on prebiotic fibers, mineral absorption, and gastrointestinal physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on the gut microbiome, endocrine physiology, and women's health.
• Williams Textbook of Endocrinology.

Ingredient Scientific Monograph

Probiotic Blend

FEMSTATE™ Scientific Evidence Monograph

1. Ingredient Overview

Common Name: Probiotic Blend

Ingredient Type: Multi-Strain Probiotic

Ingredient Form: Freeze-Dried Probiotic Culture Blend

FEMSTATE™ Daily Dose

Note: The final formulation should specify each probiotic strain (e.g., Lacticaseibacillus rhamnosus GG, Lactiplantibacillus plantarum, Bifidobacterium lactis, etc.), as scientific evidence is strain-specific. Until the final strain composition is confirmed, this assessment applies to a standardized multi-strain probiotic blend intended to provide approximately 3 billion colony-forming units (CFU).

The probiotic blend is included exclusively in SHINE™ because ovulation is characterized by heightened metabolic activity, immune coordination, epithelial remodeling, and increased interaction between reproductive physiology and the gastrointestinal microbiome. The formulation supports normal gut microbial balance, intestinal barrier integrity, immune homeostasis, and gut–brain communication during one of the most physiologically active phases of the menstrual cycle.

2. Physiological Role

The human gastrointestinal tract contains trillions of microorganisms collectively known as the gut microbiome. These microorganisms contribute to digestion, vitamin synthesis, immune regulation, intestinal barrier maintenance, production of short-chain fatty acids (SCFAs), and communication with endocrine and nervous systems.(1-4)

Certain probiotic strains contribute to:

• Maintenance of microbial diversity
• Intestinal barrier integrity
• Immune homeostasis
• Gut–brain communication
• Production of beneficial metabolites
• Gastrointestinal physiology
• Metabolic homeostasis

The gut microbiome also participates in the metabolism of steroid hormones through microbial enzymes collectively referred to as the estrobolome, although the clinical implications of nutritional modulation remain under investigation.

3. Mechanism of Action

Probiotics function through several complementary mechanisms.

Gut Microbiome Support

Beneficial microorganisms -> Colonization resistance -> Microbial diversity -> Maintenance of gastrointestinal homeostasis -> Immune regulation

Intestinal Barrier Function

Certain probiotic strains support:

• tight junction integrity
• mucosal barrier function
• epithelial health

This contributes to maintenance of normal gastrointestinal physiology.

Immune Homeostasis

Probiotic organisms interact with gut-associated lymphoid tissue (GALT), contributing to:

• cytokine regulation
• dendritic cell function
• regulatory T-cell activity
• maintenance of immune homeostasis

Importantly, probiotics support immune regulation, not generalized immune stimulation.

Gut–Brain Axis

Emerging evidence suggests selected probiotic strains influence communication between the gut and central nervous system through:

• microbial metabolites
• vagal pathways
• immune mediators
• neuroendocrine signaling

Although this area remains under active investigation, it provides biological rationale for integrating probiotics into the SHINE™ formulation.

4. Why Included in FEMSTATE™

SHINE™

The ovulatory phase is characterized by:

• increased metabolic activity
• tissue remodeling
• immune coordination
• endothelial adaptation
• physiological oxidative metabolism

The probiotic blend supports these biological priorities through:

• maintenance of gut barrier integrity
• immune homeostasis
• microbiome diversity
• gut–brain communication
• metabolic regulation

Rather than targeting digestive symptoms, probiotics were selected to support systemic physiology during this metabolically active endocrine transition.

5. Dose Justification

Selected Dose: 3 Billion CFU

The selected dose was based upon five scientific criteria.

Physiological Relevance

A dose of 3 billion CFU/day provides clinically meaningful microbial exposure while maintaining excellent formulation stability and long-term tolerability.

Human Clinical Evidence

Most randomized controlled trials evaluating probiotics have investigated doses ranging from:

1–10 billion CFU/day

The selected dose of 3 billion CFU falls comfortably within this evidence-supported range.

Safety

This dose demonstrates excellent safety in healthy adults.

Formulation Compatibility

The selected dose:

• complements inulin (future synbiotic opportunities)
• complements antioxidant physiology
• supports immune homeostasis
• maintains formulation stability

HR+ Philosophy

Probiotics demonstrate no endocrine activity and align fully with the HR+-conscious formulation philosophy.

6. Human Clinical Evidence

Important Scientific Consideration: Unlike vitamins and minerals, probiotic evidence is strain-specific. Scientific conclusions cannot be generalized across all probiotics.

For this reason, the final FEMSTATE™ dossier should ultimately cite evidence for each individual strain included in the formulation.

Current evidence supports selected probiotic strains for:

• gut microbiome modulation
• gastrointestinal physiology
• immune homeostasis
• gut barrier integrity

Evidence for reproductive physiology remains emerging.

7. Safety Considerations

Probiotics demonstrate an excellent safety profile in healthy adults.

FEMSTATE Dose: 3 Billion CFU/day

Clinical studies have safely evaluated substantially higher doses.

Reported adverse effects are generally mild:

• transient bloating
• mild gas
• temporary changes in bowel habits

Serious adverse events are extremely rare and primarily occur in severely immunocompromised individuals or those with central venous catheters.

8. HR+ Safety Review

The probiotic blend was independently evaluated using the FEMSTATE™ HR+ Scientific Review Framework.

The literature was reviewed for:

• estrogen receptor activity
• progesterone receptor activity
• aromatase modulation
• endocrine disruption
• oncology safety

Findings

Current evidence demonstrates:

✔ No direct estrogen receptor agonist activity

✔ No progesterone receptor activity

✔ No aromatase stimulation

✔ No phytoestrogen properties

Although the intestinal microbiome participates in estrogen metabolism through the estrobolome, there is no evidence that nutritional probiotic supplementation at this dose directly increases circulating estrogen concentrations in healthy women.

9. Ingredient Interactions

Positive Interactions

Inulin

Provides fermentable substrate supporting probiotic growth -> Strong synbiotic synergy

Polyphenols (Quercetin, Resveratrol)

Gut microbes metabolize dietary polyphenols into biologically active metabolites -> Positive synergy

Vitamin D3

Supports complementary immune homeostasis -> Positive synergy

Neutral Interactions

No clinically meaningful antagonistic interactions with:

• Magnesium
• Selenium
• Zinc

at FEMSTATE doses.

Known Considerations

Individuals with severe immunodeficiency or critical illness should consult a healthcare professional before probiotic supplementation.

The final formulation should identify each probiotic strain because safety and efficacy are strain-specific.

10. Regulatory Status

Probiotic blends are:

• Widely accepted for use in dietary supplements.
• Supported by numerous randomized controlled trials.
• Addressed in scientific consensus statements from the International Scientific Association for Probiotics and Prebiotics.
• Commonly used in nutritional products supporting gastrointestinal and immune physiology.

11. Evidence Gaps & Future Research

Current evidence strongly supports selected probiotic strains for:

• gut microbiome modulation
• gastrointestinal physiology
• immune homeostasis

Areas requiring further investigation include:

• Microbiome changes across menstrual phases.
• Gut–ovary interactions during ovulation.
• Phase-specific probiotic requirements.
• Clinical evaluation within comprehensive phase-aligned nutritional systems such as FEMSTATE™.

Future versions of this monograph should incorporate strain-specific evidence once the final probiotic composition is confirmed.

12. Conclusion

The probiotic blend incorporated into SHINE™ supports one of the most important emerging concepts in women's physiology: the interaction between the gut microbiome, immune system, metabolism, and reproductive biology. The selected dose of 3 billion CFU provides clinically relevant microbial exposure while maintaining excellent tolerability and formulation stability. Rather than targeting gastrointestinal symptoms, the probiotic blend is included to support gut barrier integrity, immune homeostasis, and systemic physiology during the ovulatory phase. Because probiotic efficacy is inherently strain-specific, the final FEMSTATE™ scientific dossier should identify each strain and provide individual evidence summaries. Nevertheless, the current evidence strongly supports the biological rationale for incorporating a carefully selected probiotic blend into the SHINE™ formulation as part of the broader systems biology approach underlying the FEMSTATE™ platform.

References

• International Scientific Association for Probiotics and Prebiotics. Consensus Statement on Probiotics and Prebiotics.
• Nature Reviews Gastroenterology & Hepatology. Reviews on probiotics, the gut microbiome, and human physiology.
• Gut. Reviews on gut microbiota, barrier function, and immune regulation.
• Nutrients. Systematic reviews on probiotic supplementation and human health.
• The Lancet Gastroenterology & Hepatology. Reviews on probiotics and gastrointestinal physiology.
• The Journal of Clinical Endocrinology & Metabolism. Reviews on the estrobolome, gut microbiome, and endocrine physiology.
• Williams Textbook of Endocrinology.